var title_f17_27_17840="Rotationplasty reconstruction";
var content_f17_27_17840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rotationplasty",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 15-year-old male presented with a very large osteosarcoma of the distal femur (left panel) with major posteriorly placed soft tissue mass. The patient was treated by a turnabout procedure (rotationplasty) where the distal half of the femur was resected, and replaced by the tibia but \"turned around\" so that the foot was pointing backwards (right panel). Using this system, the ankle joint now served as a knee joint, and the patient uses a special prosthesis to use the new knee joint (formerly the ankle) to flex and extend.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Henry Mankin.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17840=[""].join("\n");
var outline_f17_27_17840=null;
var title_f17_27_17841="Cystic hygroma CXR I";
var content_f17_27_17841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma in newborn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a large mass involving the chest wall of the left hemithorax.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17841=[""].join("\n");
var outline_f17_27_17841=null;
var title_f17_27_17842="Patient information: Hair loss from cancer treatment (The Basics)";
var content_f17_27_17842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hair loss from cancer treatment (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hair-loss-from-cancer-treatment-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27440233\">",
"      <span class=\"h1\">",
"       Why might people lose their hair from cancer treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hair loss can be a side effect of a cancer treatment called chemotherapy. Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"     </p>",
"     <p>",
"      Not everyone who gets chemotherapy will lose their hair. Your doctor will tell you how likely you are to lose your hair. It will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The chemotherapy medicines you get",
"       </li>",
"       <li>",
"        Your dose and how the medicines are given",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When people lose their hair, it usually starts to fall out 2 to 3 weeks after chemotherapy starts. It can also fall out after a few chemotherapy sessions. Some people lose their hair a little at a time, and others lose it in clumps. Some people lose all of their hair, while others don&rsquo;t. It usually doesn&rsquo;t hurt when the hair falls out. Most often, people lose hair from their head. But they can also lose hair from their armpits, beard area, eyebrows, and genital area.",
"     </p>",
"     <p>",
"      Another cancer treatment, called radiation therapy, can also cause hair loss. Not everyone who gets radiation therapy will lose their hair. It will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The part of the body involved &ndash; People can lose hair on the part of the body that is treated with radiation.",
"       </li>",
"       <li>",
"        The dose of radiation and how the radiation is given",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27440240\">",
"      <span class=\"h1\">",
"       Will my hair grow back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After chemotherapy, yes. After all of your chemotherapy treatments are done, your hair will grow back (except in very rare cases.) But your hair might look or feel different than it did before, especially at first. For example, it might be curlier or grayer. It can take 6 to 12 months for hair to grow back completely.",
"     </p>",
"     <p>",
"      After radiation therapy, hair does not always grow back completely. If it does grow back, it can look or feel different than it did before.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27440247\">",
"      <span class=\"h1\">",
"       Can hair loss be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, no. You might read or hear about special caps to wear or shampoos that can prevent hair loss during cancer treatment. These usually don&rsquo;t work and can even be unsafe to use.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27440254\">",
"      <span class=\"h1\">",
"       What can I do to manage my hair loss?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are likely to lose your hair, talk with your doctor or nurse. He or she can tell you what to expect and help you prepare for it.",
"     </p>",
"     <p>",
"      To help take care of your hair and scalp before you lose your hair, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use a mild shampoo, pat your hair dry (do not rub it), and use a soft brush",
"       </li>",
"       <li>",
"        Avoid using curling irons, hair dryers, rollers, hair bands, or hair clips",
"       </li>",
"       <li>",
"        Avoid putting hair spray, dyes, or chemicals in your hair",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people choose to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cut their hair short or shave their head, either before their hair falls out or when it starts to fall out",
"       </li>",
"       <li>",
"        Buy a wig, hairpiece, scarf, hat, wrap, or other head covering to use after their hair falls out. The American Cancer Society has a Web site with all of these products (",
"        <a class=\"external\" href=\"file://www.tlcdirect.org/\">",
"         www.tlcdirect.org",
"        </a>",
"        ). Many people get a wig or hairpiece before they lose their hair. This makes it easier for the wig or hairpiece to match their hair. Most health insurances pay for wigs and hairpieces for hair loss from cancer treatment. But if your insurance doesn&rsquo;t, or pays only for some of it, you can deduct your wig or hairpiece as a medical cost on your taxes. You can also check if the local American Cancer Society offers free wigs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After your hair falls out, wearing a wig, hairpiece, hat, scarf, wrap, or other head covering might help you feel better about the way you look. Whichever covering you choose, make sure that it fits well and does not hurt your scalp.",
"     </p>",
"     <p>",
"      You also need to take care of your scalp after your hair falls out. To keep your scalp from getting hurt or sunburned, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cover your head when you go outside. Covering your head can also help you stay warm.",
"       </li>",
"       <li>",
"        Put sun block on your scalp when you are out in the sun.",
"       </li>",
"       <li>",
"        Sleep on a satin pillow case.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27440261\">",
"      <span class=\"h1\">",
"       What can I do to take care of my hair as it grows back in?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To take care of your hair as it grows back in, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Wash it no more than 2 times a week.",
"       </li>",
"       <li>",
"        Gently rub your scalp to get rid of any dry skin.",
"       </li>",
"       <li>",
"        Be gentle when you style your hair. Try not to blow dry it too much or brush it too hard.",
"       </li>",
"       <li>",
"        Avoid putting any chemicals or dyes in it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27440268\">",
"      <span class=\"h1\">",
"       What if I feel sad, angry, or worried about losing my hair?",
"      </span>",
"      &nbsp;&mdash;&nbsp;These feelings are normal. For many people, losing their hair is one of the worst side effects of cancer treatment.",
"     </p>",
"     <p>",
"      You might feel better if you talk to someone about your feelings. You can talk to your doctor, nurse, a family member, or a mental health professional.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27440275\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/27/17842?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16319 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17842=[""].join("\n");
var outline_f17_27_17842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27440233\">",
"      Why might people lose their hair from cancer treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27440240\">",
"      Will my hair grow back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27440247\">",
"      Can hair loss be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27440254\">",
"      What can I do to manage my hair loss?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27440261\">",
"      What can I do to take care of my hair as it grows back in?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27440268\">",
"      What if I feel sad, angry, or worried about losing my hair?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27440275\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_27_17843="Ocular rosacea telangiectasias";
var content_f17_27_17843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ocular rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCzqA22vmHqhzn0qpqmqLB4buZ4yDhGA+tP1G4le3kjETYwR9eK851/VXGgR2mxwry7c9uvSt+dJo9ieidzt/AkCxaLCzkBpfnP410k15HGNsWD6mub0m/sotOhQEKwQDkEdqvwXELDKMrZ9KUH7qZSjZIJz5r96o3QWJhkks3QCpru9jgbCAGQ8BetRbdp8yRiz9fp9KTd2bJNFKZGH3hg+mOlFtCAfmI454qaRg5JOSRUWQQWHAXvWTszRamlBOsELN3xxWVM4lk3MMZ9+tMluA6lcj0pbdAAo+8evNK91Yq1iZU2+y4qhrF20FkTHkHoorVKgxc8k1hiE6jrGwHMNsMn0LUpR0J5uxPpFk8NsjMcu/zMT3q7PGAo2gA1qRxgRoAuSDWZrkv2S2mnZ1XCk4pez0KUranG+M78yeTp9ufnY8mtHSIfsVikS8EDJrE8OQyapqEl3c8qp+XiuguG2vgHpwawqPoLDJzbqPrt6CifM3zd/XtVPxPcxfYoIEYl3cdPSpQysPQDpWLdf6VrMC5yqVMJpXNsQnyW7nYHUZp7OCDjy4kAUDg1ntExkZ2q1Aqqvyj8qZLJiTBPPbFaKWholbQqS3DWkDSk5Cgk844rN8PSM6TTplfPYk81u+KltoPAskvmx/bJpNnlMvzAf3hXOeHnxp0abSePyqKslFKRhTftK1uyNpY5Zm2K3CjueKz/ABDbNppt5ULCZwST2rV05Q0qCQkAenOaqeOphLcQrCCu0BcGopyvdsMSrx0IdKdmhV3PzHk1qxSDqT061zsUj2qhG/OrkF3kE+lRz2OyENEiXxEvnJCu8KO9OubabTGSKeRWDIHUq3Y1Uud16WdVGyPAY5+6ap3Eq7wNxY7R97kilOSauYwi1VuaElyzDaCTmlMgiTD9fSqAkbAdcY9aexmSSJyu4t0rCVR20PQp009xzTO1/CbmPZDnKnpXUaw+jXUW+1WQzkDLHjkelc1qVzcX08EV04HlDCKoxgVdt4hgY6inZtJMwjZ1ZSL6XcKRCJGJwO5qpc33ljPqfypZbUuhKD5uvTrWY8UrAhyT7GpdRxVjoVNS1NmLUNsnnIdwRc/jWc9zNLu8xs5ySWp0JVbIwhPmJyTjrT4rEvGQpyxHHFZ+0ctB+zUdSrHbEqWPAxkYqKw82G4BXJGemOtbUFu0KKr9cc1YjaOJ1yq5JwCBVKDDmVrF63uOV8wsCQDj2qh4t1LNotnGAzTHHHULRqEKuoO5gw5DA/pVDTrJ9Q1HzPnYx8DI4rrpzaOLEQTtFdTQ0pBZ20cSjb0LE+tb0MwALFgfase8hlt58Pww6+hqxBJuZRjAByfrRGTWhTgklY1fNAjHmYB3ZGe1SeeYfMnA5KkD6U20tzcSpAI9zO4qLxQi2el3jBz+7Rh6c1ok2zCUkjzjR2ZfEVxIk3yMw3cfeOelekhgsYzjHYV5polmz6RDcShl33GC3sa70SMIV+YNsH8qqb6o5sGrJ366jDF9o1EygDC8E5rQiiKdVyPSpfD8VsdP3St87tk1tXFjt2NGUMZHr0pRTeptz8jsZlvtB8wgDHAFXpWFpYvcMPnB2r75qviNphj+Hg45FT6mkUljmT738IIq+bWxM1doxppzNGwLcdcdBWdMHxweKtOQsbbu/SqwJJzjp60X7myVgUsQN2TgflVu3bIwoIPv3qBgSFOMVZ2iK3eZiFAGeTU9SZGT4rvD9njsYMh5TlvpWfZ2jNcRnKmBBnCnJ3e9VNRuXCzXMzeZITtjRffpWtplqbazj3qFmc+Y3Pc05Svsc0PekXoogivKy5OODWXMpldjxz6VrvIhhEZGWNRWMGLgh1DAcntxQ+yOq+jZganM1lprbTgv8oHrVjwxEIbMZ++x3H1qlq0p1XVCqAfZ4TjAq8ZobO3V5CEUDj1ovZ2MkuZub2Rf1t4GsXE0rRoCCQDyfaqWlztcXayXCkRIuIkPas6ONtWkE9wXWFGykfQEeua02nVZJ3QHCKAABT5rsz5eZ83Qr6hctFDOU2Zm+QbeSPrRWZavJPqTLtIhTBbjqaKaatqZ8jnqj0Wa4k8mRTnoevNeY3UP2nXLCJZMrv3sh7e9eoxlVgd5VJwDmvIrZ3vfEsskBIMJJH4GuqekGzlqu7Ue567HFEkIRkQgD7uKw9YWAOsdluW8bp5ZwB9aovrpniSC1Ae5cYOf4avabCbZWkuHEkz8liKd1ZI2td6FOM3WnSGS6X7Rnq46irkd8lyAY2z7d81LJMCMMQfrWReWvJntm2yDnb2NZt22NlHqaocmPB4J71QupTuKRg56Gqyaj58ezbiXoVqzaW7AhnyTmsXNbI1jHS4sUThCSORzVuGUAE4qfYqp8/GeKoXRCP8ALwtbRFuxNTvxa2jOCPM+6o7k9qm0KFre0G8Eux3Mfc1y6SHUdbWNCDbwHLHsTXYhgg8tWByO1O6b1M4+821sacc7MBt5wM4Arz3xzqsl3ex2FseGILZrudUuodM0jYrL9oYbmfuB6V5to4N1qc15NzgnBNRUqcsbkzTk1BdTptIs0srJY0HzY+b3NR6hbu8eVwCT1qaKc7cEDB6GrAkRiA47dK5V7yO+MeRWRjrF5cG2QlvqKzNBtTLqNw4JIBOK6DVUWOxlfphTg1V8NwvBZeYw++c89qPZqKIm3KcV21NWOIINpwfY9qrzRhQWI7daezFyOcAU2afZgABmJ4FO8VoaO6VzJ8X3zahYeURtjt4wqjFTaFbImkQMcZI5qnrrPMjQlPmdudoq9pjlLKOEjleKiU1NK/QwpQcar80b2n6ottAY47WMuerEZJrm9WIutSJlB3Z6gcVqRsI1ySdw6Z6Vm2JWfUJDPkRk5GO1JPQ0qU1G3mQ3aIOAQT0qnLC4ACsR6ir9xGqXDHnbngU6aHdGDWTVzs2Vzn5PNSVkjYlO9TFh9njGBu+6avSxLFGc/ef9aba2EIU/aC4c9Mc1k2tiI02ncjtIjKyIOB6VduV8gqyDGPU0ttAI2BBOM9atNAjN+8baAMnIzUWOpSsrGTArS35mk9MV0NlErrkZ/KqayJMvFuqlBgFeM/WtTTjlfnba3TArSLbZjGKin5km0qrEjG0da5+aOVp2kO7HYmuuEZdcOpYMKJtM+0QLGxIHtTnT5thwqqO5zFvIxAjXCOeN3rW9ptv5MZ83Bf2qRfD8bugV2XB61ozWZimG3kAAH3qaVJp6jrVYy0RSESO59qiNojMRtBweSRWq8a8FVwQORULnaS5HQZrpcUYKT6GTqVqPLWFH2s+ee4FXfD6R2cRD5AIwT71HYWgv7h7yebYU4VD3rQMCPyo5z+FCV0Z6SbcitqzCeAsPvA8ZqrZxYw2Tg85q9dRFFj3Z2Z5z3+lRXMsEOPKfC/3Dziny63Za7I09KmZb22EbYO/GfSsf4qy/ZdNuY9ygbwCO5zWlot0sGpW84YbUkU5HOOa5j43XQu/ETWVqWYSMJDu961g9/I48UuW/oDoj+B4hEwDbQ+MfdNWdN82bTI5GHzEc4qMwPDoZtm+6sOBj6U74fTedopidvmjcgj2qebmQRj7OcV5fka9mr/Z/LKgL2PSr0YkMWASVHHJqy0QWH5U5bue1PhBHDfMBVKLNHLQqxgwkfMRk85pt7MzKSSSR+VXpFEh+ZVH4VSnH7/Y5G0DJz2FJQtqCaZmXKEkMW5PGKWGL5do9ec1NKBI52rke1OZWiXIyfWnYoqXCrsJD89NtUppHumFuAWUcnHb2qxqCs0ZZCC5O1V7mqGsXtxo+jmJ2VNx3dOS59KnW5nVkkiCOCO78RpaqFkSzG+Rx0L+lbepHIGByBWb4WtDZ6aZHLGaY+a7HqauvL5uTtbA9qpWFSg0rsorJ+9QvkdhVzWr2TT9Jlkj2ebMvlqT15qF0QAqyn5ud3pXPanfwXF+txO7LaWi8L/faqi7IK8klYtWaQ6To5nuWxK/zNnqT6VRsYZtVnM9yBHbA/JHU1nZ3OvSDUtQDR2iHEUI7++K3Xi2oohUBV4qHoTTXOrfZQ26ZEhUIFOAMAcYrMfc1vuJUea5I59Ku35WONiAC2MfjWVbkyXKRspUIeh5ovpcqo0rRRd0q2aCBlcZeTLE0Vp2qZJ4xRWiQ1G2huXskUltMsQZXVCSM9eK8Y0K4mj1S7S2TdLKxGfQZrvfFesiyhJiIMrKeAcVzfw7jWd7mWRQWY+lddV2jynly1qxiaui266VfbZjuaUZDn19K2rqdiSAwzVLX4c225MiRDuUiq9lOJ7YSHJPA/GsZPl0Oqmre6Wd7M+Hbgd/SojKSSAd3pTwCQSO9PtogGDbfm/nWDudKViqmlzH9/ASJRzjrV+O5mYKsqFZB19K19NtLlwzINo9addWTn5TH++HJOeDVRpXRnzpSv0M5JWJIbn61meILtbW1dyTubhQT1rWKGIMZBg965DVJG1PXYbZeY4juOPWtF7q1CpKy06l3w9bGCHex/eyHca6W1BTE7DcM4XNZphKRjbgEDpVrzzDaZuWGxBkVPNbQqMOWKSMrxZNIYPKQZdzliPSqel2/k26jaMVXmla9vzKpyueldRZ26mJSVzkYrGcueXKug6cdfaMXSbOC6kKzs0Zz8oqe5s1iuiIstH71bhtljAKYBHQ1O6hvnzgj1HWqUUjS75rnPa9G7W6wxj/WMAfYVYhiAhSLgBRg1eXEs+ZFXC9jTVjBlOMc+1DdxxWrZmyxscbBxmopLQvEzA9DtB962ntySV459KgNq0KgnOTziolErmOaMdxBfIYCTMOnGcVrRWUkUO6XAY/MaszR+TIsikCXpwPWnYaRVU8ketZqKUbMa1qcxSlB/gwxPapbOyVraaZ8qwPGBU1tC4nZSBt9avrmP5UIWNhhhjrVKKHNtmNbabJezFI8F+nPen3ul3FohWTbkHBA7VpNEIpA8bFee3ap2HmEknJPXNRyaPuac7TOPW0ZZBJL0zgA1cgjCyMFRXyO/auourWCSyXCgsRzWOIlhcK+U9OOtQqVi/acxlyr5ZPBPvUqyGaMKkY+UYyBWnPZFrclQCp6Edai0q0ZUYY3ZPp0p8vYrmVh1hp4MyFgecZqS/sWjlJiBx1B6VuafOlqrBlUkjGfT6Ut3KLlgFQcdOeacaaSM1VfNboZejsWLKx+deD9a14kbd8wJGcVnSQfZLhJQflY/N7Vv28Qk2lW7Zq4wIqPqOjijxuyOuKguSpwMA4PGO/1qWTkFFUAZzkd6PJJA+7x+NWo9DG9ioUYgMANuMc1RnQv8gBArdFvtiy2MDnrTPsqFQ2M96biPnMaJBGABxj0qXzY4VLE4I5q69uNpCgZFY11AZr5VYkIOuO9TaxoncWRjNalm3cnKgnhaq2tvyWmBIHJJFa32c4IIGOwxV2eweOyBkjKOfmX0xUu7K9ooKxzsMXlMSrHDHOD0rI8T2ouvEMAKqzFFIYHnGK3rqPYm8AZ74qK6tDNd29wWG8oB8vpThpcxrxU2kXLp5L+2KiGJBDFsVUHXA7+prnPC1tcabNLHINof5sGurhCxRkDO4jrjvVa2uIr3AEb/aYgQ7Mwwee1CWhMrc8exr2jpLtwwwO3WrAUI5x37Cuamgks913EzoVPK/wmugglSSNXbqRn61UanRjnT5UmiWVP3TOe3J9q568Zm+bONx/SupZrCaWCJndVYEysB+VYWoxJ5+2IZBOBxjFW2xUt9RLeDPC5Lt0qK5Bjcxt9DW5DF5cCKqLuX+PvWTPAxnAc8k8570pLQFO7KosPtDBgSSPugCuV1GEan4h+z4Zbe0wTv/veldR4h1H+xLdXH+tcYjQHkmsjT4ilrumJa4nO+V265PapXurUz5XUnboWzIrjy1X7v8VQ7hA/OeemO1SRoEYKWzmqOrX0elzrLKu9AMhP71Szq0im2Jrl7DDYym4k8tAuQV6k9hXIaRpsuoTrcXuRbg/ImPvVqabbNrutPqOoKqQMcrEvTA9q6KKCN32p8qdAMdKqU7e6tzlhT9tP2k9lsXtxNsiqm2MKFAHTFRTsv2cIow2eMU2J3NuUJwAfzpsjbYi3ORSudDSW5kaxLB9qt4GLEE7pMD7p9aXSI1a7klfGMkBjVeEtKbvUDsPzeWgPWtmx0u7bS/tSJkE5yO1Lm7HNGPPPmZbC4kCqQciiixRmky/DdDRWqbZq0cONLkurC4vLtsSspKg/wiovAD+Utwp+9uxmtXxRdC30eZE4yMYrC8GMvlyMG59K6Kmlu55aio1oo7G4IkBHWsOBza3ckPG0nK1q7j68Vm6lGVaOYDODzUTaaOuUbWaNBA2Ac4HpV+12tg4x261TR0MSEc5Aqe2YIOTzUReps1odZFewwxqsQPTkGoLyUh1mDDJ54rEF0ARzx6VJukl7YXPFb+0VrGap6jNauW+zzTvhVVcn3rnPB9qZTPeyqC0jZBPYUeMbv5YrJGOZWAbHpWvZ+Va2UaQfMqqAMjms5yTaRNuapboiwX3zbEHQ/nWP4mkllhEMWeozgVtRYjRTj5upNQtbvNLv24ArGTutDe11ZmRpNq0aI0o56dK6e1GBwMYH51Bb2vzZOa1beONYmLAZHQZ70U4curLemiGDkE9sZFWLe6iRCkyHpwRUEZLEgjC0lzbEsQnBx1q35CstmK08QjkVYgzE8N3rPjMgmyPu96exVG2k8jtVyMfuASOT1rNamtlEVJCF5wPemyRkkvv3gnGc1bgsGuQVBUBeSSapmN4ZCF5TNN3ZGjZWdG34K5Y9aIsox+UlQeuOlbJt1MRcA9M/Wq9pEzOCQVyeR2p8gKSRBHGSWbGM1JJCSTt57itRoUhlIByvrTliUsMA5quQlz6mLJG2DlelOQDgAHd710H2BHTcGOT1oOk/vC4XOBUqAOqjFMLFejHvUF+i/ZjujZs10gtSqK8gATOOvNQz2u4BgAUzTcQhUVzmmuVjhWNF5x901oWlkphVl2hjzkHioHtF+0vlDj36mtPTVZUKyDAHQGiK6M2qNWvErLYMsmdwI7UhjZJMMGwehFa3TvwP1pDCzYYgBB83Wm4JmKqPqUVVd6x3ABR/WrsFm1qd1o4dMco/P5U+5QFFUfMM4FamhD97sxlV+8vehR1syZ1LR5jFltr8wljGqcfdzVGC9ljukt5YihboeteiXVsWhnYRHGRgZ6D3riNdQRPFJgbg+AVonDl1ChWVXRo0Yo1dTk7ia24fDM0lks0ksUSuu5NzY3Vlafex24LSwJKHXHzHp71J9pdyYkZ/K6hSeKS7sxnzt+6Zt4/2ZZGA+76d6xbmJjbxz7CJgdzY710U9qbp1VlOwc4FJNajYyjA4pOLNqdSz1MuMLOgdSckVofa3WAqSXym0g9hUen27yp5cMbN9Bz9ar3iOFIPC8j61GxcrOVijJbedGVbHX5cUPauE37eBkfQVZg/1YB4cc49KlY5QgtgZ6A8UIJN3Ml3HlHYMHFZ+kAJPI+Pmc+tbv8AZm52kwN2PXiqkemv5rK/AHJ20rA7NonvljGmzCd8KVOCe1Y+j63B9nEVxuBXhWx1FTC0uNUuWtVci3U/Me5q7HoMUR8rbmIfeGOTUNSbVjoTgo8snqWbQiQb0IbPoe1KwWS6Qp/CeTSw6LPbo6aeryO/CrySB6AVo6bYGCEG5XbJn5lPUVor7Mxcoq7TJ5AUiU4256VQm2RxPPK6hV+Zj6CujsZIZLWeN4Q87Dgn+ADvXI6vZXOrmSxtRhFGZSO/sKvm0ORS3bOMaV9Z1d9VnyLS3O2FSOvvWtAPMjLEE55rX8Q6MdP0T7PEoQoBkdKz28u2sEZ+uABjufSsp35jroqMYcxmahP9lQSbckdBWbBpt34hD3LxOYIFzI/97ngAelbp0LVJo/tc8EkdrN8oJXhvat22vIrDSpbKCIiac/MxPCqOwpp8uhjK9V36GHolvbxGZriBmVIiI1XjDdqW2jKWUrlcA1vqiRaTIzIAScBu5qXQNPbUIpMRGZU42g4BpRjY3dRJNvY52wj3wsWAIHTFVNVUpbtGgJmnby419WNdTd6ebOaWJ4PIPGF3ZrmdOuY7zxpCGXzIrMk+g3U2rGNSpdOxX1rQZdAksdPlUfaWhDuB6mur0TRNQaGPeJVgbGD25qzpcS+JPF73F82IxhAAM8D0r2gpbRWUUMUafZ0Hccn0q4wUpHDUxUqMVFLVniGp6ZJp+qPDneQMhgOtFbuuvHd6vIyxtFtGGy3JorblXQ3jVdlc8D8YyE2qL3c/nWf4Y/cOrE/f+WrPiSXz9RjiXnauah02NhYuw6q2aVR2RyW5q3N2Ot8zaByPes/U70yZjQZ9ajhnJtwTzkdKs21oroZCM561zSm5OyPTS0uV4J3WILGCfX2q/bSs6AE/MeOO9QLYSeYSjbQavQwNAoByT3NRBSTdzRtcqLVtCx+9k4q7KwEZK5IApIMCI4yRTJo3aLYoOSa6YmMpHKPA1zrLTSfMqHABFbmnYlmzzsQ4HPWkksXgBYnljirllEIAiAfN3NZuL5+YKcUou3U1o4FkUHAH1qaSFY4+CDSRsFhwoBOec01pcjgDPpW/MkKzGKwUfKM+9KHbcoYYzzxT41DOCBgY6e9aVnprXJ+UKAByW6UrX0Q3Ll3HPb2yaers4Mj9FUdKzLl2ihYsfmPFdLZ28i2zw+R5yqcB15x9aoLa273oF4G+zqcuF4zTcbLQVOfVmTptspKtNyTycity204XEoWFSF9cdBUiwW01432Enyc4VX6gV3Ph/TTp0Kzy4ZW6hRkge9VGFtGZV8Qoq5xmoac9ooSAKdwyTnrVNIVQDaAXIw64+7XpF/pMN5C8sMaBmX5QDkg1jS+HpWtnlk8tCi4bnr/9ercOxjTxUba7nFx/uXZWztzwKuxRr1kUj8Kr6hZyWzELIORkUumXO1yjrudTlT1qdtGdclzLmiTzxrtPJB7UllBKw+5uAHWrN+bm7mDxxAtnkKMAVZ0RI7W8LasCIjz8uTj8KUtyHK0PMn06xViwLrkDJyavtbgKWRBtAyM1QuYrN78fYLnzbUHIIGCPqKmjla4uDhnCA4x2NUYSTepBdaZJNatJCBnrg9/fFc5cX7Rq1u4+7x0/WvTdAmEkrYgAA6Z5/SuX8b+GGtJ1v45N0cr5ZMY20pRvqisNiI+05KnyOTtoHX5yd+4ZHPSr3GzIU5IpVIRiY2Ru3y0pQfKTkAjoDWR2y1epnxNcIS4JZQeRVuG5ilPzk56be+KmKAR/IuPXmqGpxqsIlQbWU4oQ1absaiNA29WBIA+XPXNXNOv7ax2M8TeeCQ7E5BFYCTH5MsMYqRZFe5j8x8RucFuu33o5uxnKjdWZ3M/iWK6kWO0t2BK4YkZFc5q2nX1xEbixtmnihkySF4rW8J2dxBc3cthJHcwIhJLcEr3rQuPE32WzNtZNlCuDlMYPp71d3JanJF+yqWpK5xg3eaoYKH67em010Ascoj2jLPEoAdkGAGPauTFzL9tkN0dzyNkN612/h6cMI4baHBl+SRmOVz6gdqyg1zWOjEqUEpFe5Q2bNFMoWUfw56VQlfzk2noPSrOswG31GWKWYOyH7wOcis65vVt4mBIxjggVbepFKN7NDdKeUQSeTIYyCVyOtVXSQxt5hyV7Hv71e0IMlupIyXJJyKlljZp5BxtboSKlptGrlabTMyaHdCkhABPU1aS3s/PiRpJGiYDJA5B9KfPbhVMbdVHrWXMJkkUAZIOAR296l6IS97qaCSiGXCASdRhuaiu2S3tHkOM45NMjjkRS+ctjpisnWbxrgNEi8JgsD2ovpqXSp80tDT0K2Edt5gAy/OfWtaKNRNGZAxTPO0c1R05w1jC0bLt2gEVrafeLaypMFDOrBgW5H0xS3RlVvd2O28O22li9he0ilEpJ+Zh93A6GuU8VRhdcuFwqoDkADqa27HxLLdagcCNIuXCjgBsVheJLi3vL1J4DJ5rL+9yeN3tWl9DhoQnGpeXYxJLmRWdbdQj7cZJ61u+AdIjGpbmn/f8AXpnNczdo5mCIfmPOa0dLmlt5hJuZWUcduaiyudVWPNDTqSeObVoprmKeQMWJ+b1/CsnQdNgmtUurpS4hB2nHBNXdYaXU5JZJDvPXNT+HoZpNFnQoYWU5CY+8M9aqS99McbqjZvax2Xha5t9S0g2l1GGESEpu6D8K5PT/AA1Fqfi+SIMPJBJYjtXT2GnvFos19bqEmA24I6Vk+Ep57S9muEXdI+Rj1JokrqzOSnJw55U2a3iTwxZw2HlwyDIOfrXJeGoDbao8FtHuLcgZ6mtzxdeXBVBcK8TEYwDwaq+CZCmqvdSjEdvGWY+lEkloiqcpxoNydzjfidfXFlcyRhWe/uDsiXHI9/pXNWOkS2djGkJZpnO6V8dT3rq5rxtd8Xz63eQ5Utst0bgKo4ziu91TSIZraHUdJhjWOOL98pGMk+3espw520mbRrey5VNHnGgzTafciWMYI9O9dpDrdzKNrSnDcADtXMXljcQyElGw5JDYwKmRCka5JGBjcTV05OJdSEZ+8WpBEZrlp2LSMR9SKKz7WQF52RTI4GOT0oq+YiSSdjwoNHJrFzK3zbRgVJpayM0kYGFc8UzSo/MluJf7zV19nHZf2cUKlbgdGqZrnbsTQWqkzEtrUkMhYqyGtjToiqhQSR65qm0Xl3PX73StawhxIDgkA9KyjDllc7VK8bGjbW6bMsBn1pzwAtgdG61et9PeaN2TaoUZOTUBQITjntzXRtqRvsEcagKqgnHrVny8xlscdyO1MhUlc4INPuDIsbKnCkc+9DnZNonluzLunSe7RVY7EplxGVkVgML3PpVby3SQnBDZ5NaqQia0w/GRXDQxLqVHGR1+zjBXQ22YvgLk571djiAB3YU4781m6YQk3lMxOD8prpLrTp7W1juHRmgOCWA9feuqCuZytF2ZRRF3h+SK2IWlliAjjKoMAkf1rLc2z3CNE0ioWGQea6u216007TpLeG3LyOwYO/f2IraG9jCrfSyK0NxNYE+W7RA8MvZq67RL7R7YRo1oZzMvzibGQfauUJl8Q3wS3jVZCM7AcDNZN1Bc2100Uu4NG2D83THpVswlRVRWejPStZ0G0a3Oo6XCiKvJh6HPfFWfDV7A8IVJFZyOVYYOfSsvwd4hF20Ntf8AlgwriMn+L61pWGltMtzdwW0aSxzE/K/BHfApp3R59RNRcKvTYp6qsgvjNZq8cCuBM6noK6w2wjsDMmJomG9lKj5hiszULGBbyMTFzYTrmRIudre9ZVlqeo20ssFuftGkxsY1J64pt63JadVLlexk+KdHTZb3VvBLiYEkAZX8Kk8L+HrW5mdmDNIDjHTaa7fRPJijUOsiSKSVRxkYNb0UUG7zI4grNz0xUy1dxTxk4x5DnItChgHyweYD1XFc14o0NL2eL+zxHGG4dc9MdzXoV5IUibyhISv3tg5rn5otPe1kktmWWVslwz7WBqvIihWmpc1zgJNPltr1U0+Pa5GxmHIJ9auG1m0a5t5JICNw5V+ma6KzMVv9lcFdxY7o29PrU2ra7bT+Yn2KSXJwrFflxU6I7HiJydraHOHVZre4nlswiMq845BHtUGoa9Lr1k1q1rg4wHHUU+a6trSRVQt5TkkpjpWsDpS2UE/2iOKV0wVHRh/jU82trmvuxtLlPPILN4kky48yNiNpPUVJboCVZzlQc5PatjXFsF3/AGJXZu0h6VhW7xkYZsH1rKbUXoehFuorlq98syEQNuTGSelZt4huLUjaQzdBmrcCD5mLYwcADvV61ghniljKjzW+4xOABUcxXwbHKJFIYxuzvTqO5qxJny9y8Njp6065tprSV3Rg6DqKihmWeRV+6cfxdRUN2R076o29C1ue0UG3YqCDux1+hqvc3IlmKjIcnJAPaoHszCweNjtYfhSWtpJcXm1mCZU4Jzg0+d2sZezhFuQy4QPE2CWccrgd62fAviCK2uZrnUycFdqIi/xdOadYaPOgS5V0aIsRuXnafeucv7Saw1BriDEjLIC4B+U07NaodqdaLpnU6rdW9xqEjxltp7OOc1i6yqeZau5GzeM5qLWtfn1nU47rZHE6IF2RjAwKkZ4722aNz279qpyUmKnSdNJs6G2dTGNp4xxipY2BBziuZ8OTMqS2srs0kbfKfVa3l5AzgZrSnJOJzVaThJoS6jU9/oahMC7DtIHqafcFghCt04+tRbn2HngU3YUYsfbNFDITdRs0YHzAHBP41lvZw3DzO0ZAfkY/rUF7dzu0saDEaD5jV+yffax8Y4HPeounobxg6fvJmbohe1mktZMnbzGT3rXZGYZA7ZJBqG6TYTNH/rF6e9Ot5fN2HoMVntoEvefMW7ZwoPGGHINLJJli2ACahxmcRggkDOTSXDbTyBjdyB9KtGPLqVhdRiWUyMCB+laWktbXQkMkmMoShB4B96xQqPdS7iqoV5HrVXTYtl5cRJkRZ4xS5rG0qSlHsb93KkNo8it90Hp3q7oV2jQCbLf6sAAjGDXOXNp+8iR5W8tj909K1xtgi2qQAOMAU23cynBKKXc9DsNRRvDVyszgnBPB61V8FaZFNHJcSOVQjCduTXKWc8wszIDmAfeH96op9R8yIJDNNGqnKpkgZqr33PP+rOzjF7l3x1OHmMe9t8RwM+lYnhnV/s76lHIcpLFsGfWpL9/Ohj353kZLHuayoYwu4YwM8H0pVH1OqNNez5GXLf8AdygTqCvbtXoXh24m1G3TTYmQwLySDyRXnNyrGDuTilsry4s3EtvI8b4wNpxURYq1H2i03PW9f06H7NDCgVtvHXnJ7VxWvaObadIFEZdlHH92pPCfidbNpJ79XnkJ+XJzzW5PaR6tpF9q05dGGWj2/wAJrVNS2OKKnQlyyeh5Zqcn9mC4G/yrp2CRpjO40U7S41/4Sc3+qqJoIV/crnO4+tFZ3fQ7pOz1jc8p8K2sTWxaUEE5Nb0NoA+Ryvam2kEUJQQn5Mcitqwh811RCFJHetLDhHlikzF1C0lYx+WnzDv2rT06Jo8eaBvHWtix0qW9u1tkYBi2MnpXYaH8N7u5uJI5nEYXox6GpVN81xzxFOC95nJ28D3GFizk/rWrqfhW5sraGeaB0VgOnP416V4T8J/2a1wHSGTt8wzj6VL4g025edDCrXKEY8snpW8Yp6M4XjFz2jsea6f4fubgL5MZkzxlen41fuvDlzbfufIzMBk+4rtdBe10+SZL4/YieQR61y/jLxIl/dj7PLgxDZ5icFqORLcqFarUnZLQ891a38qQ71wSTnis8TlFZQcgjArT1edGRi/zsawXUtg9F9jXg4j91W5onvUE5Q942tHaK1g8wiOVnGNp7VuJrLy6RNYyzT7GOY0HI/GuUtowgwM57GtW0PKiQEY7gda7aGJUloZ1aSvdlSVJovlUkoTnJWpxcsq4lVgQK9At9O0b/hHgdQuXWXbuiUEGuHvIlyVj5Unjjmt5XS5jKnWVXS1rFjTTJczbrRmjkRcnLYz9K0rkoETJzM2d+TnmsfTUeNlPPB5Irdl0aSO1jvQ6uknTnn8a0hPQiaipXYum2LNcx+W33/7p5roI55NHvMxXibZBtYPzj8K5iG9+yEAKQ+eDXZ6XbaRfWkKakyoznd5xblfari7nNX933pbHQeGr6+l06Q2gtbgJksc/NXN63qltFG8dpFLBdyEiZc5Q/hWdeSrol+w0m8LRA8Mp4NZF1cNc3Ek07biTyRxmk520e5jSwq5+foeo+HGFvpNrdm7R0YBZA/UVv6nq1tYwCYSxvxwA3avDm1CTyfLErCPP3R0zTvt0hiwWJb0pKpbQh5bzS5mz1K08Zwk3G+LJHIINcNd38h1VrmLCbnzjsPrXPWd4yXciN91q0JJN0Z24Gec0nU5lodMcHCi/d6no82gW3/CPm5nnZpim8Hd8vPatTw+9pFo0LyywBVHIbHFeRSatctbJE1xIyLwFJqOW6lfam4hTwaSqLRnO8BNxtKXU6jxvfabeXTm0T5gAFePge+a5W6kgiMaQlyWHPsaUIu7apJB681DdssLo7HKjrx0rKc3ud9GlGC5VqMhEqOTlsHoPSlsLAXN8sY4BbBzTvtkSqHGCKZBMdxlBI9MHFcbq66GzUmtNDU8R2UVtelbdoygUDEZyDWZanDnPKgcgdaf56srPJwo9aqQz4LFB8uetVKqnK6FCLULM0CisBzw3asjVrbDpLDgMrc4FWnumV9rqMnkGqGsX6xxAE4JHPNU6qehpThNS0NPT4jOjgxyyDHykZwPetybxE1qLCGKGELbqVaUR8kHrnNZ/gC9uXik8mVURwVkVjjI9qm1K2t/tBTLMzNkNnj8a1pt8t4mFRJ1XGa2Oq0PV4rfwvdxLAn75iQ25ec+o7VwOpxRqTt3Nu9q2TYRwQCSO4R2zhkHX6/Sqk0OcjIJzWkpS5bMihCNOblHqc8LXYSYVBwOT6U2SDIDLw46EGtoWn3sqOehqldQSWwyqgpn8qzTtqd0anNoZmjM51eWQA7cYb3NdGbjBG3kH2rmbK6FveyjOELZIrRW+z91ST2JqoTSKr03KVzRluCMBjz1xTZLwRxgkgr3BqpJOog3EZLcc+tUI/MuD/sKcYI6mqc7bGUaSepqbke2kIGN+aXT2xZrlxkcVVjDcIQdpGcVWikSC4eLBx1FLnKUOZWRrPO3lNxuzwPYUsYKRrxxVe1jKNukY89M1edwqFiDWfM2zKStohqHY+QMlj3p0rB2UY574pInyobAqMNskYoCQeSa2Urk21Kl9Z/vln3sE6MAcVo20EUZHlcg889TVO/OLOQ5GMfrTdNmdbePdydoyaOpUk3DcsaqwEKsMjaw69qQzGWLPcYFR6m/mWkmPqKr2UyvEuTnjkUm/eEoe4jZtLvMJhmLMmeMUTN5avIAc9gR1rOtJP37IeB2zVi7uRtKAkn0p30M+RqWhKz+bEh2ADg8VHJbsJWbgDOcDvS2NzHaWwtzGHbduaRjxzRdz9BHz6+lC13J5WmSOm6P5OuPWo/I2xqzfjmqiXThxEeHJ4qe4l+XbuYk9qLg4NFUXAinLp8vJ6c1eu9d1K7sBpaTlLaU7WxxxWddxeUqsgOe9LbkMPnHPUmhOzuE4KS11LElvb2MEcUTuZB1J6YoqxYWr6hdLDCjSbu2OlFNXZlKpCDtJ6l6T4bQpoIvYhLC8abmVuc1ymjXcel6xDPPEs0aHBUV7X491KNNIEKpMitjcV4BFeEarGiXr+WHVM5AYc12OKUL9TmwkpVovnPTfDOoaVf66Z4o0gVmyEYcV6rHcW0VwkKtGWYZGD0rw+GLSrLw/a3kN0klxuG6InBFdZHraBbW7jgiSGVdh2NlvrUrXU5MRh+Z3jsdnqOo21ndpDFMu6ZvmQHv9aj17V7e0shLG6pOh+761j3Hg6G7s2vYLqQSlNy55rzM+fdawtlLcMpzt3OeBQ31JoYaFTVPbc7G1tbjxTd3RjCBSM5JwAayfEHgi503TJbt2RijcgelI+py+FZ3to5g+erRtnIrJ8UeNLu+sBZQMRE3Ut1P1qKk1HWex6FKnW517P4Tg9QnLyMo+72rc8IXuiW1rex61YPcySL+5ZT901z7xtIe2R61ZhjIUZHSvAm5SnzWPcnGLhy3J1Cb28pcRk/KD1FbegWT399DAhwXOPpWRarub8a27fNqqyRMQ6nII4xXTh6bWrOaq9LR3Og8SaEumapDYRybwwHXsTWh4k8E/YdMiuoSxG0eZXJPfTTXCzySM0mc/Mcmu0k8WXV7ov2KdEZNoBbviu+Li5eVjz6sa1PkafqcbbwGIjPft2NXFLMu3cSAOBSsoIO3gE8Uhj8tCyk5PrSSa2Nr8xTOPNbI796FmdcqDhe1NkcBiRiopJNg3KMih6HQkTNIWOxzgDnPrT3KeUQjDp1rLuZAUUg4bvzVV5ZPLZVchcVKdilC5oeYQgCDI/lTklVc4b5hzzWQl4VyrHvSy3PPyseRzijmRpyMmuLvZc+Yg47kVoW2oRyBfn6diK52aQpli34VLY3IVSCOSc5NZ8+ppKmmjo5pN8Rwck9Kal0ijy2Yq5HNZIvG6c4J61FPOhkV3JzjFVKXUj2XRnS2t0jg/NkgVDczblPJOf4axhODwrYXjpUizjYQH5Hc1MpXVhKmk7ouxqpJbadw7UxpOoDYI6iqssreV8kip0PvVXcw3Eykse1cNSDTvE0Ub6ssXtxI0flxknAzwat6bPGbcEn5sYxWdCMxsA2XIPFR2zGLmT5T2FRyNalOKceU2JWBYPj5h2rP1CJZJ03Bdh5YGkN5hsKCfegSAyBpD9Ket7BBOLuX4THDDtj+X0wao2N6Wv50MhZR0zUjSBiuD+frWDBIYNblil4znDDoRWvNKKsVTgpXud9aSDYjtuK98HrVpWDN82R2rndNmmSQq0oMQ5XFbAmUx538+tdUJcyOOpTsyw8iq2EOQOuao3znySu3Jb36VXe9Cklx9aq3NyJYxjlz71WhVOk00UY4o/tzkAbjxmtiCGJXBYdB0rH05V8593BHvmtVnDSbYyQ2B1qTorXvYs3aRNEojUfQc5/CnwWyrGoAzgZ4FMt12k9QMcGtNLhWgVQqBkGMjgn61SVzknJrRGZeqEhduMAdO9ZwhVYUm/iB5q5qcjGQRxgNkVSMcs8jR4KrjJ9qmSN6a01NhYwYRIwBTrVOaR5CUXdsPtVnT5AitAX3Mo4FNmUibcMEZ496l7GXwtpkkYEaBTznoDU8SxuzA9McEGrnmWx09YzCBcA8ODyfrXPz3bCV41GX6ZzVKTSRnCLqXHXEBnuPJDfIDk+9WxEscZ44ximRkQwq5IJ6Gp4ypiPBCnp71smVK9jPvkU2b54G2s/T42NshDbfr3FXtVytu6nhSOD70acji3RSg4HaofxGq92BDLIYY96jBHc96ntIm2h5PmZxknPApt5sEeZF3DOOv3antV3IAB8oIAprcmXwkhjBwcdaCigbUyRVmNflOeDn86hnbZ1OGPQVZgVZYyrIV555+lXVjUEEelU1ZiPnzkHIx/KrQZW6DA60kErkkm2RNrAEniqVwAisoUZGB1qYFix2j8uKbMcIW4yOvFUyUrM2vCGujR7xnKBldcc8kUVgYwVbJz70U4uxz1MLGrLmZ0d740W+1F/NXEAH7tScjPrTX8FXms2S6o0yAPkhR6Vwl8yC6eSEhhnOK7Pwf4oWeKO2vp5I4kPUNgV1SnrZ7Gc6UqUVKl8x1j8OLq+EpWXaq/d3jkmtLTfDn9g3cD60wS2TOxxyDXSX3ie20eD7RDex3AK5WIkZ/GvJ/Eniu/wBcupDNIRCG+SMfdFJ2jqyKCr4i6lpE7zxL47itrd4dFkfBGCe2K8wu7ySaXzFyWY5yTVEPIzkMeParMETHkP8AnWLnzaHo0MPCgrRF+0M53yM28HvTWyzEk5HYGpDGGP7wDOODStGSgI4x3rCoro306FTpnKnmp1SRkGBgmpfIOASwzTy22PnAArmgk3Ybk2OgV0AzwQOtWHuEVMHO4+9VBKpQEsRj3qjNOVnDFcjpWyaigULmpBc5lAxxita3ul+XaTn0rnIZTISVzitC3kG4cgY96cd7k1IX6G75hOGX8qrXd0QrIv51UFyoPJ6+9ULy6GfUCtHNJGUKTuWSQBknI9CahmueCAPpz1rPN2dpy2OaglvI1JJOD9aydRHRy2LUrnYQ2ef0qq0hCgE9qz7jVU2tglvwrOm1V2+6oziocmy1OKNt5xuIAPFRvcjcMYGK51r25kyM7RUDNM3V2/Ops+ovbwR001wpXl1Bpi3UKgfvQK5Zt54LH86Zhz0JzT5fMh4uy0R1i6lEgIZg1Ry6xb8AtnHrXNIj/wAXeneSS1NU0zN4qXRG8NYt89Wp66zaADcXGetc80Jxzn6UxoCFzmnyIn6zM6ca7ZAlvmJ6cipBr1my43H64ri3Q5I5qIo+7gGl7OIvrUzuU1m0BHlyVOmqWpIHmA/U1wiAg4binA7c4NS4I0WJfY9BS6t2AHmKR2G6phMjn5XXr0zXmLzurEAmnxXTgArI2fTJpezKWJXY9N3k4B5A9aVoEkdJnUblGM5rz6HUrtc4mbjtVtNavQf9aTS5C/brod5CUTIOQccDPWhrtgpALcdBXHRa5c4+fBxViPWzj5owW9c9Keq2LU4vU6o3G6LBOarNeEZTB2iscarHImDwR70nml9zRuoH1pOT6m0Ixepfe7ETEx43Hr2rTsbhmw55981gxgqoLjfu61fguFVdpGwGkpGk4po6aO7BZVPB61Y89Q/yqORkkd65f7UQQqEVMty6YywJ7jPat4zRySoG3I4D5Kg5560sTqwZh175NZD3hZCCB7Yqpb3j7yCSV7DNDmio0m0bd0PK/eR9ehxU9tL5wycgD09azIrsFWDrkA8CrjYMQ8skHPajdkyj0Zd84ohZmBCjFVl8qQ7l4bOc1lajcMGWLdnPJqzA0YiyMZPApqzYez5Vc0ig8tlYg1LBwqkruUDpVJspsJycDOKsRy7n+XIp+ZjJaWKtxBLc3WJeIlbOBW1pM1nCXW8hMiFSF2nofeqalWkxnrxmpGXa5zyR096nm94icuZcrKt7GrJLgYBPGO9R6dLui2sdu04NWnbcQp+6DzVOIol7MqcKTkZq7lxbcbGmrYPzZ2+orNvXeWf5DlR1JqW7mYBUU5bGMU2KNthVu/UU2+gklHVkduCxO/IB6E9asqrB+cgds96fDFsTg8d6mJ+T5hznpUpkSeugwZ6KvzEZqrdrJMNiDGcY9c1a8l7maKKPguwUZ6c0+5is4dVaGSWY26fI0i4DbuhIHpmtG9DNOzK0i+SxinUpKnyshHIPvRTdRgax1CaKV97Icb/73oaKnmsWtVcfbab4el8OvK168eoj+EmuRO2Fm8tiRnqKHVickimFCSAM1dSaslYdOHLfW5bWQuvckDHNEEWFLEe/FLBGwU1Yj/dvtbgGnF8xe2xDEi4HGOO9ThSF2r9088VNGibcHGc1GzpG3GcdqBXZGS4b5sHFSKnzHuG7moy4yGc8ntTixbhOgrMoc3GcA57VWu8kDP3cZqViWBGSGByarzfOw6Y7ZqJNIpKxWYbcAE49aGLMuRg4/KiWYKSWYYxVZrjK4SsHUWxfMkiZbhlU4wB0yKjlvxA2CwJqlKJSRg4HtVJ4CWzy3PNT7R9BOpzbI0X1ZycITknrVaW6uJG+8RmnQW+R935cVbitwRn8jSvNmTkzPKytjliKQwMflJ69M1uRWhYDofwqUaaWcdvarip9jKUrbs5o2bMDhTTBYsDnFdimlHgKO/NPk0wIudvvV8shKornIeQIweCfaq8i5bAWupuokiRi6fiBWSCjSE7cipatqdFOPMrmSYMjpUltYPICQMbfWtcMhB+TA+lSwTAHG3ApqY5UzJayYDoBinJYklcDJrRmcK5XIOelX7QKF/eAbsdaOfUzdJpXMZrB84xxj0qGSwycDmundkZdqfjinRwBgCBkgY6VfMRy23OUGjN95hwfSpf7KULjaSD7V1zadLKBjj2FCaaYlO/kjvT5hcyOEuNOzwOOKzpbVk6rXobaaJM5HBrOm0sBjhMipbZceV6M4ZrfcDUbWpUcGuuOisJMlcKarS6UeQOlCkV7NdDlSGRjkGrkIJAJHFaUumgZXByKriNo3244FFxezsIFLrnGDTgrIcH7vqKsrGCo7N3qRIjwhHHrQ7FqJAihjjnmpxE6nr+tTLZ4wVOanjgOORx/OosPYrrNMmADwOtSC6kYkvz9KkMLAFiOhqN4uORjvmiyLjUkgF0QSQxBNPivtvytnnvmqrgdzUUiZBP5UrLoaKtJbm1HqQ8oAMODii1lBmLZypPTNc+c428g05JmjOASPelymirLqdtAc4+bjt2q4JTgqMk+tcRDqU6MMOG9jWvZ6ypOJ3Kk96pNxJdnrc1boAz+a33iOafbTgSEADaBmm2dpFqZCQ30G8nADtitPWvCWqaMkcsirJAR9+Nsimm9wdSHwt6hHOhQNI2OMCklnKuipjPGTms6SN44t7coO1Zs8zSXXzbgMZFXz2RMaSbOojm3yZyAx6+lTSzCPBYjP1rEsZlRAZDgjnnvTZ77LDZ94npU31uT7K8rG3Exkc4z83c1XLK90UA+51NUmuJfs5+bbnv61QttQCSSFjlx61XMVGk7No3YRuuW9h1NX4XRTgnJ681g6bcSys7SDYM5A68VoRFwcsCc/hS5jGrHWzNlduAUGB/Oo5VbzSe1RJKSTzxUiuxznnPWtUc1mmKqt5ieUW35yuPXtituWCcyedc2Gmfa+pd5wMn1K+tYtpOsN3G+7aquDuI6c1Y1b+yriWV11PaXYnBhLHn3qrmc05SS/wA/0MfWpJBcTi4dWlLZdlOQWPoaKqXNmRcBElM0Qb5X243D1x2orGTbZ2wUUrFBokVSD29qqxxPLJkZwOmK0rgAdRwKrKwUct19K1mrmMW2rk0SEKBnBPSopyFcKTz6mpASMKrHaaZKy5+Ycj1q7JIcdwL9cenTPWoZJNvzA4NRySFmICkjHaorm8QIFKhWx171DnoaWsaFuLZ4nknmKOPujHWrdvpt9Pb+csTCEDhjxkVyhvsPlRk9K1zr2p3kCWxmZIRwFTjilGSfxGU5OPwjJ7ny5ShO5+lV5JJZD2A7Vaj0qU7XZHGe5HWtCOyC4UryKhwciJVjBNq3Vhk1ZgtMqCR8vrW+logQHHOO4qIwFSTgemKXsEtWR7W5mfY1K7gKSOyz91eMVrMo2sMYpIYuTtAB/nWnKkhqbsZv2LbGX/hA7GooVCScg4PY+lbksBjhO0AZ7VmpC0pKoMEHrUSdi4SUlqSxJ/dOOelaUaA4zgGo7a0cY3HGa0ILfIOeo6U4MwqNdCNVGOBmlePIJyM08oyk8cAdBUbudoLYAFVKREVfY5+/3yXZiIG0njIplppapJmQk/Wrd/LFI2VzvB6gVVhmdJCZCcdsmuZvU9GN+XQsSWUYXgAD3rJmtQbkADjPStqGQ3GQoxxxViCxUNvcc0S12JU3Dc56/wBPwFdBtxwKsw2m+NCzfN7Vs3sGYiByBzmqMMblgAOKi1mUpucbli1sVC5IBHcitS0giAGQOegpbaEKgDc8VfgixyFzWqOGpUbbIxACBgUyaBSvOa0UQ4GRgnrTHTHB71sYKTMfyAH68EUslpGVHC896vSwkMWHGBxTXXKNkZOam9jXmZRW1ixngntVW4sY2P3FNacNvheemfrTniIOcYq9Gg52nuchqWnDBYJjHU1zN7bAPxwfSvSru3zGxI6iuRbS2nvSOduefapcTtozUlqYsULBOQKsxwpKMNwfUV1MWiARgbc4HekOgnkAEe+KzasP2se5z0UJhfBJKnoKn2Jgnla1X0eSM7SSV7Gqd5pskI3ckDtRbm1RSlGRRljJHy9PSmGHK44x71MpcYIXk02eYJ/DjjNHL1K5exQu4to5qk54xmtCedJOhP41nzEBgPapbNIwfUjbJ7dKhI56H3qyCrcfzp6xgnlhRzIfIVUX5uQKsCIFRgZ/SnBcHoCatQQMxzgsPamRJWRVjUod2SCPwrSXVL1ohFJdzGPpgucVEYhk7jz9KaYQAMZPfNNNrQzevQt/2hdeWVEpK8fKaZFfuhDEc9OlVc4/HvSsgYjHHvQ0mXGbRfjv97lmIOf0rXsL7Smg2XMLeZ2dT0rk2h5HXNRMGQ/LkGos0W58x3WqRWLwK2n3XnnA/dkYIrCTT5Y5t12jK/Xaw7ViRXc0EodWJI71sw+I7iQx/a0EoUcZ4NVdSeo41OVWNaydd4GfwA4rSnuAdu3CovBNZc2sWF3GjRWgtp+MlT8pqSGTzX+XkHtRazIdp6mpZ3Bll/drkdOtaDPsyCBn0FYVrMkG8IOc81q204kUMw5HIrWLtuYzh16EtpfXVnHIYTGA7birIH/nU1rrV80xEggxjI/cLVN1VpSSSBnt0qDzla6AjP7sfe71XM7kckXfQuXUjzXTSPjzHOSFGBRVqX7JjdbGZkJ6uADj8KKTi3qSpI5OeXehEZzVJt38LcilchcheBVK5voYEO5hu9quRUdC+J2RQd3T1qrfammAGOGxgBawLzV5JiywgqBVJCXYFyWasm2w5kjcGrTrkRAAH1FV03yOWbO48+vNV4EeQ4VSQK9X+Hvw5m1iFLu6YR259+TTjHm0RlVrRprmkzjNF0W51CZY7eKR3PoK9l8HfD+10+JbnVyGYc7G6CuiMOi+DbI4VFcdh941wOv+L7jVJGSJjHB2Qd66I0VD3pHmTr1cTpTVo9zpPGlxYPB9msYUYJ1ZQK8+IHBwRjmtaLVA1i0Ij+bGM1n+WXODnPWqnJNIdKPs1ysjUd+/vTREWb3PrV6OAAjpxUhgBYYAzWDkac6MW6jO3IB49Kns4wVxVu5tjg9dw71HZkqxDKMg49qlnQp3joPkjAjJYc46mqOnqvmuSQST0rYIDZLcisicrHe/uxgUpKyuFN8yaNSOIEkkds1P5ITDD+dV4ZgSPm61ZC5PPzD6042MZXW4GNW6r16mq13a5jIGOnBq+cBMngduablWTJ5qnqEZ21OUjTYzRuuW6dKq6nDlB5anJ9BW9sT+0CCN2e1X/s0bJjaNw7GuZQvc9B1+RpnK6XIQoXacgcgitbJ+8x+XHpUd3b/ZrhZF6DtV63eOaPIGeMGmo9B1JKXvJFLa05ITKg8HNTQ2AR1NTwIEm2MeK0UVTt+XGOBRyGE6nLohsUG3B4FWkXlcACpFTK9OtTRxcAVqos45zuMK4HA5PrUbJ6jFWQuG5pspUFeCfaqcTNMptGSD6GoTb4xWjt5yBwexqKSMlsj7tS46XNFU6EIiWNODSPFnoMmrZGdoAyKXyyuOOvX3q1GxnzmbNbExnpj0rHt7IpdbpBwT9K69ovlzgYx2qlPaBjnjPatbaGkK2jTK/wBnAAI/CjyQCN2c+oqxDC4wCckc1I6fNkDkVhKnfUnmKhtwFwVBH51Tu7RGjZQgNauOPQVRmOXOOMdjWTTjsaU5tO5xuo2wgk2jnPaqk0EbkAlc966S9ELSnzFywGAfSud1OBJH+QhTUqT6nr0p81jJubZPMYIRkdBVKS04+brU1vHNHclj8x96t3O8puMRBobTOyzRhyIFJDZzUbxsseQas3NrcSfvApx2qK3jZnCPkH3rNl2TC1Yg5YcV0GlXKQyqcfJ3FZ39nyIA2OB1p6r8h2huKIyMJxUtD0d/DdjrWm/abJxHOFztyBn61w09s0M7RScMh5BrV0e9uoI1EbFc9TTrmJrmUyOMknORXQ5KS21OBRlBvmd0Y5t1fqOnYVB5ZHUcitlrfYMbfqaSW2VlwR+IosVzWMVog21uWA5FQvEOmOfWteWDy19KqvDuPHpSaHGZlSx8kYOO5qCRSpGMnr1rXaHjBUn3qKSDAbdyaViuZMzkcjB4q7Z6jPayJJC/3T3qu0JGR+tM2gYB/KkUdbF4kt5wRe26qxH34xir8V/ak5gnDdtp4xXB45GQePWn4KncMj3Bqk2Fkd7DMkl1brM+2AyLvIPbPNdOEmsJLh4IYEvr248uBE27REvf6HjJrynS7uee7t7VX5mkWPJ5xk4zXY3Oo6RBYsXspdttffZGJkO+UAc/TJ7CtE+pjVSbSNDU723GqXQgZPKVyF29PfHtmiua1Ty7HV721jcssLbVLHnGMgH86KTnqaRpKyscZeatJI3yZA6ZNUm3zcsc571GkbOcYPFbFhZ/dY80fEcrl1ZUgsi3Y1o2umFiGI6VqQQD7q5rSs4MNjGa0UDN1CtbWiJxjtXfeHPF+oaVp/2a2ClP4cjpXLhEL4A59K04IgoAAAFbRhbVHPVcZaSF1S6utTnaW6ZmfrkmsqWMwyAkjFbwjBPzZxVW9t1eM4xmqkr7lU6i+HoOs3DqMirm/wDGsayfySUc4GeK0o5CcAYwe9Z2T3IqJ3LsJA5J5/Q1Mg75/KoYAM+v1qwnBwOlHJcxegwplTVCYCKTGDtPOa1OMHJqndrlTtGQvrQ4aF05a2CPDLx06VBNYGSQPGwDH17VZshuj/CrYX5c4IrPluUqjg9ChDp+Ijnlh3zUhdoVIkB46Yq8vv8AgKl2q5G8DGPSl7NrYTrX+IwpHnvThMpEDz2qOKO6tiyrmRSPyrawqsRgDPSm5wxIHGOKnlb3NFX6W0KVjaGN/OnIMhH5Vc25J447c02ZiDnGR7VE8wxtxiqVkrCcnN3K2obGBBHOccjtWG0zWM25WJjJOcVsTEsxB/P2rn9SgduFbg9KxlLXRHZQklozZtNQWZ1fcAfU1tQSBiD1rzyBpLR1LBsE49q7TTJN0Kk5P40lPuLEUuXVG/GQwx0p8b84z16VTjIK8A1PGpAyOvat1K55z0JC3FRyuWlQBRj+tLIpPrx2qIho2BC0ncaLUKkgZXtVgrkDPGOtRxYY+3FSsDxnpitY7GT3GxhCepIHWpdmFyRTYxgYyNop/wB0Z4J+tUhEWOcYPHWo5FI9/wAO1S5HYdeoHWoyN5+bp656UWHexGRgA4DUj4LZHX0qfA25PrUDFRn5uTRZlJ3GNhgQetZ9ygXJJxxV8JyNwPtiq9xCOKzkjaBzF5G/mFwflHTisIp5+obW5x0rsbuMKp+Wuf06MS6pIMdK5ZKzserRl7rY9tNWRB8gHuKkhsMLtlAOOma2hF2A5psqj9KfLZmft29DBkshvICqOORWZdaVCGzJx+FdBczxiQovLfSo5rKW6QcYX0p8qOiNSS3Zix+X5YjONg4FILOMSAqRtJrYbSTGpO3k+9Y81rdCUhCRg9KzlG2qLjJSvZmla2yA84JPrUjx+Ux29fX2qil3JDhZVwR3xV1bqKVOoBx61UdrHPOMr3IpY1HOeKcEQjJ/IVXnl2ocHOT1qVJ18sIMbupPcVpF2JlB2GTQqy5x19aozwYJAGMetaysjY4OaqSjewBwe9DkOKZlleMGoJY8ZwfzrUltSHyDgdqiljIyCv8A9eny3Kv2MWRMY+X5hVVlKtwASecVsvDu59DVCeEozHpnris3oXF3KrISQAMY5ppX5Dvzg9KsgDbyefeoLjdjPrSLSYy2RnnRImCsXAVicbTng57V3zRa4sy2sw8Ny3/mCQNJKPML4wH29C2O+K4TTWa0u4LgKH8uRZNhPXBzW9NaaJd6hJqZ1K7VHlM5g+ykygk52hunXvVxZhWV3r+VzJ17S9RsZHvLySK4EsrK80Mm8CTqVb0NFaGr6nBcWGpYV0vNRvBO8BXAhVQQvPdjnJopPc0pNte8ZttYFmyQMfStaK18pAWHJ9KlhQIAcfKfWpkw5IycV2RjbU8uU2xbeMMSM9uuKuKm1eAcg0sMQUfdBapyCQB0rTlI57i2kLM+4k49K1I06BeT15qK3HyDA+tWUOB0496uMbamE53HjGMP6dqhkU7SAfxqfOegpG4602tCYyMS/tsLvTIPc0unzFgAxORV27wVI5JrFicwXRzyCetYTR3U5c8LM6aJxxkk1aWQEdAOayraTJGTkVeRiV4FOJyzVmWhg+gHSo5V65OeKaJPekdsgYBOabI63C3cKx559KvJgjOcZqiibeR1NTwy5GHPWpSsOWpaCjORyaDnODTlPI7U5jzVWM7kbKSp4H1qModwyM+9TqVJ44pp+8fX1o5RqRWZABjrVGQAT47dxWk4wOSDVR4xuLMDmolFG0JFGWEsM88/yqtNbr1boK1HkUAjp6VCVEmCRhf51k0uhvGTMW7tkdckYXtU8EjxKDH93gVauoF2kHAGM02MAwrg4wMgVlKF2dKqc0bM2LViNrYzmr6Sc8Lz0rK0yRSgAz8orRibPOelawTOGqrNospuLEHBNOEeR8x5NNXOOCCD61Ir4+la8phdkUJZXZG6DoasBst1OMdKqXcgRgwpVk3AEnmpWjsW1fVFw4yNpz60xuvtQkwC4wKCwxzz3q9DMep+XgjJ61E4CjDYwakDrknoDTPLGSc5p2sMgM2F4A4qncTOqltuAf0rRdFVTgdqrT7dhwRyOalmlNoo2t8Zm2LwR71NKWI+ZuRzWBqcT2r+Zb53emappqF/IBHKPLU9TWUpHoQw/Orpm7e3MIDKzAevtWBZN9m1R2XPlN/FXRWFlCIdzqJGI5NUtU8oTJGqAEnt6Vm4XVy6U4puMS4CSNygE9aydTvmz5EPLnqasXN2ltasQ3IXArP0mFp5zPJ35Galuw6cVG85dC7ptoFTfJ8zHnntW1EinqAMVXhVd3b2q4oJx9aqMTmqVXJjZYQqnjtWRdQAAtit6TlfWs26iYqcflTmroKU7GabNLiLn86oPoqtuCHB9q0IJDDMyMTg98Vdx8ueMZ9KyjZm7qSpvc5G80idFYK5xWdA81rNiVSwWu92ljjaMetZN5aKJSSvOaqUFa5vSxPNpIyorpJcHO09hVq1jSSTcXyfQU8afFOG+XDD9KhbTpY/9SxXuPelFD5ovQt3ca9CRkelUpEOSMA0x4LxXznK471X33KHMiEkVa0JUPMlaPH3sEHqarXUIKEnBYdKnFyHwHG09xUUp3PlDk9x6UPVBytMxpUYEj0qvcqVU9cYrXnVSDgdKz5xuBLVnJWN4u5BojxNqFsLnHkecm/PTbkZrv5tS10PqUFsgkvbW8Ro7dI1Ie3bOMAdV6c+9ef2MCyX0ETP5ccrrGzn+EE9a6DU7rR9O1CaJdM1ASQsYvNF6yMwHHboDRB2M60OZ7XM/wAURlPEmpYkMw80/OTk5wOM+3T8KKoPLFPPM1tE8ULElI2bcyj0J70Umy1GySOqRN0eOhpsY8tzgfnVhcA5wc05Iy7c857163LofP8AtCeNsoMgj3oHMoGTipEjwg5B+tNjYK5I61XKJSuXojsA61ZX5vvc+1VU5HPHep0PHJz9KoxbJC2Dg89qaxzxnGKaxIBxzmmnOeGA+tDBENxghgRise8VTMpU/KDWtKQCcZ/Kse/YqgwOfeueR3Yd6mpatsiXjP1q+kmU6DntWBbXJaMZbANXYZ3K/McUkKpuaO70/nSRuTKRkj1qrv4JJzkU+BueRwaZnexoxSeYxAPAHWpsqV+XOaoxMEOV4JNWEkDKTjFMzvYuwyErhs5HvVgZGPYVleZhlZeR3q1FccZbrTRDiWi3XpnFNYjaSD271A0oHVqhkuN54+lMaROxC5yR04qvI67cnBNP4K9ajkVcZzipsWmQoozk9amJGOD1qHaW5BwO9PEOJAdxNZchpzIq3IIUgYqpbl1U71ylac6jBVfvHuKZDHmMq/b1qZQN4VUlqP0102sFI+lakbADH4VgRoLeQhyQSeCK0opHRRuweOtEdDOqru6NSOQggE0SduozVVXHBzmpTICODx9a1Wpz2GXbjYN5GM+lLEytHkkADpVe5KsVGc1JCgCZHy1lJe8aXtAnO7duB49PSpUJ+vekiGR8xJNTRJ36HFWombmhUViPmPHpTiRx2P8ASjOcjtUbMwPQEVVrEXuDOGXpVaeMeWOaldskA4H0phG5gOtSzSLtqUhah2JYZ+tR3NjG+Nw4HpWqVUDkZ71HKATnHNQ0bRqtPQ5gyXWnSFVDPD2z1rE1jVz56mNSXHGMV2t2uVwyk5rPfTIHR3aNST3xzWMovod9GvFO8lqc5Y2s15Is1y3ydQK2p7hYFEcC/MBk1BZgwXTQgHYRwKlsEK3zhxwc4JqI6PUurLmd+ha08TumZBzWtByqhiAR1pIVBHBNTCNVJrdK55s5pvQax4Pb3ojAdOOuOeKJTnHTPSliIChT9OKXUV9CvdWaOo+U57GooY9mVz079a0CQysMcDiqcyArkA5HpUyj1KU21qIyhQSRj29aqXlt5ysVwB1FXE2sO+fehVw/JGOlO11YcZuLujEWCW2ySQc1Mh3Dn7vrVy+XCZC81Wgjbyi2M57VDi0zfn5lcrsnPzHNOkhRlwVIyM8U+ZSkefTms+3ui85Vsg5o5rblRTauiteWcYOF6+uKzp7VxnA5rfkgPzFyeT0FIkQbjvTN41LbnKmKVPlbPqDVO4BBORzXYT2yYGOc9axr+yCgleRUTiawqp6GJZRCTUbYSx+bE0qhox/GM8iuz1JPFg1CZbeCBrbcfK2xxEBP4Rzz0rA0uPTAkg1KW8jcHMYt0B49896sy2/hwZ/0zV/++FqY6IdR80tvwuYWqLdDUrn7eoW9MmZQoAAb6Dj8qKS7ihF3N9laaS2Dfu2kGGI98d6KRulodfhQMLnjuamhYfw8etVAxODggHsamR9owAMGvbtc+SuWyw28daqlv32MZ9xSmYAncck1DES7kn1oemhUW9TUUglQvQdeKnRSfu/jiqcLqrYYkgc8Vcku0jXCAHNNRIbHMhALDn2qtISRkgjFMe8cZIORn8qryzO5yc8/pSloVEdJPsXkHOKydQbenJBqzct8nXLGsPUpSEJJOR1rmmztoK7NG0IESkc59a1YexzjjNYOnyboUZjntitq2w3apir6hVepY3b3Cjk+1WkHsaqREBieh9amRvmyTxWqWpzyZaIHXkY9aPNK8nvURYDqDUhwy9OPSqsQmSRy705IGOeKcMhm5578VDuCKMADPtTTcbSBTsO5YUlu9TKFHUfrVGJuSQTTvMxk5zihITZoAgD+VRNlwM8f0qOGUso5x9afv3AnIJp8ugKVmP8Au4z1NJNJsjyOageYIQOcUshDrwM+vNZ8o0wRmkY5GOO1PQkDA7d6pRyLFJ8x4Jq2jKByQAaztc0crEzIJEIYDgZzUcbtBtWTDD+92pTJxwBjp+NPDBhhxxRygpvqWV2MoIHBoCjdhcg1CjoF+VsGo1uGEgBxz0NNKwrstQxZkJPOKvoo6d8Vn2twvmuOp4q6JAQOKcYoio22PJ2kdqlRix4BqAlW244oxxkscDmnYguDqCCPoajlIJ6CoEb0bj3p5kBX1+lIBjtkZGMg01cjkmggDJwaaMkMPbio5TVMkLZ6E1HJweeaazBd2MVGjA/fyf8ACpem5aKt7I64YYCk9M1LGxkj547dOlQXBMx2AYQHk1Zt9qoADn3rC2pu9IpGbqNnIJo5Y+SDUltYyvIkjkZHA960ZI96sG7ik0+XqhILCjkV7le2lyFhEKAA9x2qQkFfT0JpTnaGwDRKuR92tNtjmvdlZz5j7B26mpTwqkAk0xQUOGGfep+CCRwPekvMciu5KngcdxUTNk4HAz3qwybhlqhkUbc880vQERggMODinOw6gdexqIKd3OQD0oVvm5yTmmmMk5Yc8g9KpSgwSblPB6irYIKkADj9KpXbYwD1pS2NKTu7MkdPNjycfN2rDvbaSFyc4OetdDbMGUA9QKju7YTZwOtQ4c0bmtOryyszMsmacEfxCluEKDK8cc0+0heF2DcY6GrMqZBXGQaUU7alykubQoCYumGUA4wAetZt6AMr0Y8Veu7YoxZOnUCsm7EpJIHB61Lb2Oimk9SCHSJrzzWintYwrAHz5Qh/CrC+HJyf+P3TSfe5FJb2iXd1bwyn5ZJFUnsATWvdPpFrb3Mv9iwmK2uxbSLuO/ac/N9eOlJRXUqVWSdkcnqFs1pPLCzI5jOC0Z3K30PeirPiJhaarfQmOOMRyYVEGFAxxj8KKze51wbcUy/kbR84zihSdy8jBqnvOAR1PFSCU7QP1r6B+R8gmXbxI1jUqx3d80kJxEuOveqAlaSblunSponzkk5PeperLb0sXjIFA7Uhl7fjVZGwPmpgk+Y5PFMhFovgbveo2m2jbySemaZkKDyeuahkfALN+FRJGkdQmkyCO1YOtnABBrXEmc96wdfkbgA1hON9TrotpmtpbA2yDuR1rYtpMDae36VgaPJmFUJ7VrRsowORRBCqbl5ZDkY7VOkmc5PFVI5FA4oaTI68GtrIwbLySAMO/wBamEoL9MVnwtxzyabNIyYK8rVIi+pqGQY6496rTnByeT2qGKfenTmmyuGPBNVa4kyZJ8YHpSs43bs4B7CqqyAMT+dDSKM/NwKXKDkaEU5fPPTvVtJQBjjisQTD5ir8kU6KYb8liQKdhNmrOQ4BAqMOQu0dR1qI3IKgZwKr/aSGOenTNLlGpD2ljVyxBZqctw2xWION36VTeZGwCMtmmtcqrBAcj1zWbhqa86sbK3Hm7WH4UyW4KNuxuB4xWX9qaPYgI56Uv2rkAjJzyKTgQpammLgsflXB9amhnBGcA4PWswzoBxwTUUl18oRWAFLka1LU0zesn3MXwOtX2kBAwcGuYsrvbGVU55xxWpDP8uW6dqUFcmpubKvgDFS72YHArJ+1HAyeKmhuMrwevSrcTHmLYkddwA60+PJBz09KqNIRkg1LHKu35up71Ni+YuKRgE8/0pkn3Sy1GZQRhT0qtNcbUOT/APrqWVHV6E0zL5eP4jVQiRv9UR/Wq+ZGbdkn2FT2cTIzM55bsTWDfMzp+FE1qCm4yLx0pSw3NsHHY1IDmPrwKruxDYwNtJxsiea+pYHCfN6VTAaO7DKeO4NTCQlQQKriX/SwOu4elS2XB7mosjHjPFOLtjnIUVCJOCAM8UgbcmD0pmZIWI6Akn9KWHIJVic5yPSoQxXjBOTT2YgZwRxUWLJsncee2c0uVIIK9f0qK3bzFw3bjNTZGSM8gY+tUlcTKojOc1GyHPcEVMX+cg0FgcAj8KpRFcrKNhI7E5NRXKBwAwz6VZdc8VXkXY3Jz35pNFRZFAuyUDJq40gXI7HuaqB9swOe9Sy98/d60oqxU3dhMg2lhjFRqWaPqBg96bOx2YIxxUKT7kKnBBGKG0OKdgkfem1VBIOM1QCBmKsvU9MVbtwwlOSQO9SuqkY9/pUtcxqpcqsYslqxuERQS7MFTBxyTxVua4uLPXpkm1KI71WOadoQ8e5Rxle+D/FUslvchkuIFY7JVUMBkBz0FXrjTxLMbifw9fGdm3tGkmIi3rjrjPapcTVVE9zz7W4bmPVLuK/cPc7z5j/3j6/Sir2vJPPqd1JepsuGcl06bT6flRWD3PRpy91XIzhvmU49qbJKqpzwfWoFm7nGTUE0okkCKfY46V9C3ofJRWpetDkEg53VZDAdCfpVKJ/LXHtU5cE5GAMVKRTJvM3fdOM0wHG7pjPrVR5Sh9z3prOOgzg81Nyki2ZxjahyKikZuNw4HpUSFVOCcjPWn7g+cHgUnqUnYcpAPuaw9X3PKAB1IrULbcknB7Gs+7x5ysOQPWpcdLG1OVncu2UYjiyMk+tWlmLnggbepqgs4C9ceoqW0nHIHQnrUqNtAcr6mqJdozwxqYSLt9Bj86zVkAzlgSamikBXGa2SOeTLqOVypPJ7VMzAoQ2MEYrNM+DknOP1pBcADGRzWkYmTZZZtjnbwB1pyy4xgkjoTWfJOq7cnP8AU1A93jdzg4p8th3ujTEw8w89OcVVnu+oPA61kSX5Xkfiary3+4H3paAmbcF0JCeelWlucSjLd+lcus7RlfmBB9KtRXe4jkj3pxV0TJnRS3QQ+meMVWe62uRuJb3rCuLxhyDn1PvTGvQQu5ufam46gpG013vcAkZzUMkoEmS/IPSsNLn5mIJJ9zSNd/N8xwDUchXObpvSzg7gCOlSx3uSd5Nc9LMDg7gQOlAnBU8/rU8gc99jozfgrnJUjt601bsMxyRiufE7bQu7r14qL7UYnbcRjrSaHF2Ou065Cq2T3zWpHd4wOue9cRp95n5jnb3rYjvyqD07CnTimrinLU6n7Z8o+bcPpViG6KoNpwT29q5KO+98Y7VMl6xAKnmqcSOY6trv35qWO7DLjIBrl1vAQBnnINSpdkKSDnnBxWLRcVc6YXe1c9u9E1xG0WGIHesIXYZADwB6d6bBIjyYDE54OazmtDaCSNqzZ92/cdo6VeSTew+as2KXCcnn2pySgYbP0qFTsinK5rbtvXgdaryMHYsMhR+tVRdZYKSfrUwICnBGDSkkNaEm/wBOlZk92Ev1DnHarueOmeaxb7P9ooGHFYTizpopNs6O3lV4wVzirKcjjH0rKgbZzu4PftVtJ1IOxhk0J6GbXYtqWY8dKk37Rj0qCDlOuCP50khIxwSfWqJ62FicJOQTkHkAGpy3z8Y9xnpVXsG7g1MhDEe9TAcyQqMnBGadEqkHPJ7ZpjcMAMCnDI+XGa1SMnIHVd2Qc96gkAbgjvTnfGR+FQ5ZzuB4FIpaK5FLAEHXntUOXkHJx7Doasvk5JG6qsjhW2rxUOKNIyuPkJ2so4z61RkMcPzlhu6Yq1IxABJAJrOePfJhs7fWpa0NIO+5Y81pSGXhcU8byoA7eppqQhYwQOR0FLHuVj2BqoxvuDn2GBJZZY4QHbe6r8px37e9S3q6PHfNbSXWpgBthlDDANIHbzQUYqwOQR1z2rZmtzJL5k9lph1HhtjzkEt6lOmfanKGlwVSz1OQ13TIIVuZLWS4ZrabyZ0nwTkj5WBHUGik1K6uXhmtpogkrzmW4kI+aRh0B9APSiuSUddDup1GlqcjLII0Jzx6Umn92NZ8ReRtz/cBxirkcgUEdD2r273dzwL2Ro+YucH8qbNMMkZPrVBrjbz+lOjbzGBIp3BMc04zySCe9O3h4ySx54FNnClSSOe1QR56MaztqXfQ0C21RnpR5gzwapqQF25OCe9IzEZwQFHeqeoXLEsnfHH86rFt7cCogxkBy3Q9KduABx19KXKPnsK2WYAkc9QO1MV/KfrgDtQZduMrz61VupNzAqDn3pODD2mhrQzbkzjANPW5CkgH6Y71kpOAOM4pj3OPUVtCLtqYymbZuADyQKha4AUkY4rFkviRjjFV5LwZHzcV0RsYuRryXZBz1H8qhe4Dc8++axpLvrzmovtg2kA4/Gh2JcjSuJVJz0AHSqHnlJTuJwelUnvwr88g+tU7m/Unrz65rKSvsNTOhS7XaATilF3tB+auTbUCTwaa1/JjhuKadtyXJnUvfDJ3HGfeozfIBjNcnJeOx68VGbhz1am5oV2dYdQRJOvXrzTJNRjGc461yfnNnJNL5pPJOalyC7OpOqKMcgilXU1B4OM/oK5QyNikEpHepcguztP7RQrkE5+tV7q5Ei/eOc+tcqs7DGGOKf8AanzwxobTVilJp3Ozt70RbAuSPrWil8pwP4sVwSag64yeKuQ6nx1xRFpaBzM7RLrLct19amhvSjEbicmuMj1Ta+QT7mrSakpwavmQXO0W7AXdnr71I95txzx9a5KPUxgAHP1qy2obkXnDdhUOzRpCZ1sN4NmTn29qv2dyoXJ4JGcVxsVwxX7wGe1atpcYiG9gKz5bs15zrYLoTL1Kj1zUpuiPl/I1zkFzjGGGAKsx3e88HkdKUkVGWprw3Z4BJHPU1pwXIJAJ4IrAiuF24YAVcguEAHP05rFwsa8xryyKBkHms6+JLrKMkrTY5/Ml+c4X0qcqjKwzlSKzaNqcuVk9tchosjByPWrSqGIGdua5qXzI2+Q4UGtHT7wA/Pkn36ismjZx0ujoYX24DH5umcVbJBj6cdDWVFOshHYirSyq68HnPSqSsc730JbhDgBDg1DB5isN2TmmNdZYqqksDipoN6kk9SKnd6DvZWZK0mWwwBPenl/lpqggbiBg0hU9Fxj61Wpk2mISGPTrSKAd2DxSONvB6imrxk9qLjJCvA7A1VnjBJOQKsgncD2psvynaQD6Vdrkp2KpHAz1FV3QksSMelTMzEOOw6cUzcSgwOazdjRNoYW2qOcntSlgQAB0NI8RIO0j3pYiFQjjjtVLQObQIpTDcJMVB8tw2MdcGrN5badc3TXP9pIkcj7yrofMGTkj3PvSQWV1eq7W0DSheDt7VFNoepnYfsMwwRzx/jTaCMtdzO1qYXWpXNwgZFkfOCMH0/OipfER/wCJ5fAZ4k5BHsKKzcVc6Yz0PLoX4Uk49qllmXBA5JqiGKjD81IOW46Yr0FoeW9y1GcZ3cj1qZZAp544qosnIHb+dIZTnAOKaEXjMCTnoRxUDOQcr0zzUBdmBx0pmWBBzx6VJadtC/IwJHp71BO+OAT06VBJPgKFI3HvTVfHLHdmrRLZJGSo6nnnNP3gqeo9/WqxlDE56jpURnC5GcZ6H0rSMDOVQmmkPXPToaiNwGHJwaqS3HzYB4qjLcYOSapxSM3UfQ0ZLnB68VXkuycjtWfLchhgmqb3e0nB46UaIXM2aMkzDnt25qvNdKAM4zWZNeFhgcVUaYk9fxobsSaj33ygd6rPdknI6VQZmPQ5pAT3qOYLFiSdnYk5zUJfJ5pM55FB6e9Te4xMmnAmkHNOGKQBRS0mRTACPakHU0pPHFIDwaQCNnFN5xS54xSZpAA46UpNJkUnWgAzzTg2BTeM0ds0hkwfPQ8Uqykd+KhFKtAFxLpl71Ol+xxuORWaTTc+9FwOnttRDYya2rS+DEDP4VwUUpXvV63vWTnNWpBd3PQ47gbV+bjuKsx3GCCG4rhYNUYfxYrZtdQDr8xHNPRlqZ2MM+7kDp1yatxylCDwQehzXLQXJY5DAZq5HeENyeB+RqXE2jM6BLjdICPvE4NX47whSOnbPqa5kXGGDrhge2amj1ISNtGOOtc01Y6Yu50kZV0DM2SeaVoxlWQ49RWdBdYXA4z1q3HKrDOcAc81lbubKT6GrFKo2b2GcdqtwsApIOT1OK5qS8MZbGMDpU1heo6FhId3oaiTL5DpI2/0jKnORk1daXCDB5rm7WeUyCR8lfStiLMgDdc80Rl2MaisXFnXfnt0AqO4vdrbsjb7DvUZ255yD7VFMmVIPIPpVO5muUtwzechOM/SgMFBVRnJ71mRO8TBQMgmtK1BycjPfmpWo2DbwDwSKaZdxwwI4xViYblIyc+3aqboCNyn5h1rRIzuDZxhCd1RYKgcHn0pyttfoc02Z+Mnt096LDuOkyQAeo96iYDdn3x16UwligJOFzSLjaVBznk4NOw7itK2SI2ZOP4WIpoZ2R2M8nyjpvPNXdLSynmaK8EvnPxEVk2gn+6fr61WnuNIViHs74EHB/fj/CiwKRi3OQ+4EknqWOc0UmoTwtM5gV0hJyiuckD3NFQ7G8Z6Hm8kgdgMcetPiClgMmoIQQOo5qaJj3Az713LU89slcbW+ppGIXBPJNI7AdOlVnkLHr1qmkhJlkPgEjgk0ySQKME81EsmTtJ+XrUbuC4A6U0tBNj1Ybg5H40kkyjoeKryTDb04HrVKWfbzmqSsS5lxrgZ4JyKrS3Bx1qlJcgNk1Vnu8jANWjFu5cmus98CqFxdbWxnPFU5ZyepNVWl5PNTKQIsvcE8A1C0pJ61XLHNJms3IolLZOaaT/+qkB9aUEDmkA4cig8Ubu4pjnNAEqnjtShuO1Vt2OlPD5p3AlLU0NTc9qDSuA4tSbu1R7hmmlvmpASl/Sk30zPNNJobAfuANLvFQ5FLmlcCRW5pWaoweKCaAHBqeGyKgB4p4PSgZKGwOacGB71ATzTlNICbPHNNJz9KjLUbuaLgSZxTg351EPrTwRihASiQ5681ZhvGRhzVGjPFUnYVjo7TU2DDJOK3LPUQ3BYEVwiOQeKvWl4UwAfrVKRSbR27XSnaIxirNncRxjBIznmuTtb4buTknpWtBLHIMkc1E48zujanVsddbXylgM1Za6GTt/SuUhYgZiYA1ehnlbA+XNc84tbnXTqJ7GrGxmlY7z7VoWMLJy+Dk9qzrQrCm98Fj6etakMhdtw4B54rBU9bs6HV0Ohs5I2jC45GMiru4RL+7yATmsK3nBGAPm9avQ3A4DnHtWisczu2aYckZI5pVd+clcH0qHcGXAzinIzDGQMHihom5PChUhpCvtmrAZgwIxioFcbQHxz2qTeFUYAxmnGJLZPI528YBz1qtJyM9T60HcxO3p3pWBWPBJ59a0JZXZsZ6EnkioJXGMZ/AUSSYPIwelRFgDkDPaodikyTcNuBnFQ7sPgYw1JI3AxyfY0wn73bHrQFy7ZWEt+JHgMQEY5Ekm049fpTLjRrhlAS5sBnnm5Wq2nC+fUA+nKXkjGSWwFC/7RPGKdPoF86ExLayuedkUyk/gKTdxpGHdxvFdywNIjbDtLRtuU/Q96KrvE8czI6lGU4Ixgg+9FTqbaHBb8qAB7CpkkKYDYqlGdpAHNSuw5OOa70ee2Wi+V6fhVeRlBwD0qEzYXAPNQtKPvHr3qyWyZ3Cr1qt53zk5qGWcEY4NUJpueeDSE2W57ggnnis+WYk9aiknJJ5NVpZaroZ3JZZwRVWWWoZJM9DUW7NQ5DJGc0zOabnNOFQ9QFxmnYptAPFAxc+9LkYqNjSbqYEhamsaYTTSfWkA6lU802jvQBITz1pSflGKjZuRQrY4PSgB+QRikYZGaQD0p/SgBmaGOBTSeaO3NACZpN1IaKQx4PFKTTBTiaADNLngU0YNBOKAHA0ueKYDmjNIB2aUGmE0oNAEgPHNOB4qLNKDxTAmzS5GMVEpzxUnQCgBw4PFLkhu1MzQxpAWI5ihGOta9hfEABm5JrnwTUiMQevNNOwjtoLkdjV6G43MuK4u1uzGMYya6CzukeMEHBo+I0i7HSxTHpnI/u1ZhluVcNyUP8NYVvcDHHJ6YrVtbrAAbINZSgdUKrOltJpHRSCMjqe4q6s5A/e9TWHaz5QsvBz371ejcSRj5uBWco2NVK5v2rOygqw2471MJGi7bh2xWLYXEykxkZTtjtWkm7O/cTgZwanoJ6MsLds3PlsXzT/tcv3WVgPU9KI2V9u3Ab2NObKHkBgfSiz7k8yJ7a4Gfn+gNWJHDnr8vSqCvhjsXcPQdqkWU5xIpH0q4u25m1rdCzhFHOfrVWYEYOevrRcTAkYGT7VDLvdSpIA7cUnYaGtcbcq2PrSBw565I9D1qCSMbDkj8KWCQR5HXjt2pIZoWctvLp93Z3VwbYTSLIku0lSQCNrAdqItPsoWVpNYtSqkHMKsX/D3qbTP3OmXd7BbxzXSOigOu8RqQctt700xQavEZ7OFYdQhIM0CfdlXPLIPX1FNCbMjVbtb/AFO5uo1KJIxIB6/j70U/xLiPxBqIQBVEuAAOAMDtRTsHMjyLcST60Mxx1qJc4655pskmOBXalY5HIVn+Yiq886ovqTTJpiF6gVnTy5YZOaCXqSNN3PSq0s25+OlMkfIqs8ozT2FuPkl9KqyPk02RyTTCahyAduzSUgpagYopc0yjPNMQ7ccUqtzTM0gOKBkjGmZoBpSPSgBM+1IaQ8daDzQMd2pM4NJnFLxikAFsikzSUUATIac/AzUcZpzdMUxEZ60maVutJSAKKTvRQMUGg0gpeooAFNOY9KRRSnrQA2lpO9OpAJ3oHWjvSjrTACacBnpTTzxTwMDNAh6jA96XNRls0E0ALnNKDTAaVetAyRacx9KYDilZuKQEkbkHrV20uXRhg1nA8U5Wx0oA6uzu8/f6+1acF323D8a5PT7r94N3NbcUyllwKdtC4zszprW+MYXL7vataO4Eg3AnHYCuVhdcjPb0q2100abo+g9TWMk0dMJc2h1i3ku5dqfKOua0ob0vHwM1xUGrNuUNzkYyK1oLgjB38+maw5jo5bnTWczCQ57dqvecXIx8prAtLkZOTk9K0IJsnOTgHGapMzlE2I3QAeopXlGMlgKy/tMbfLkjB60hvF+ZVyxHf1q+YzcC28hUbcrj2pjMrxgkgEetQjLJkjBxmoZmaLO4fKT1pCUR7fM+eMUg4JUtk0xZA69OlQu4DcEZp20uUW1u5LVme2meFypVipxwe1Z0NxLHMskUrRMvKsvykfStrRLMOvnny2leXyYjIu5Y8KWZyO+FHAos72W6W6W4umvIY1MggnQESxjrg/wNjkYppE3RjXUstxM81xIZZZG3M57mijVIls76a3VyyI3yk9SDyP0NFWRc8pkkx06VTluODk8+1STfcrNl6tXScwssp6E5qsxzg0TdaiPShCY13AHWqrvk0+TvUJ61MmAhNFFFQMXNGaSk70xj80hopDQIKSlpKQIXtQDSdqBRcB2cim9DS0jUDFzSZxQKa1ADqXtSUtAAvBqUgEVFUqUxEbe1JT3+9UdDQAelITxS9qae1IY4UtNHU0rdKAHL3NHpQnSjsKAADil6Unag9RQAZpR0zTTS9qBDu/vQx7Un8Q+lIepoAN3pSgj1pgpRQMkA70oGOtA7000CHk4o3ZpnYfWnDtQMep4pucHihetIeppASxyEH5a1dPuyrBT3rFX71WbbqlCYHXQyhsHrV9CrLz0x0rCtScDmtOP7hpyRpTk0XIkRpNqjHoK2LJDvy5GK53Sz/pr100NcnKmdqkzSiBMgKdcVfjP7oYJz39qz4v4atp3oLvctxgyIyHripYQkQAbqO9V4fvH6VLJ1H0FNIzky6Dnnt2qGYBlA496iXo1O/hFaeRnYa8aqcAlT7UzyRu5ye+akn61EfvH6ULYGzQ0y9S3DQyvJGhcSxyou4xOOMkd1I4IqzLcWcKSs8tgIpB+8SxjbzJhnO3LcID3rGb+lRT/dqkRYq6jdyXd5LPMAGlYsQOg9AKKqXPeigEf/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the&nbsp;lid margin telangiectasia and&nbsp;irregularity and&nbsp;the conjunctival hyperemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Image created by Christopher J. Rapuano, MD. Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17843=[""].join("\n");
var outline_f17_27_17843=null;
var title_f17_27_17844="Ezetimibe: Pediatric drug information";
var content_f17_27_17844=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ezetimibe: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"    see \"Ezetimibe: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/57/19348?source=see_link\">",
"    see \"Ezetimibe: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F169566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zetia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F169567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ezetrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antilipemic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholesterol Absorption Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"      see \"Ezetimibe: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Adolescents &ge;10 years and Adults: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Bioavailability increased with severe impairment; no dosage adjustment is necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Bioavailability increased with moderate to severe impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild hepatic impairment (Child-Pugh score 5-6): No dosing adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate to severe impairment (Child-Pugh score 7-15): Use of ezetimibe not recommended due to increased bioavailability",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F169545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zetia&reg;: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F169532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be taken without regard to meals or time of day; may be administered with an HMG-CoA inhibitor (eg, atorvastatin, simvastatin)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct to dietary therapy or in combination with HMG-CoA reductase inhibitor (atorvastatin, simvastatin) to decrease elevated serum total and low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo-B), and triglyceride levels in patients with primary hypercholesterolemia (heterozygous, familial and nonfamilial); in combination with HMG-CoA reductase inhibitor (atorvastatin, simvastatin) in the treatment of homozygous familial hypercholesterolemia; in combination with fenofibrate in the treatment of mixed hyperlipidemia; adjunct to dietary therapy for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia (FDA approved in ages &ge;10 years and adults) (see Additional Information for recommendations on initiating hypercholesterolemia pharmacologic treatment in children &ge;8 years)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F169597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ezetimibe may be confused with ezogabine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zetia&reg; may be confused with Zebeta&reg;, Zestril&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F169594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased (with HMG-CoA reductase inhibitors) (&ge;3 x ULN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, pain in extremity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Influenza",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, anaphylaxis, angioedema, autoimmune hepatitis (Stolk, 2006), cholecystitis, cholelithiasis, cholestatic hepatitis (Stolk, 2006), CPK increased, depression, dizziness, erythema multiforme, headache, hepatitis, hypersensitivity reactions, myalgia, myopathy, nausea, pancreatitis, paresthesia, rash, rhabdomyolysis, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ezetimibe or any component; active liver disease; unexplained persistent elevations of serum transaminases",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal or mild hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The incidence of rhabdomyolysis or myopathy in clinical trials with ezetimibe was no different than that of placebo; however, rhabdomyolysis and myopathy are known adverse effects of HMG-CoA reductase inhibitors which are often used in combination with ezetimibe; follow rhabdomyolysis and myopathy monitoring recommendations for HMG-CoA reductase inhibitors when used in combination; also when ezetimibe is used in combination with HMG-CoA reductase inhibitors, the incidence of elevated serum transaminases was higher than when the HMG-CoA reductase inhibitors were used alone; monitor serum transaminases when used in combination with HMG-CoA reductase inhibitors. When studied in combination with fenofibrate, an increase in cholecystectomy rate (0.6% vs 1.7%) when compared with monotherapy was observed; monitor for signs and symptoms of cholelithiasis when used with fenofibrate.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of SLCO1B1",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F169539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Ezetimibe. Ezetimibe may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fibric Acid Derivatives: May increase the serum concentration of Ezetimibe.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F169541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F169554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been established; use during pregnancy only if the potential benefit to the mother outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum cholesterol (total and fractionated), CPK; liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 1 week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 2-4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively conjugated in the liver and small intestine to a pharmacologically active metabolite; may undergo enterohepatic recycling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic impairment: Child-Pugh score 7-9: AUC increased 3-4 times; Child-Pugh 10-15: AUC increased 5-6 times",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal impairment: Severe renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ): AUC increased 1.5 times",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 22 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 4-12 hours (ezetimibe); 1-2 hours (active metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (78%, 69% as ezetimibe): urine (11%, 9% as metabolite)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/57/19348?source=see_link\">",
"      see \"Ezetimibe: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dizziness or fatigue; may impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Nutrition, &ldquo;Cholesterol in Childhood,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(1 Pt 1):141-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17844/abstract-text/11345978/pubmed\" id=\"11345978\" target=\"_blank\">",
"        11345978",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, &ldquo;National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(3 Pt 2):525-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17844/abstract-text/ 1538956 /pubmed\" id=\" 1538956 \" target=\"_blank\">",
"        1538956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Daniels SR, Greer FR, and Committee on Nutrition, \"Lipid Screening and Cardiovascular Health in Childhood,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 122(1):198-208.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17844/abstract-text/18596007/pubmed\" id=\"18596007\" target=\"_blank\">",
"        18596007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gagne C, Gaudet D, Bruckert E, et al, &ldquo;Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2002, 105(21):2469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17844/abstract-text/12034651 /pubmed\" id=\"12034651 \" target=\"_blank\">",
"        12034651",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCrindle BW, Urbina EM, Dennison BA, et al, \"Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(14):1948-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17844/abstract-text/17377073/pubmed\" id=\"17377073\" target=\"_blank\">",
"        17377073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stolk MF, Becx MC, Kuypers KC, et al, \"Severe Hepatic Side Effects of Ezetimibe,\"",
"      <i>",
"       Clin Gastroenterol Hepatol",
"      </i>",
"      , 2006, 4(7):908-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17844/abstract-text/16797241/pubmed\" id=\"16797241\" target=\"_blank\">",
"        16797241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo; May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12909 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17844=[""].join("\n");
var outline_f17_27_17844=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169566\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169567\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058609\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058602\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169545\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169532\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058613\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058605\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058612\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169597\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169594\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058617\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058601\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058600\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837686\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169539\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169541\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F169554\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058608\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058599\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058615\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058616\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058607\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12909\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12909|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=related_link\">",
"      Ezetimibe: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/57/19348?source=related_link\">",
"      Ezetimibe: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_27_17845="CTA segmental narrowing of intracranial vessels";
var content_f17_27_17845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64318&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    CTA showing segmental narrowing of intracranial vessels in a 33 year old woman with postpartum angiopathy (reversible cerebral vasoconstriction syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 481px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Head CT angiography (CTA)&nbsp;six days&nbsp;after onset of postpartum occipital headache&nbsp;reveals segmental narrowing of the left middle cerebral artery and the A1 segment of the right anterior cerebral artery (panel A, arrows); in addition, there is segmental narrowing of the posterior cerebral and left distal vertebral arteries with broad narrowing of the basilar artery (panel B, arrows). Head magnetic resonance angiography (MRA) two months after discharge shows complete reversal of arterial pathology (panels C and D). The magnification is similar in all parts of the figure; the white vertical band denotes 5 cm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Maalouf N, Harik SI. Clinical reasoning: A 33-year-old woman with severepostpartum occipital headaches. Neurology 2012; 78:366. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17845=[""].join("\n");
var outline_f17_27_17845=null;
var title_f17_27_17846="Principles of molecular genetics";
var content_f17_27_17846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of molecular genetics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/27/17846/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17846/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/27/17846/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17846/contributors\">",
"     Anne Slavotinek, MBBS, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/27/17846/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17846/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/27/17846/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of genetic and genomic information in the practice of clinical medicine is increasing at a rapid pace. Examples include advances in the scope of prenatal screening, including testing of maternal blood for disorders found in the fetus, diagnosis and molecular classification of rare genetic disease using next-generation sequencing, tumor classification by gene expression analysis, and pharmacogenetic applications for medication dosing. Gene identification for complex traits is also progressing rapidly. Findings from these investigations will undoubtedly translate into changes in clinical diagnostics in due time. A collection of online tutorials and instructional videos are also available at",
"    <a class=\"external\" href=\"file://learn.genetics.utah.edu/\">",
"     file://learn.genetics.utah.edu",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Physicians involved in the care of patients will require knowledge of the basic principles of genetics to adequately incorporate these applications into clinical practice. The basic principles of molecular genetics are reviewed here. The material summarized here is essential to understand topics related to the basic science and clinical applications of genetics addressed elsewhere within UpToDate. Readers are encouraged to consult introductory texts in molecular genetics and biology for more detailed reviews of these concepts. Examples of suitable texts are provided in the reference section [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17846/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A glossary of genetic terms is available separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"     \"Glossary of genetic terms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF MOLECULAR BIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fundamental processes by which heritable information is stored, transmitted from generation to generation, and translated from genetic code to function in living organisms are common to all eukaryotes. These processes were termed the &ldquo;Central Dogma of Molecular Biology&rdquo; by Francis Crick in 1958 (",
"    <a class=\"graphic graphic_figure graphicRef54914 \" href=\"UTD.htm?39/61/40926\">",
"     figure 1",
"    </a>",
"    ), although the use of the word &ldquo;Dogma&rdquo; has been debated subsequently.",
"   </p>",
"   <p>",
"    Heritable genetic information is stored as long stretches of deoxyribonucleic acid (DNA), a stable molecule that is replicated and transmitted from one generation to the next. Segments of DNA can encode functional elements called genes that are transcribed into messenger ribonucleic acid (messenger RNA or mRNA). mRNA then serves as the template for protein synthesis in a process called translation.",
"   </p>",
"   <p>",
"    The flow of information from DNA to RNA to protein is predominantly unidirectional. Although there is mounting evidence that the interactions between DNA, RNA, and protein are more complex than this simple process, these basic principles are useful for understanding how the genetic code translates to the normal development of an individual and how disruption of the normal DNA sequence can impact health and disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nucleic acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA and ribonucleic acid (RNA) are molecular chains that have a repeating modular structure consisting of 2-deoxyribose (for DNA) and ribose (for RNA) bound to one of four nucleic acids. Both 2-deoxyribose and ribose are five-carbon, ringed sugars (pentoses) and have numbered carbon atoms (1&rsquo; to 5&rsquo;). The sugar moieties are connected to each another by the formation of phosphodiester bonds between the 3rd and 5th positions of adjacent carbon rings (",
"    <a class=\"graphic graphic_figure graphicRef62789 \" href=\"UTD.htm?40/35/41520\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In RNA, the 2' carbon is hydroxylated, making RNA molecules less stable and more susceptible to environmental damage, such as heat or ultraviolet light. DNA lacks this 2' hydroxyl group and has significantly greater stability. DNA may therefore be better suited for long-term information storage. The relative instability of RNA, in contrast, is ideal for an intermediate moiety involved in gene expression. Expressed genes (that is, genes transcribed from DNA to RNA for protein synthesis) can be readily \"turned-off\" or inactivated by RNA degradation, mediated through the enzyme ribonuclease (RNase).",
"   </p>",
"   <p>",
"    Nucleic acids can be bound to the 1-carbon position of either ribose or 2-deoxyribose. The four bases in DNA are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenine (A)",
"     </li>",
"     <li>",
"      Guanine (G)",
"     </li>",
"     <li>",
"      Cytosine (C)",
"     </li>",
"     <li>",
"      Thymine (T)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adenine and guanine are purines; cytosine and thymine are pyrimidines. In RNA, the pyrimidine uracil (U), which lacks a methyl group on its ring, replaces thymine (",
"    <a class=\"graphic graphic_figure graphicRef60245 \" href=\"UTD.htm?14/24/14724\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     The double helix and template-directed nucleic acid synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eukaryotic DNA exists, in its resting state, as two strands of DNA running antiparallel to each other that are wound into a double helical structure, called the double helix (",
"    <a class=\"graphic graphic_figure graphicRef56556 \" href=\"UTD.htm?13/44/14017\">",
"     figure 4",
"    </a>",
"    ). The strands are held together by specific hydrogen bonds that form between the purines and pyrimidines: A and T (2 hydrogen bonds) or G and C (3 bonds).",
"   </p>",
"   <p>",
"    The A:T and C:G pairings are specific, and thus the two DNA strands are complementary to each other. Transcription occurs from the antisense strand (3&rsquo; to 5&rsquo; direction). The rule of sequence complementarity provides the basis for accurate DNA replication and transcription, meaning that sequence is conserved both in newly synthesized DNA molecules and in transcribed RNA (",
"    <a class=\"graphic graphic_figure graphicRef73442 \" href=\"UTD.htm?28/18/28965\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mitosis and DNA replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitosis (M or M phase) is the stage of the cell cycle during which somatic cells divide. Mitosis produces identical daughter cells from the dividing cell (",
"    <a class=\"graphic graphic_figure graphicRef52419 \" href=\"UTD.htm?20/35/21040\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Essential to this process is the need to maintain normal, diploid (2n) DNA content and conservation of sequence information among daughter cells. This is facilitated by DNA synthesis during the S phase of cell growth (",
"    <a class=\"graphic graphic_figure graphicRef68250 \" href=\"UTD.htm?22/48/23301\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    DNA replication begins with the separation of DNA strands (denaturation), a process facilitated by DNA helicase (",
"    <a class=\"graphic graphic_figure graphicRef73442 \" href=\"UTD.htm?28/18/28965\">",
"     figure 5",
"    </a>",
"    ). The weakness of the hydrogen bonds between strands allows denaturation to occur at physiologic temperatures. DNA polymerase binds to the 3' end of single strand template DNA and proceeds in a 3' to 5' direction, adding nucleic acids that are complementary to the single-stranded template (antisense strand). The nascent DNA chain grows 5' to 3' manner, with DNA polymerase catalyzing the formation of the phosphodiester bonds between the nucleic acids.",
"   </p>",
"   <p>",
"    Both strands of the double helix serve as templates. The orientation of the antisense strand (3' to 5') is amenable to continuous DNA replication in a 5' to 3' direction. This strand is referred to as the leading strand. The other strand is termed the lagging strand or sense strand. Its replication is discontinuous, as the replication complex must await exposure of the 3' portion of the strand. Okazaki fragments are the newly synthesized, discontinuous DNA segments on the lagging strand that are then joined together by DNA ligase. In general, DNA replication is semi-conservative, in that each replicated DNA molecule contains one old and one newly synthesized strand.",
"   </p>",
"   <p>",
"    DNA replication occurs with high fidelity, with an estimated error rate of 10",
"    <sup>",
"     (-9)",
"    </sup>",
"    to 10",
"    <sup>",
"     (-11)",
"    </sup>",
"    per incorporated nucleotide in eukaryotes. These low rates reflect the low intrinsic DNA polymerase error rates of 10",
"    <sup>",
"     (-5)",
"    </sup>",
"    , and the fidelity of 3' to 5' exonucleases and cellular proofreading machinery.",
"   </p>",
"   <p>",
"    Despite this high degree of accuracy, both germline and somatic sequence errors (sequence polymorphisms or mutations) can occur due to the magnitude of DNA sequence replicated over a lifetime (6 x 10",
"    <sup>",
"     (26)",
"    </sup>",
"    bases). Some common error types include single base pair substitutions or slipped strand mispairing that can result in missense mutations or insertion deletion mutations or polymorphisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=see_link\">",
"     \"Overview of genetic variation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Meiosis and sustained genetic diversity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meiosis is the process of cell division for the purpose of gamete formation (",
"    <a class=\"graphic graphic_figure graphicRef61539 \" href=\"UTD.htm?38/34/39460\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The goals of meiosis are different from those of mitosis. The goal of mitosis is to generate diploid (2n) progeny cells with identical genetic information. In contrast, the goal of meiosis is to generate genetically distinct haploid (n) cells that can participate in fertilization with other haploid gametes.",
"   </p>",
"   <p>",
"    Meiosis differs from mitosis in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two sets of cell division occur, resulting in four haploid cells.",
"     </li>",
"     <li>",
"      Chromosome information is exchanged between chromosome pairs (typically each comprising a maternally and a paternally inherited chromosome) through the process of recombination (",
"      <a class=\"graphic graphic_figure graphicRef59656 \" href=\"UTD.htm?6/11/6323\">",
"       figure 9",
"      </a>",
"      ). This recombination results in swapping of homologous chromosomal material between chromatids and the creation of novel haplotypes that contain genetic information from both chromosomes. A haplotype refers to the specific combination of alleles on a chromosome.",
"     </li>",
"     <li>",
"      Chromosomes segregate independently from each other during both sets of cell division. As a result, this independent assortment yields four haploid genomes that each contain a mix of maternal and paternal chromosome material.",
"     </li>",
"     <li>",
"      The combined processes of recombination and independent assortment assures that each gamete is unique, different from that of the individual in which they are formed, and different from those of the individual's parents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chromosomal recombination and independent assortment are the primary forces of ensuring genetic diversity during reproduction.",
"   </p>",
"   <p>",
"    Errors during meiosis can introduce structural genetic variation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=see_link\">",
"     \"Overview of genetic variation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Non-homologous recombination, often referred to as non-allelic homologous recombination (NAHR), is an error in crossing-over because of faulty chromosome alignment. Non-homologous recombination can lead to the creation of gene duplications or deletions, or more complex chromosome rearrangements. Examples include the exchange between chromosome 9 and chromosome 22 that results in the t(9:22) translocation of chronic myeloid leukemia.",
"     </li>",
"     <li>",
"      Segregation errors due to nondisjunction can lead to numerical chromosome aberrations, such as monosomies or trisomies. Nondisjunction describes an error in meiosis in which chromosomes or sister chromatids segregate together into one gamete, rather than each segregating into different gametes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     RNA transcription",
"    </span>",
"    &nbsp;&mdash;&nbsp;RNA transcription is template-directed, but differs from DNA replication in several fundamental ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DNA replication is a global and simultaneous process across the genome that occurs during the S phase of the cell cycle. In contrast, RNA transcription is a local and contextual process, occurring at distinct genomic positions at defined times in response to various triggers.",
"     </li>",
"     <li>",
"      RNA transcription is regulated through the coordinated actions of cellular machinery that control DNA unfolding and chromatin activation, transcription factor binding, and regulation of mRNA metabolism.",
"     </li>",
"     <li>",
"      RNA transcription is initiated by the binding of specific transcription factors to DNA sequence motifs flanking the gene of interest. The binding of these factors initiates a cascade of programmed protein recruitment ultimately leading to the binding of RNA polymerase to the 5' end of the gene DNA sequence.",
"     </li>",
"     <li>",
"      Like DNA polymerase, RNA polymerase catalyzes RNA chain elongation by reading the DNA template and driving the formation of 3' to 5' phosphodiesterase bonds. However, RNA polymerase substitutes uracil for thymine moieties.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Post-transcription modification of mRNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the process of translation (formation of specific proteins from an RNA template), precursor mRNA (pre-mRNA), the first RNA transcript that contains both exons and introns, undergoes several modifications: splicing, capping, and polyadenylation (",
"    <a class=\"graphic graphic_figure graphicRef70605 \" href=\"UTD.htm?21/43/22193\">",
"     figure 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Splicing",
"    </span>",
"    &nbsp;&mdash;&nbsp;RNA transcription is a continuous process, yet the DNA sequence that codes for protein (exons) is often interrupted by intervening non-coding sequences (introns). These intron segments must be removed or spliced out of the RNA prior to translation.",
"   </p>",
"   <p>",
"    The splicing process can lead to production of several different proteins from one gene. The following factors are involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spliceosomes are enzymatic ribonucleoprotein complexes that remove introns from the primary RNA transcript (pre-mRNA) to produce mature mRNA.",
"     </li>",
"     <li>",
"      Intron boundaries are marked by conserved splice donor (end of an",
"      <span class=\"nowrap\">",
"       exon/start",
"      </span>",
"      of an intron) and splice acceptor (end of an",
"      <span class=\"nowrap\">",
"       intron/start",
"      </span>",
"      of an exon) sites. These splice sites provide sequence recognition sites for the spliceosomes. Mutations that alter splice sites can impair normal splicing and can cause disease.",
"     </li>",
"     <li>",
"      Tissue-specific splicing is regulated by the binding of enhancers and suppressors to DNA. Differential exon splicing leads to formation of related but unique mRNA sequences that encode different proteins, known as protein isoforms.",
"     </li>",
"     <li>",
"      Differential splicing of coding exons results in differences in the ultimate protein structure. Hence, genes often encode more than one protein (",
"      <a class=\"graphic graphic_figure graphicRef68285 \" href=\"UTD.htm?25/17/25872\">",
"       figure 11",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Capping",
"    </span>",
"    &nbsp;&mdash;&nbsp;To improve transcript stability, the 5' end of mRNA is modified by the linking of an inverted methylated guanosine (m7G). The cap prevents 5' binding to other nucleic acid chains. Other functions include protection from exonucleases, initiation of translation through ribosomal binding, and mRNA translocation from nucleus to cytoplasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Polyadenylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A long tail of adenine molecules is added to the 3' end of most transcripts (polyA tail). In addition to increasing transcript stability, the polyA tail is needed for proper tertiary structure formation and subsequent initiation of translation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Translation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mature mRNA serves as template to direct the synthesis of proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17846/abstract/3\">",
"     3",
"    </a>",
"    ]. Like DNA and RNA, protein is composed of modular units (amino acids) linked together in a chain. The protein backbone is composed of aminocarboxyl moieties linked together, with the chemical characteristics of each amino acid determined by 1 of 20 side chains (",
"    <a class=\"graphic graphic_figure graphicRef78753 \" href=\"UTD.htm?1/29/1496\">",
"     figure 12",
"    </a>",
"    ). The mature mRNA dictates the linear sequence of amino acids.",
"   </p>",
"   <p>",
"    Proteins differ from each other by their polypeptide sequence. The collective interactions of the various side chains confer tertiary polypeptide structure, which in turn confers distinct functions.",
"   </p>",
"   <p>",
"    mRNA is transported from the nucleus to the endoplasmic reticulum in the cytoplasm. The endoplasmic reticulum is composed of ribosomes, complex ribonucleoprotein structures that include the enzymatic machinery for protein synthesis. Ribosomal proteins bind the 5' end of mRNA to initiate translation.",
"   </p>",
"   <p>",
"    Protein synthesis is template directed and the base sequence in mRNA specifies the amino acid sequence in the protein. The specific amino acid sequence can be decoded by reading groups of three consecutive bases. These base triplets are known as codons.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are 64 codons (each codon is a 3 base triplet and there are 4 possible bases for each position). Almost all codons encode one of the 20 amino acids used in protein synthesis with the exceptions of three stop or termination codons. Most amino acids can be specified by more than one codon, termed functional redundancy or degeneracy (",
"      <a class=\"graphic graphic_figure graphicRef73711 \" href=\"UTD.htm?4/23/4471\">",
"       figure 13",
"      </a>",
"      ). One codon, AUG, serves the dual functions of signaling the start of translation and encoding methionine.",
"     </li>",
"     <li>",
"      Codons differing only at the third base position typically code for the same amino acid or amino acids with similar chemical properties.",
"     </li>",
"     <li>",
"      Three codons (UGA, UAA, and UAG) do not code for amino acids but signal the end of the protein (stop or termination codons).",
"     </li>",
"     <li>",
"      By convention, codons are listed as mRNA sequences, with U for uracil replacing T for thymine. The nucleic acid sequence is written in a 5' to 3' direction, and the protein sequence is recorded from N-terminal to C-terminal. These directions correspond to the direction of synthesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RNA translation is initiated when the ribosomal unit recognizes the initiation or start codon (typically AUG, coding for methionine). The ribosomal unit exposes the AUG codon, enabling binding of transfer RNA (tRNA). tRNAs are RNAs that bind specific codons.",
"   </p>",
"   <p>",
"    Each tRNA has a complementary 3-base sequence (the anti-codon) corresponding to the 3-based codon encoding a specific amino acid. The methionine-bound tRNA binds to the initiation codon, facilitating 3' advancement of the ribosomal machinery and in turn exposing the subsequent adjacent 3-base codon for recognition by the appropriate anti-codon tRNA. The corresponding amino acid residue is joined to the methionine. This process is repeated so that successive amino acids are incorporated into the growing polypeptide chain (chain elongation) (",
"    <a class=\"graphic graphic_figure graphicRef59052 \" href=\"UTD.htm?14/48/15109\">",
"     figure 14",
"    </a>",
"    ). Translation is terminated after one of the three stop codons (UGA, UAA, or UAG) is reached; thereafter, no additional amino acid is added.",
"   </p>",
"   <p>",
"    The progressive movement of the ribosome along the RNA molecule allows multiple ribosomes to simultaneously synthesize copies of a protein from a single mRNA molecule. This can be observed microscopically by the presence of polyribosomes, termed polysomes, which represent tight, spatial arrays of ribosomes translating a single mRNA molecule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Post-translational modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteins often undergo additional modifications following translation. Possible protein modifications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation through cleavage of an upstream leader sequence by a protease (eg, the cleavage of proinsulin to active insulin)",
"     </li>",
"     <li>",
"      Regulatory modification (eg, addition of a small chemical group: glycosylation [addition of a glycosyl group], carboxylation, phosphorylation [addition of a phosphate group], and oxidation)",
"     </li>",
"     <li>",
"      Structural modifications (eg, attachment of membrane anchoring molecules)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The general principles regarding the unidirectional flow of biological information (DNA to mRNA to protein) are reflected in most cellular processes. However, exceptions to these principles abound.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Not all functional RNA codes for protein. Many DNA sequences that are actively transcribed to RNA do not encode proteins. In addition to mRNA and tRNA discussed above, other types of RNA include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ribosomal RNA (rRNA), the RNA contained within a ribosome. rRNA may combine with ribosomal proteins to facilitate translation.",
"     </li>",
"     <li>",
"      Small nuclear RNA (snRNA) molecules combine with splicing proteins to form the spliceosome.",
"     </li>",
"     <li>",
"      Some double stranded RNAs, known as short-interfering RNA (siRNA), direct the targeted degradation of homologous mRNA molecules, interfering with their translation into proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17846/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many viruses store their genetic information as RNA rather than as DNA. Several different mechanisms have been incorporated into viral life cycles to accommodate this difference from the biology of their host cells.",
"     </li>",
"     <li>",
"      Retroviruses utilize reverse transcription to integrate into the host genome following infection [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17846/abstract/5\">",
"       5",
"      </a>",
"      ]. In these instances, the flow of genetic information is from RNA to DNA, then back to RNA prior to translation.",
"     </li>",
"     <li>",
"      The mitochondrial genetic code differs from the nuclear genetic code in that UGA encodes tryptophan, rather than a termination codon [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17846/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Epigenetic modifications, including DNA methylation and genetic imprinting, are inherited (transmissible from parent to offspring) changes in gene activity that occur without alterations to DNA sequence. These modifications can impart parent-of-origin effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IMPLICATIONS FOR MEDICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of specific base pairing for the development of a normal organism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the maintenance of health cannot be overstated. The mechanisms of template-directed replication and transcription allow for preservation of genetic information that will encode functional proteins.",
"   </p>",
"   <p>",
"    Errors in these processes, as well as intrinsic properties of this molecular machinery, have direct implications for the practice of medicine. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Errors in replication account for mutations (either inherited or de novo) that cause a wide variety of diseases, including inherited disorders and malignancies.",
"     </li>",
"     <li>",
"      Divergence between humans and bacteria in the transcriptional and translational enzymatic machinery provides the molecular targets for an array of antibiotics that are lethal to bacteria but harmless to humans.",
"     </li>",
"     <li>",
"      Sequence-specific DNA and RNA hybridization methods, predicated on the specificity of base pairing, are central to many routine laboratory methods. Such methods include the polymerase chain reaction (PCR), in-situ hybridization for measurement of gene expression, chromosome microarrays for measurement of copy number, genotyping using single nucleotide polymorphisms (SNPs), and characterization of structural genetic variation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17846/abstract/8-11\">",
"       8-11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The flow of information from DNA to RNA to protein is most commonly unidirectional. Heritable genetic information, stored as DNA, is faithfully replicated and transmitted from one generation to the next. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Principles of molecular biology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DNA replication occurs prior to initiation of cell division (mitosis and meiosis). Complementary base pairing allows a single strand of DNA to serve as the template for copying a new complementary strand and preserves the encoded genetic information. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'The double helix and template-directed nucleic acid synthesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meiosis is the process of generating gametes through two successive sets of cell division. The goal of generating diverse, haploid gametes is achieved through the processes of recombination and independent assortment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Meiosis and sustained genetic diversity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Copying DNA into RNA, through the process of transcription, activates genes. There are several important structural differences between DNA and RNA (see",
"      <a class=\"local\" href=\"#H7\">",
"       'RNA transcription'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In DNA, the sugar is 2-deoxyribose, whereas it is ribose in RNA. DNA is therefore more stable.",
"     </li>",
"     <li>",
"      In DNA, thymine is the pyrimidine complementary to adenine, but uracil replaces thymine in RNA.",
"     </li>",
"     <li>",
"      DNA is double-stranded and RNA is single-stranded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Post- transcriptional modifications include intron splicing, mRNA capping, and polyadenylation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Post-transcription modification of mRNA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Translation is the process of template-directed peptide synthesis. Post-translational modifications confer additional functional properties to mature peptide sequences. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Translation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Post-translational modification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Nussbaum RL, McInnes RR, Willard HF. Thompson and Thompson Genetics in Medicine, W.B. Saunders, Philadelphia 2007.",
"    </li>",
"    <li>",
"     Strachan T, Read A. Human Molecular Genetics, 4th ed, Garland Science, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17846/abstract/3\">",
"      Nirenberg M. Protein synthesis and the RNA code. Harvey Lect 1965; 59:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17846/abstract/4\">",
"      Plasterk RH. RNA silencing: the genome's immune system. Science 2002; 296:1263.",
"     </a>",
"    </li>",
"    <li>",
"     Temin HM. The DNA Provirus Hypothesis. Nobel Prize Lecture, 1975. Available at: nobelprize.org/medicine/laureates/1975/temin-lecture.pdf (Accessed on March 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17846/abstract/6\">",
"      Barrell BG, Bankier AT, Drouin J. A different genetic code in human mitochondria. Nature 1979; 282:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17846/abstract/7\">",
"      Hall BD. Mitochondria spring surprises. Nature 1979; 282:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17846/abstract/8\">",
"      Chee M, Yang R, Hubbell E, et al. Accessing genetic information with high-density DNA arrays. Science 1996; 274:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17846/abstract/9\">",
"      Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996; 14:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17846/abstract/10\">",
"      Sapolsky RJ, Hsie L, Berno A, et al. High-throughput polymorphism screening and genotyping with high-density oligonucleotide arrays. Genet Anal 1999; 14:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17846/abstract/11\">",
"      Liyanage M, Coleman A, du Manoir S, et al. Multicolour spectral karyotyping of mouse chromosomes. Nat Genet 1996; 14:312.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2900 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17846=[""].join("\n");
var outline_f17_27_17846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF MOLECULAR BIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nucleic acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      The double helix and template-directed nucleic acid synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mitosis and DNA replication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Meiosis and sustained genetic diversity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RNA transcription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Post-transcription modification of mRNA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Splicing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Capping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Polyadenylation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Translation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Post-translational modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IMPLICATIONS FOR MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2900\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2900|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/61/40926\" title=\"figure 1\">",
"      Central dogma molecular bio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/35/41520\" title=\"figure 2\">",
"      Chemical structure DNA and RNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/24/14724\" title=\"figure 3\">",
"      Nucleotides building blocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/44/14017\" title=\"figure 4\">",
"      Structure of DNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/18/28965\" title=\"figure 5\">",
"      DNA replication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/35/21040\" title=\"figure 6\">",
"      Mitosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/48/23301\" title=\"figure 7\">",
"      The cell cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/34/39460\" title=\"figure 8\">",
"      Meiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/11/6323\" title=\"figure 9\">",
"      Chromosomal recombination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/43/22193\" title=\"figure 10\">",
"      mRNA processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/17/25872\" title=\"figure 11\">",
"      Differential splicing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/29/1496\" title=\"figure 12\">",
"      Structure amino acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/23/4471\" title=\"figure 13\">",
"      Genetic code",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/48/15109\" title=\"figure 14\">",
"      Translation RNA to protein",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_27_17847="Skeletal muscle dysfunction and exercise intolerance in heart failure";
var content_f17_27_17847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Skeletal muscle dysfunction and exercise intolerance in heart failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/27/17847/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17847/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/27/17847/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17847/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/27/17847/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17847/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/27/17847/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hallmark of heart failure (HF) is exercise intolerance due to dyspnea and fatigue. These symptoms were, in the past, thought to result entirely from central hemodynamic derangements, which might be reversed by inotropic agents",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vasodilators. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, it is now clear that significant skeletal muscular pathology is also present in HF and may contribute to the associated symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/1\">",
"     1",
"    </a>",
"    ]. The evidence associating skeletal muscular abnormalities and exercise intolerance, and the beneficial effects of cardiac rehabilitation for patients with HF will be reviewed here. An overview of normal exercise physiology, the use of measurement of peak oxygen uptake (peak VO2) to assess exercise capacity and prognosis, and the ability of cardiac rehabilitation to improve exercise capacity in patients with mild to moderate HF are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"     \"Exercise physiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPACT OF MEDICAL THERAPY ON EXERCISE TOLERANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise capacity is reduced even in mild heart failure. Exercise intolerance and fatigue may be the result of a reduction in cardiac output, which is due primarily to impaired myocardial function, and may be exaggerated by decreased plasma and blood volumes caused by excessive diuresis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the cardiac output may be relatively normal at rest, it is usually unable to increase adequately with even mild exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/3\">",
"     3",
"    </a>",
"    ]. As in normal subjects, peak VO2 in patients with HF is directly related to peak exercise cardiac output and muscle blood flow (",
"    <a class=\"graphic graphic_figure graphicRef65079 \" href=\"UTD.htm?7/45/7902\">",
"     figure 1",
"    </a>",
"    ). However, the inability to appropriately increase cardiac output in HF results in an insufficient increase in perfusion to exercising muscle, which can cause early anaerobic metabolism, an inadequate increase in muscle strength, and muscle fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the success of medical therapy for HF in the early 1980s, several investigators evaluated the acute impact of inotropic agents and vasodilators on exercise capacity in patients with HF. As an example, one study evaluated 11 patients with New York Heart Association (NYHA) class III HF and a mean left ventricular ejection fraction (LVEF) of 20 percent who underwent exercise on a bicycle ergometer before and during infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/5\">",
"     5",
"    </a>",
"    ]. Although dobutamine improved peak exercise cardiac output (6.5 versus 7.4",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    p &lt;0.01) and reduced pulmonary capillary wedge pressure (PCWP), it failed to significantly increase exercise duration (5.5 versus 5.8 minutes).",
"   </p>",
"   <p>",
"    Another study investigated the effect of the potent vasodilator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    on blood flow to exercising skeletal muscle and exercise capacity in 10 patients with NYHA class III HF and a mean LVEF of 19 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/6\">",
"     6",
"    </a>",
"    ]. Hydralazine, administered intravenously, substantially increased peak cardiac output during exercise on a bicycle ergometer (5.6 versus 6.7",
"    <span class=\"nowrap\">",
"     L/min,",
"    </span>",
"    p &lt;0.01) and improved femoral venous flow, indicating improved femoral arterial flow and delivery of oxygen to the exercising skeletal muscle. However, maximal oxygen consumption (VO2max) was unaffected because of a reduction in systemic and leg oxygen extraction after hydralazine administration.",
"   </p>",
"   <p>",
"    A similar lack of improvement in exercise capacity, despite hemodynamic improvement, has also been noted after the acute administration of other vasodilators including angiotensin converting enzyme (ACE) inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/7,8\">",
"     7,8",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/9\">",
"     9",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"     prazosin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/10\">",
"     10",
"    </a>",
"    ]. The inability of inotropic and vasodilator therapies that acutely improve hemodynamic function to increase exercise capacity has suggested that exercise impairment in heart failure may reflect additional factors such as intrinsic skeletal muscular defect in oxygen utilization.",
"   </p>",
"   <p>",
"    In contrast, chronic therapy with ACE inhibitors does improve exercise capacity and symptoms. It is uncertain if these beneficial effects of ACE inhibitors are the result of improved cardiac output or are related to skeletal muscle factors. One study obtained muscle biopsies from patients with HF prior to and after therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    and compared them to those obtained from normals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/11\">",
"     11",
"    </a>",
"    ]. Enalapril had no effect on skeletal muscle metabolism or on the number of capillaries per muscle fiber, both of which were reduced in HF. There was an increase in muscle fiber area but this was probably due to increased physical activity. In another study, treatment with either enalapril or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    for six months improved exercise capacity in association with a shift in leg muscle contractile protein composition toward more fatigue-resistant fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/12\">",
"     12",
"    </a>",
"    ]. How these changes might occur is not understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SKELETAL MUSCLE DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inability of an acute increase in cardiac output to improve exercise tolerance in patients with HF suggests that factors in addition to the low muscle blood flow during exercise may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. One such factor is skeletal muscle dysfunction induced by chronic hypoperfusion, which can lead to muscle wasting, interference with oxygen utilization, and delayed recovery of muscle and total body oxygenation after submaximal exercise (",
"    <a class=\"graphic graphic_figure graphicRef54643 \" href=\"UTD.htm?29/58/30638\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/4,13,14\">",
"     4,13,14",
"    </a>",
"    ]. Physical deconditioning also may play a contributory role [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocyte apoptosis is seen in the skeletal muscles of patients with chronic heart failure and its magnitude is associated with the severity of exercise capacity limitation and the degree of muscle atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Capillary density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary density strongly correlates with human skeletal muscle oxidative capacity and may play a role in determining exercise capacity in patients with HF. In one study of 22 males with HF and 10 normal controls, those with HF had a significant reduction in microvascular density in the absence of other major peripheral skeletal muscle alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/17\">",
"     17",
"    </a>",
"    ]. There was an inverse relationship between capillary density and maximal oxygen consumption and total exercise time, suggesting that a reduction in capillary density within skeletal muscle may precede biochemical and functional alterations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oxidative stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxidative stress and the generation of reactive oxygen species (ROS) play an important role in the development of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27337?source=see_link\">",
"     \"Role of oxidative stress in heart failure\"",
"    </a>",
"    .) Oxidative stress may also be related to exercise intolerance in these patients. As an example, one animal model of heart failure found an increase in the generation of ROS within skeletal muscle; this was associated with ROS-mediated lipid peroxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Biochemical abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal muscle fibers of each motor unit are homogeneous and may be either twitch type I (also called red or slow fibers) or twitch type II (also called white or fast fibers) based upon their myoglobin content and time-to-peak tension (",
"    <a class=\"graphic graphic_table graphicRef62260 \" href=\"UTD.htm?4/16/4363\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I fibers have a high oxidative capacity, are fatigue-resistant, and are recruited for low-level endurance exercise.",
"     </li>",
"     <li>",
"      Type II fibers have a high glycolytic capacity and are recruited for short bursts of rapid, heavy work. There are two subtypes of type II fibers: type IIa are slow twitch, while type IIb are fast twitch.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of biochemical abnormalities in skeletal muscle have been identified in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/1\">",
"     1",
"    </a>",
"    ]. In one study, for example, skeletal muscle biopsy revealed atrophy of both type IIa and IIb fibers, an increased percentage of the fast twitch, easily fatigable type IIb fibers, and preservation of type I fiber size [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/20\">",
"     20",
"    </a>",
"    ]. There was a significant inverse correlation between the percentage of type IIb fibers and VO2max, suggesting that an increase in this fiber type may be in part responsible for the observed exercise intolerance (",
"    <a class=\"graphic graphic_figure graphicRef66406 \" href=\"UTD.htm?28/14/28909\">",
"     figure 3",
"    </a>",
"    ). There was also a significant positive correlation between the percentage of the slow twitch \"endurance\" type I fibers and peak VO2. In addition, there is increased synthesis of fast, more fatiguable myosin heavy chain isoforms that have higher oxygen and ATP consumption and reach anaerobic threshold earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/16\">",
"     16",
"    </a>",
"    ]. Despite the shift in fiber type, myofibrillar contractile capacity and calcium sensitivity are not altered; however, there are alterations in mitochondrial function, suggesting that the myopathy in HF is metabolic in origin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To further delineate skeletal muscle metabolism in patients with HF, magnetic resonance spectroscopy has been utilized to evaluate high-energy phosphate fluxes during exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. The energy supply for skeletal muscle contraction comes from the breakdown of adenosine triphosphate (ATP) to adenosine diphosphate (ADP) and inorganic phosphate (Pi). Phosphocreatine (PCr) serves as the high energy phosphate store in skeletal muscle, and donates its phosphate group to ADP to regenerate ATP and creatine (Cr). When energy is available from nutrient metabolism, Pi is added to Cr to regenerate PCr. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=see_link\">",
"     \"Energy metabolism in muscle\"",
"    </a>",
"    .) These reactions can be summarized by the following three equations:",
"   </p>",
"   <p>",
"    &nbsp;ATP &nbsp;--&gt; &nbsp;ADP + Pi",
"   </p>",
"   <p>",
"    &nbsp;PCr &nbsp;+ &nbsp;ADP &nbsp;--&gt; &nbsp;ATP &nbsp;+ &nbsp;Cr",
"   </p>",
"   <p>",
"    &nbsp;Pi &nbsp;+ &nbsp;Cr &nbsp;--&gt; &nbsp;PCr",
"   </p>",
"   <p>",
"    Magnetic resonance (MR) spectroscopy can detect the phosphorus-31 radioisotope of each of the three phosphate peaks of ATP as well as the PCr and Pi peaks (",
"    <a class=\"graphic graphic_figure graphicRef77265 \" href=\"UTD.htm?42/54/43885\">",
"     figure 4",
"    </a>",
"    ). The ratio of the areas under the Pi and PCr peaks provides an estimation of the high energy phosphate supply available for utilization. An increase in the",
"    <span class=\"nowrap\">",
"     Pi/PCr",
"    </span>",
"    ratio suggests a reduction in energy supply and is an useful indicator of the rate of energy utilization during exercise. On the other hand, the normalized PCr ratio (PCr &nbsp;&divide; &nbsp;[PCr &nbsp;+ &nbsp;Pi]) increases as high energy phosphate supply increases.",
"   </p>",
"   <p>",
"    One study compared exercise MR spectroscopy data from the flexor digitorum superficialis muscle during finger flexion exercise in 22 men with HF and 11 age and size-matched normal volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/22\">",
"     22",
"    </a>",
"    ]. The following findings were noted in the patients with HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significantly lower intracellular pH at each workload, suggesting lactic acid accumulation due to anaerobic metabolism.",
"     </li>",
"     <li>",
"      A significantly lower normalized PCr ratio at each workload, indicating more rapid depletion and less efficient utilization of high energy phosphates during exercise.",
"     </li>",
"     <li>",
"      No difference in forearm venous blood flow during exercise utilizing plethysmographic measurements, indicating that the metabolic abnormalities were not due to vascular insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later study noted similar findings, with PCr depletion occurring at a much lower peak VO2 in patients with HF compared to normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, muscle metabolic capacity was correlated with peak VO2 during maximal exercise.",
"   </p>",
"   <p>",
"    Other changes that have been described in patients with HF include fewer capillaries surrounding each muscle fiber, higher lactate dehydrogenase activity, and reduced succinate dehydrogenase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. These findings suggest a reduction in effective mitochondrial number",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function.",
"   </p>",
"   <p>",
"    In summary, patients with HF have skeletal muscle atrophy, an increased percentage of type IIb fibers, and intrinsic skeletal muscular metabolic defects, leading to less efficient use of high energy phosphates and more rapid accumulation of lactic acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Functional abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to these structural and biochemical defects, a number of functional abnormalities have been identified in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skeletal muscle ergoreceptors or metaboreceptors are enhanced in HF, possibly resulting in an increase in the ventilatory response to exercise and the sensation of dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/13,26\">",
"       13,26",
"      </a>",
"      ]. Continuous inspired oxygen may reduce ventilation at rest and with exercise, and increase exercise duration, suggesting that suppression of peripheral chemoreceptors may improve exercise capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The inadequate forward output leads to increased sympathetic tone, peripheral vasoconstriction, and reductions in renal blood flow and urinary sodium and water excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/27\">",
"       27",
"      </a>",
"      ]. This response to exertion explains in part the tendency for patients to retain sodium and water during the day when they are more active.",
"     </li>",
"     <li>",
"      Increased levels of inducible nitric oxide synthase and nitric oxide within skeletal muscles may contribute to reduced muscle contractile performance and muscle wasting [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/28\">",
"       28",
"      </a>",
"      ]. In one report, for example, the relative amount of mitochondrial creatine kinase, a key enzyme for rapid energy transfer from mitochondria to cytosol, was significantly reduced in patients with HF compared to controls; the amount of mitochondrial creatine kinase was inversely correlated with inducible nitric oxide synthase expression [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Involvement of the respiratory muscles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal muscle dysfunction can involve the respiratory muscles as part of the generalized skeletal myopathy in HF [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/30\">",
"     30",
"    </a>",
"    ]. This abnormality may contribute to dyspnea on exertion and may help identify patients with a worse prognosis, particularly those with an intermediate VO2max (10 to 20",
"    <span class=\"nowrap\">",
"     mL/mg",
"    </span>",
"    per kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diaphragm shows a different adaptation from skeletal and respiratory muscle. There is a shift from fast to slow fibers with an increase in oxidative capacity and a decrease in glycolytic capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/32\">",
"     32",
"    </a>",
"    ]. These changes are similar to those seen in the limb muscles that occur with endurance training, suggesting that they result from the increased work of breathing.",
"   </p>",
"   <p>",
"    There are also changes in pulmonary function in HF. Even in the absence of pulmonary congestion, HF is associated with an exaggerated increase in minute ventilation in response to exercise, out of proportion to the increase in carbon dioxide production [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Hyperventilation is primarily due to",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    mismatching, the severity of which is related to the severity of the heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17847/abstract/34\">",
"     34",
"    </a>",
"    ]. The combination of increased ventilation and normal gas exchange (unless limited by pulmonary congestion) means that arterial hypoxia does not generally occur during exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2925527\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise intolerance in patients with heart failure is caused by hemodynamic derangements as well as by skeletal muscle dysfunction. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Skeletal muscle dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise capacity improves with chronic angiotensin converting enzyme (ACE) inhibitor therapy, although it does not improve after acute administration of drugs such as ACE inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36198?source=see_link\">",
"       isosorbide dinitrate",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Impact of medical therapy on exercise tolerance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic hypoperfusion and physical deconditioning may contribute to the structural and functional abnormalities in skeletal muscle seen in patients with heart failure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Skeletal muscle dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with heart failure have skeletal muscle atrophy, an increased percentage of type IIb fibers, and intrinsic skeletal muscular metabolic defects, leading to less efficient use of high energy phosphates and more rapid accumulation of lactic acid. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Biochemical abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skeletal muscle dysfunction involving the respiratory muscles may contribute to dyspnea in patients with heart failure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Involvement of the respiratory muscles'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/1\">",
"      Kokkinos PF, Choucair W, Graves P, et al. Chronic heart failure and exercise. Am Heart J 2000; 140:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/2\">",
"      Feigenbaum MS, Welsch MA, Mitchell M, et al. Contracted plasma and blood volume in chronic heart failure. J Am Coll Cardiol 2000; 35:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/3\">",
"      Reddy HK, Weber KT, Janicki JS, McElroy PA. Hemodynamic, ventilatory and metabolic effects of light isometric exercise in patients with chronic heart failure. J Am Coll Cardiol 1988; 12:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/4\">",
"      Harrington D, Anker SD, Chua TP, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 1997; 30:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/5\">",
"      Wilson JR, Martin JL, Ferraro N. Impaired skeletal muscle nutritive flow during exercise in patients with congestive heart failure: role of cardiac pump dysfunction as determined by the effect of dobutamine. Am J Cardiol 1984; 53:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/6\">",
"      Wilson JR, Martin JL, Ferraro N, Weber KT. Effect of hydralazine on perfusion and metabolism in the leg during upright bicycle exercise in patients with heart failure. Circulation 1983; 68:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/7\">",
"      Kugler J, Maskin C, Frishman WH, et al. Regional and systemic metabolic effects of angiotensin-converting enzyme inhibition during exercise in patients with severe heart failure. Circulation 1982; 66:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/8\">",
"      Wilson JR, Ferraro N. Effect of the renin-angiotensin system on limb circulation and metabolism during exercise in patients with heart failure. J Am Coll Cardiol 1985; 6:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/9\">",
"      Franciosa JA, Goldsmith SR, Cohn JN. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am J Med 1980; 69:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/10\">",
"      Wilson JR, Ferraro N, Wiener DH. Effect of the sympathetic nervous system on limb circulation and metabolism during exercise in patients with heart failure. Circulation 1985; 72:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/11\">",
"      Schaufelberger M, Andersson G, Eriksson BO, et al. Skeletal muscle changes in patients with chronic heart failure before and after treatment with enalapril. Eur Heart J 1996; 17:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/12\">",
"      Vescovo G, Dalla Libera L, Serafini F, et al. Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition. Circulation 1998; 98:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/13\">",
"      Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J Am Coll Cardiol 1996; 28:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/14\">",
"      Belardinelli R, Barstow TJ, Nguyen P, Wasserman K. Skeletal muscle oxygenation and oxygen uptake kinetics following constant work rate exercise in chronic congestive heart failure. Am J Cardiol 1997; 80:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/15\">",
"      Chati Z, Zannad F, Jeandel C, et al. Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure. Am Heart J 1996; 131:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/16\">",
"      Vescovo G, Volterrani M, Zennaro R, et al. Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart 2000; 84:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/17\">",
"      Duscha BD, Kraus WE, Keteyian SJ, et al. Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations. J Am Coll Cardiol 1999; 33:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/18\">",
"      Tsutsui H, Ide T, Hayashidani S, et al. Enhanced generation of reactive oxygen species in the limb skeletal muscles from a murine infarct model of heart failure. Circulation 2001; 104:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/19\">",
"      Pette D. Metabolic heterogeneity of muscle fibres. J Exp Biol 1985; 115:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/20\">",
"      Mancini DM, Coyle E, Coggan A, et al. Contribution of intrinsic skeletal muscle changes to 31P NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. Circulation 1989; 80:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/21\">",
"      De Sousa E, Veksler V, Bigard X, et al. Heart failure affects mitochondrial but not myofibrillar intrinsic properties of skeletal muscle. Circulation 2000; 102:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/22\">",
"      Massie B, Conway M, Yonge R, et al. Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood flow. Circulation 1987; 76:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/23\">",
"      Okita K, Yonezawa K, Nishijima H, et al. Skeletal muscle metabolism limits exercise capacity in patients with chronic heart failure. Circulation 1998; 98:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/24\">",
"      Massie BM, Simonini A, Sahgal P, et al. Relation of systemic and local muscle exercise capacity to skeletal muscle characteristics in men with congestive heart failure. J Am Coll Cardiol 1996; 27:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/25\">",
"      Schaufelberger M, Eriksson BO, Grimby G, et al. Skeletal muscle alterations in patients with chronic heart failure. Eur Heart J 1997; 18:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/26\">",
"      Chua TP, Ponikowski PP, Harrington D, et al. Contribution of peripheral chemoreceptors to ventilation and the effects of their suppression on exercise tolerance in chronic heart failure. Heart 1996; 76:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/27\">",
"      Millard RW, Higgins CB, Franklin D, Vatner SF. Regulation of the renal circulation during severe exercise in normal dogs and dogs with experimental heart failure. Circ Res 1972; 31:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/28\">",
"      Riede UN, F&ouml;rstermann U, Drexler H. Inducible nitric oxide synthase in skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 1998; 32:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/29\">",
"      Hambrecht R, Adams V, Gielen S, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol 1999; 33:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/30\">",
"      Walsh JT, Andrews R, Johnson P, et al. Inspiratory muscle endurance in patients with chronic heart failure. Heart 1996; 76:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/31\">",
"      Meyer FJ, Borst MM, Zugck C, et al. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation 2001; 103:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/32\">",
"      Tikunov B, Levine S, Mancini D. Chronic congestive heart failure elicits adaptations of endurance exercise in diaphragmatic muscle. Circulation 1997; 95:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/33\">",
"      Sullivan MJ, Higginbotham MB, Cobb FR. Increased exercise ventilation in patients with chronic heart failure: intact ventilatory control despite hemodynamic and pulmonary abnormalities. Circulation 1988; 77:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17847/abstract/34\">",
"      Buller NP, Poole-Wilson PA. Mechanism of the increased ventilatory response to exercise in patients with chronic heart failure. Br Heart J 1990; 63:281.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3473 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-4C9EBFD82E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17847=[""].join("\n");
var outline_f17_27_17847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2925527\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPACT OF MEDICAL THERAPY ON EXERCISE TOLERANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SKELETAL MUSCLE DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Capillary density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oxidative stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Biochemical abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Functional abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Involvement of the respiratory muscles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2925527\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3473\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3473|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/45/7902\" title=\"figure 1\">",
"      Exercise in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/58/30638\" title=\"figure 2\">",
"      Muscle abnormalities in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/14/28909\" title=\"figure 3\">",
"      Muscle fiber type VO2 in HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/54/43885\" title=\"figure 4\">",
"      MRS at rest in HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3473|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/16/4363\" title=\"table 1\">",
"      Muscle fiber characteristics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14008?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in heart failure: Mechanisms of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=related_link\">",
"      Energy metabolism in muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=related_link\">",
"      Exercise capacity and VO2 in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27337?source=related_link\">",
"      Role of oxidative stress in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_27_17848="Indomethacin: Pediatric drug information";
var content_f17_27_17848=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indomethacin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"    see \"Indomethacin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/34/550?source=see_link\">",
"    see \"Indomethacin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Indocin&reg;;",
"     </li>",
"     <li>",
"      Indocin&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Indomethacin&reg;;",
"     </li>",
"     <li>",
"      Indocid&reg; P.D.A.;",
"     </li>",
"     <li>",
"      Novo-Methacin;",
"     </li>",
"     <li>",
"      Nu-Indo;",
"     </li>",
"     <li>",
"      Pro-Indo;",
"     </li>",
"     <li>",
"      ratio-Indomethacin;",
"     </li>",
"     <li>",
"      Sandoz-Indomethacin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Non-narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipyretic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patent ductus arteriosus, treatment: Initial: 0.2 mg/kg/dose, followed by 2 doses depending on postnatal age (PNA):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA",
"     <b>",
"      at time of first dose",
"     </b>",
"     &lt;48 hours: 0.1 mg/kg at 12- to 24-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA",
"     <b>",
"      at time of first dose",
"     </b>",
"     2-7 days: 0.2 mg/kg at 12- to 24-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PNA",
"     <b>",
"      at time of first dose",
"     </b>",
"     &gt;7 days: 0.25 mg/kg at 12- to 24-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In general, may use 12-hour dosing interval if urine output &gt;1 mL/kg/hour after prior dose; use 24-hour dosing interval if urine output is &lt;1 mL/kg/hour but &gt;0.6 mL/kg/hour; doses should be withheld if patient has oliguria (urine output &lt;0.6 mL/kg/hour) or anuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patent ductus arteriosus, prophylaxis: Preterm neonates: Various regimens have been evaluated in VLBW neonates with first dose administered within the first 12-24 hours of life. Typical dosing: Initial: 0.1-0.2 mg/kg/dose followed by 0.1 mg/kg/dose every 12-24 hours for 2 additional doses (Fowlie, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"      see \"Indomethacin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inflammatory/rheumatoid disorders:",
"     <b>",
"      Note:",
"     </b>",
"     Use lowest effective dose: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;2 years: 1-2 mg/kg/day in 2-4 divided doses; maximum dose: 4 mg/kg/day; do not exceed 150-200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 25-50 mg/dose 2-3 times/day; maximum dose: 200 mg/day; extended release capsule should be given on a 1-2 times/day schedule",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 75 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Indocin&reg; I.V.: 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Indocin&reg;: 50 mg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Indocin&reg;: 25 mg/5 mL (237 mL) [contains ethanol 1%; pineapple-coconut-mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes oral suspension, suppository",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088612.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088612.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food, milk, or antacids to decrease GI adverse effects; extended release capsules must be swallowed whole, do not crush or chew",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Administer over 20-30 minutes at a concentration of 0.5-1 mg/mL in preservative free SWI or preservative free NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Do",
"     <b>",
"      not",
"     </b>",
"     administer via I.V. bolus or I.V. infusion via an umbilical catheter into vessels near the superior mesenteric artery, as these may cause vasoconstriction and can compromise blood flow to the intestines. Do not administer intra-arterially.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F182715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Furosemide, insulin (regular), nitroprusside, potassium chloride, sodium bicarbonate.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amino acid injection, calcium gluconate, cimetidine, dobutamine, dopamine, gentamicin, levofloxacin, pantoprazole, tobramycin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dextrose injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1053412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral suspension: Store below 86&deg;F; do not freeze",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. product: Protect from light; not stable in alkaline solution; reconstitute just prior to administration; discard any unused portion; do not use preservative-containing diluents for reconstitution; will precipitate if reconstituted with solutions at pH &lt;6 (product is not buffered)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of inflammatory diseases and rheumatoid disorders; moderate pain; acute gouty arthritis; I.V. form used as alternative to surgery for closure of patent ductus arteriosus (PDA) in neonates; has also been used for prophylaxis of PDA in VLBW neonates",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Indocin&reg; may be confused with Imodium&reg;, Lincocin&reg;, Minocin&reg;, Vicodin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F182714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, fatigue, headache, malaise, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain/cramps/distress, constipation, diarrhea, dyspepsia, epigastric pain, heartburn, indigestion, nausea, rectal irritation (suppository), tenesmus (suppository), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute respiratory distress, agranulocytosis, allergic rhinitis, anaphylaxis, anemia, angiitis, angioedema, aplastic anemia, arrhythmia, aseptic meningitis, asthma, bone marrow suppression, bronchospasm,  chest pain, cholestatic jaundice, coma, confusion, CHF, cystitis, depersonalization, depression, diplopia, disseminated intravascular coagulation (DIC), dysarthria, dyspnea, ecchymosis, edema, epistaxis, erythema multiforme, erythema nodosum, exfoliative dermatitis, fluid retention, flushing, hair loss, gastric perforation (rare), gastritis, GI bleeding, GI ulceration, glucosuria, gynecomastia, hearing decreased, hematuria, hemolytic anemia, hepatitis (including fatal cases), hot flashes, hyperglycemia, hyperkalemia, hypersensitivity reactions, hyper-/hypotension, interstitial nephritis, intestinal strictures,  involuntary muscle movements, leukopenia, lightheadedness, necrotizing fasciitis, nephrotic syndrome, oliguria, paresthesia, parkinson&rsquo;s exacerbation, peptic ulcer, peripheral neuropathy, proctitis, psychosis, pulmonary edema,  purpura, rectal bleeding, renal insufficiency, renal failure, retinal/macular disturbances, seizure exacerbation, shock, somnolence, Stevens-Johnson syndrome, stomatitis, syncope, thrombocytopenia, thrombocytopenic purpura, thrombophlebitis, toxic amblyopia, toxic epidermal necrolysis, ulcerative stomatitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to indomethacin or any component; history of asthma, urticaria, or allergic-type reaction to aspirin, or other NSAIDs; patients with the \"aspirin triad\" [asthma, rhinitis (with or without nasal polyps), and aspirin intolerance] (fatal asthmatic and anaphylactoid reactions may occur in these patients); perioperative pain in the setting of coronary artery bypass graft (CABG)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection is contraindicated in preterm infants with untreated proven or suspected infection; congenital heart disease where patency of the PDA is necessary for pulmonary or systemic blood flow (eg, pulmonary atresia, severe tetralogy of Fallot, severe coarctation of aorta); bleeding (especially with active intracranial hemorrhage or GI bleed); thrombocytopenia; coagulation defects; proven or suspected necrotizing enterocolitis (NEC); significant renal dysfunction",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Suppositories are contraindicated for use in patients with a history of proctitis or recent rectal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiac dysfunction, hypertension, renal or hepatic impairment, epilepsy, patients receiving anticoagulants and for treatment of JRA in children (fatal hepatitis has been reported; monitor children closely; assess liver function periodically)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including potentially fatal MI and stroke",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease; carefully evaluate cardiovascular risk profile prior to prescribing; use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk. Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; an increased incidence of MI and stroke was found in patients receiving COX-2 selective NSAIDs for the treatment of pain within the first 10-14 days after CABG surgery. NSAIDs may cause fluid retention, edema, and new-onset or worsening of pre-existing hypertension; use with caution in patients with hypertension, CHF, or fluid retention. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin's cardioprotective effect.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may increase the risk of gastrointestinal inflammation, ulceration, bleeding, and perforation",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These events, which can be potentially fatal, may occur at any time during therapy, and without warning. Avoid the use of NSAIDs in patients with active GI bleeding or ulcer disease. Use NSAIDs with extreme caution in patients with a history of GI bleeding or ulcers (these patients have a 10-fold increased risk for developing a GI bleed). Use NSAIDs with caution in patients with other risk factors which may increase GI bleeding (eg, concurrent therapy with aspirin, anticoagulants, and/or corticosteroids, longer duration of NSAID use, smoking, use of alcohol, and poor general health). Use the lowest effective dose for the shortest duration of time, taking into consideration individual patient treatment goals; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     NSAIDs may compromise existing renal function. Renal toxicity may occur in patients with impaired renal function, dehydration, heart failure, liver dysfunction, and those taking diuretics and ACE inhibitors; use with caution in these patients; monitor renal function closely. NSAIDs are not recommended for use in patients with advanced renal disease. Long-term use of NSAIDs may cause renal papillary necrosis and other renal injury.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Fatal asthmatic and anaphylactoid reactions may occur in patients with the &ldquo;aspirin triad&rdquo; who receive NSAIDs. NSAIDs may cause serious dermatologic adverse reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Avoid use of NSAIDs in late pregnancy as they may cause premature closure of the ductus arteriosus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F182702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (minor), CYP2C9 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Indomethacin may increase the serum concentration of Tiludronate.  Management: Separate doses of tiludronate at least two hours before or two hours after indomethacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triamterene: Indomethacin may enhance the nephrotoxic effect of Triamterene.  Management: Consider alternatives to concomitant treatment with triamterene and indomethacin.  If the combination cannot be avoided, monitor for development of renal failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1053426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food may decrease the rate but not the extent of absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7688406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies indomethacin as pregnancy category C. Indomethacin crosses the placenta and can be detected in fetal plasma and amniotic fluid. Indomethacin exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of an NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester, including myocardial degenerative changes, prenatal constriction of the ductus arteriosus, failure of the ductus arteriosus to close postnatally, and fetal tricuspid regurgitation; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; and pulmonary hypertension. The risk of fetal ductal constriction following maternal use of indomethacin is increased with gestational age and duration of therapy. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). Indomethacin has been used in the management of preterm labor. Indomethacin should be used with caution in pregnant women with hypertension. The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     BUN, serum creatinine, potassium, liver enzymes, CBC with differential; in addition, in neonates treated for PDA: heart rate, heart murmur, blood pressure, urine output, echocardiogram, serum sodium and glucose, platelet count, and serum concentrations of concomitantly administered drugs which are renally eliminated (eg, aminoglycosides, digoxin); periodic ophthalmic exams with chronic use",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate Release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: Formulation specific",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: Rapid and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended Release: Adults: 90% over 12 hours (",
"     <b>",
"      Note:",
"     </b>",
"     75 mg product is designed to initially release 25 mg and then 50 mg over an extended  period of time)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: PDA: 0.36 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Post-PDA closure: 0.26 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.34-1.57 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver via glucuronide conjugation and other pathways",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates, premature: Percent bioavailability reported in the literature is highly variable and may be influenced by formulation components and indomethacin physicochemical properties (Scanlon, 1982); some have suggested that aqueous formulations are less bioavailable compared to ethanol based formulations (Mrongovious, 1982; Scanlon, 1982); aqueous suspension (in saline): 13% to 20% (Mrongovious, 1982; Sharma, 2003); ethanol based (96% v/v) suspension: 98.6% (Al Za'abi, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: &sim;100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Postnatal age (PNA) &lt;2 weeks: &sim;20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     PNA &gt;2 weeks: &sim;11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 2.6-11.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Significant enterohepatic recycling; 33% excreted in feces as demethylated metabolites with 1.5% as unchanged drug; 60% eliminated in urine as drug and metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Preterm neonates: ~19 mL/hour/kg (range: 4.7-45.5 mL/hour/kg) (Al Za'abi, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/34/550?source=see_link\">",
"      see \"Indomethacin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID); NSAIDs may cause serious adverse reactions, especially with overuse; use exactly as directed; do not increase dose or frequency. NSAIDs may increase the risk for heart attack, stroke, or ulcers and bleeding in stomach or intestines; GI bleeding, ulceration, or perforation can occur with or without pain. Notify physician before use if you have hypertension, heart failure, heart or kidney disease, history of stomach ulcers or bleeding in stomach or intestines, or other medical problems. Read the patient Medication Guide that you receive with each prescription and refill of indomethacin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     While using this medication, do not use alcohol, excessive amounts of vitamin C, other prescription or OTC medications containing aspirin or salicylate, or other NSAIDs without consulting prescriber. Indomethacin may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Notify physician if stomach pain or upset occurs, if swelling or redness occurs in painful area, or if any new symptoms appear. Stop taking medication and report ringing in ears; persistent cramping or stomach pain; unresolved nausea or vomiting; respiratory difficulty or shortness of breath; unusual bruising or bleeding (mouth, urine, stool); skin rash; unusual swelling of extremities; chest pain; palpitations; or weight gain.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indomethacin may mask signs and symptoms of infections; fatalities in children have been reported, due to unrecognized overwhelming sepsis; drowsiness, lethargy, nausea, vomiting, seizures, paresthesia, headache, dizziness, tinnitus, GI bleeding, cerebral edema, and cardiac arrest have been reported with overdoses",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Al Za'abi M, Donovan T, Tudehope D, et al, \"Orogastric and Intravenous Indomethacin Administration to Very Premature Neonates With Patent Ductus Arteriosus: Population Pharmacokinetics, Absolute Bioavailability, and Treatment Outcome,\"",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2007, 29(6):807-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17848/abstract-text/18043480/pubmed\" id=\"18043480\" target=\"_blank\">",
"        18043480",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coombs RC, Morgan ME, Durbin GM, et al, &ldquo;Gut Blood Flow Velocities in the Newborn: Effects of Patent Ductus Arteriosus and Parenteral Indomethacin,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1990, 65(10 Spec No):1067-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17848/abstract-text/2241229/pubmed\" id=\"2241229\" target=\"_blank\">",
"        2241229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fowlie PW, Davis PG, and McGuire W, \"Prophylactic Intravenous Indomethacin for Preventing Mortality and Morbidity in Preterm Infants,\"",
"      <i>",
"       Cochrane Database Syst Rev",
"      </i>",
"      , 2010, (7):CD000174.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17848/abstract-text/20614421/pubmed\" id=\"20614421\" target=\"_blank\">",
"        20614421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersony WM, Peckham GJ, Ellison RC, et al, &ldquo;Effects of Indomethacin in Premature Infants With Patent Ductus Arteriosus: Results of a National Collaborative Study,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1983, 102(6):895-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17848/abstract-text/6343572/pubmed\" id=\"6343572\" target=\"_blank\">",
"        6343572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kraus DM and Pham JT, \"Neonatal Therapy,\"",
"      <i>",
"       Applied Therapeutics: The Clinical Use of Drugs",
"      </i>",
"      , 9th ed, Koda-Kimble MA, Young LY, Kradjan WA, et al, eds, Baltimore, MD: Lippincott Williams &amp; Wilkins, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mrongovius R, Imbeck H, Wille L, et al, \"Variability of Serum Indomethacin Concentrations After Oral and Intravenous Administration to Preterm Infants,\"",
"      <i>",
"       Eur J Pediatr",
"      </i>",
"      , 1982, 138(2):151-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17848/abstract-text/7094936/pubmed\" id=\"7094936\" target=\"_blank\">",
"        7094936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scanlon JW, \"Oral Aqueous Suspension of Indomethacin Should be Abandoned,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1982, 69(4):507.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17848/abstract-text/7070912/pubmed\" id=\"7070912\" target=\"_blank\">",
"        7070912",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sharma PK, Garg SK, and Narang A, \"A Preliminary Study on Pharmacokinetics of Oral Indomethacin in Premature Infants in North India,\"",
"      <i>",
"       Indian J Med Res",
"      </i>",
"      , 2003, 117:164-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/27/17848/abstract-text/14604305/pubmed\" id=\"14604305\" target=\"_blank\">",
"        14604305",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13380 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17848=[""].join("\n");
var outline_f17_27_17848=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708920\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182656\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182657\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053416\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442631\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053409\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182629\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182613\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874619\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053420\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182715\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053412\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053419\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182717\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182714\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053423\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053408\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053407\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182702\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182622\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053426\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182625\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7688406\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053415\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053406\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053422\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053414\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053424\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13380|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=related_link\">",
"      Indomethacin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/34/550?source=related_link\">",
"      Indomethacin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_27_17849="Hypertrophic lichen planus";
var content_f17_27_17849=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62561%7EOBGYN%2F60224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62561%7EOBGYN%2F60224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypertrophic lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 395px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vulvar erosive lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythema and erosions on the vulvar labial mucosa in a patient with erosive lichen planus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Ridley, CM, Neill, SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford 1999. Copyright &copy; 1999 Blackwell Science.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.blackwell-science.com\">",
"      file://www.blackwell-science.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17849=[""].join("\n");
var outline_f17_27_17849=null;
var title_f17_27_17850="Elder mistreatment: Abuse, neglect, and financial exploitation";
var content_f17_27_17850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Elder mistreatment: Abuse, neglect, and financial exploitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/27/17850/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17850/contributors\">",
"     John M Halphen, JD, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17850/contributors\">",
"     Carmel B Dyer, MD, FACP, AGSF",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/27/17850/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17850/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/27/17850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/27/17850/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/27/17850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The problems of elder abuse, neglect (including self-neglect) and exploitation are common. Abuse of older individuals is associated with depression, cognitive impairment, loss of functional capacity, and increased mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Health professionals who take care of elders have an opportunity to impact the health consequences of abuse, as well as a legal and moral obligation to identify victims and intervene when maltreatment is suspected. Healthcare workers encounter mistreated elders in emergency departments, nursing homes, hospital, and outpatient settings. It is crucial to be aware of the manifestations of elder mistreatment, and how to respond.",
"   </p>",
"   <p>",
"    This topic addresses abuse, neglect, and exploitation as defined in civil statutes or governmental regulations. Self-neglect exposes older persons to significant harm and is discussed here as well [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elder mistreatment is perpetrated by those with an ongoing relationship that involves an expectation of responsibility toward the victim. Abuse, neglect, and financial exploitation by strangers are not considered elder mistreatment unless someone who is expected to be responsible for the victim, such as a caretaker, breaches a duty to protect the elder.",
"   </p>",
"   <p>",
"    Definitions vary among jurisdictions and authorities who have written on elder mistreatment. The following is an attempt to consolidate and simplify these definitions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elder &mdash; Persons 60 or 65 years of age or older (the precise age varies among jurisdictions).",
"     </li>",
"     <li>",
"      Abuse &mdash; Behavior by someone with an ongoing relationship to an elder, and a duty towards that elder, that may constitute:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Willful infliction of physical pain or injury or unnecessary restraint (physical abuse)",
"     </li>",
"     <li>",
"      Willful nonconsensual sexual contact (sexual abuse)",
"     </li>",
"     <li>",
"      Willful infliction of emotional harm (psychological abuse)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neglect &mdash; Failure of a person to provide for the needs and protection of a vulnerable elder when that person had an ongoing relationship with the elder, and a duty to provide for those needs and protection.",
"     </li>",
"     <li>",
"      Abandonment &mdash; Desertion of a vulnerable elderly person by a caregiver or caretaker. Abandonment has been considered either as abuse or neglect.",
"     </li>",
"     <li>",
"      Self-neglect &mdash; Self-neglect, a subcategory of neglect, is failure of a vulnerable elder to provide for his or her own care and protection. Self-neglect is said to be a failure of the elder to thrive in their environment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/9\">",
"       9",
"      </a>",
"      ]. The definition excludes the elderly person who has the capacity to make and carry out decisions regarding self-care and protection, and who freely and knowingly chooses not to provide adequately for such care and protection.",
"     </li>",
"     <li>",
"      Elder mistreatment &mdash; Elder mistreatment includes abuse, neglect, self-neglect and financial exploitation as defined in this article.",
"     </li>",
"     <li>",
"      Financial exploitation &mdash; The nonconsensual appropriation of an elderly person's resources, for the benefit of another, by someone with an ongoing relationship and duty toward that elderly person.",
"     </li>",
"     <li>",
"      Consensual &mdash; This refers to decisions freely and knowingly made by a person with capacity to make such decisions.",
"     </li>",
"     <li>",
"      Capacity for self-care and protection &mdash; Ability to make and carry out decisions regarding one's self care and protection. It has two aspects: decisional capacity and executive capacity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decisional capacity &mdash; The ability to [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/11\">",
"       11",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Communicate a choice",
"     </li>",
"     <li>",
"      Understand the relevant information",
"     </li>",
"     <li>",
"      Appreciate the situation and its consequences",
"     </li>",
"     <li>",
"      Reason about treatment options",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Executive capacity &mdash; The ability to execute one's decisions [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Domestic mistreatment &mdash; Abuse, neglect and exploitation of the elderly individual in the community setting.",
"     </li>",
"     <li>",
"      Institutional mistreatment &mdash; Elder abuse, neglect and exploitation in an institutional setting.",
"     </li>",
"     <li>",
"      Vulnerable elder &mdash; An elderly person with an impairment, usually cognitive, that renders him or her unable to arrange for adequate self-care and protection; a vulnerable elder is one who has diminished capacity for self-care and protection as defined above [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Caregiver or caretaker &mdash; A person or entity who has a duty, or whom it would be reasonable to conclude has taken on a duty, to care for and protect an elder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REGULATORY AND SUPPORT SERVICES (US)",
"    </span>",
"    &nbsp;&mdash;&nbsp;All states and territories of the United States, including the District of Columbia, have enacted legislation providing for protection of elders found to be abused, neglected, and financially exploited. Most (excluding Arizona, Delaware, Georgia, Illinois, Indiana, Montana, Vermont, Rhode Island, Puerto Rico, and South Dakota) have statutes or regulations specifically providing for protection of the elderly from self-neglect [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Community dwelling elders are protected in all states by state adult protective services agencies (APS). These agencies receive and investigate allegations or complaints, and provide social, legal, medical and material interventions to help the victims.",
"   </p>",
"   <p>",
"    Elders in institutional settings in all states and territories are protected by state Long Term Care Ombudsman Programs (LTCOP) that receive complaints and advocate on behalf of long-term care residents. The state LTCOP may have authority to investigate and intervene as needed, or it may refer the case to another agency (an APS agency or licensing agency for the involved facility) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    APS and LTCOP agencies are designed to protect the elderly from mistreatment by nonstrangers, such as family members, non-family caretakers, or employees of the facility where elderly victims reside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization issued a report on elder abuse in European countries in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/15\">",
"     15",
"    </a>",
"    ]. The report estimates that elder maltreatment (involving people aged 60 years and older) affects 4 million older people in Europe annually. With increasing life expectancy, this number is anticipated to grow unless effective prevention programs are put into place. A systematic review from 2008 found that 6 percent of older people surveyed in a wide range of countries (including European countries, Korea, the United States, and Canada) reported abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/16\">",
"     16",
"    </a>",
"    ]. The range of abuse across cultures varied from 3 to 27 percent, with psychological abuse reported by nearly one-fourth of older people who were dependent on carers. In 2005, 41 percent of community-residing Medicare beneficiaries over 65 years of age had difficulty performing activities of daily living (ADLs) or instrumental activities of daily living (IADLs) and potentially needed support from paid or unpaid caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many elders do not obtain the needed medical and social support due to lack of resources and refusal of care. The elder individual may lack awareness of their disability. This situation allows for the condition of self-neglect that is a phenomenon frequently encountered by adult protective services agencies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Domestic mistreatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding domestic elder mistreatment are somewhat limited due to differences in definitions and data collection across the different jurisdictions in the United States. In general, studies have confirmed the expectation that cases of abuse are underreported to APS, and that self-neglect is the most common condition among reported cases. Some estimates of the prevalence of elder abuse in the community range from 2 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/1\">",
"     1",
"    </a>",
"    ]. Reports of several studies are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 1998 National Elder Abuse Incidence Study (NEAIS) evaluated the 1996 incidence of domestic elder abuse and neglect, including self-neglect [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/7\">",
"       7",
"      </a>",
"      ]. The study collected data from Adult Protective Services agencies and trained government employees with frequent elderly contact in 20 representative US counties. It was estimated that nationally 551,000 adults were subjected to abuse, neglect",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      self-neglect in the domestic setting in 1996; only 21 percent of cases were reported to and verified by APS. Self-neglect accounted for approximately 38 percent of the reported cases.",
"     </li>",
"     <li>",
"      The National Center on Elder Abuse (NCEA) surveyed all US APS agencies in 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/6\">",
"       6",
"      </a>",
"      ]. Among slightly more than 250,000 reports involving adults over 60 years of age and older, self-neglect was the most common type (39 percent), followed by caregiver neglect (21.5 percent), and financial exploitation (14 percent).",
"     </li>",
"     <li>",
"      The National Social Life, Health and Aging Project, a nationally representative study in the US, asked community-living older adults (aged 57 to 85) about experiences of mistreatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/18\">",
"       18",
"      </a>",
"      ]. Among 3000 survey respondents, 9 percent reported verbal mistreatment, 3.5 percent financial mistreatment, and only 0.2 percent reported physical mistreatment.",
"     </li>",
"     <li>",
"      The overall rate of elder mistreatment (physical abuse, psychological abuse, and neglect) was 3.2 percent in a sample of elders in Boston, Massachusetts [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/19\">",
"       19",
"      </a>",
"      ]. A similar sample in Canada reported a prevalence of 4 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2002 review by the World Health Organization found combined rates of 4 to 6 percent for elder physical abuse, psychological abuse, financial abuse and neglect in studies from Canada, Finland, the United States and Great Britain [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/21\">",
"       21",
"      </a>",
"      ]. Data from developing countries was limited.",
"     </li>",
"     <li>",
"      In a survey of 220 family carers of British older patients newly referred for dementia, 34 percent reported abusive behavior \"at least sometimes\" (most commonly verbal) and only 1.4 percent acknowledged occasional physical abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/22\">",
"       22",
"      </a>",
"      ]. Another study of 129 persons with dementia and their caregivers detected mistreatment in nearly half (47.3 percent of sample, with abuse categorized as psychological only for 60 percent, neglect 20 percent, and some physical component 20 percent); participants had been informed prior to study consent that suspected elder mistreatment would generate mandated reporting [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Institutional mistreatment (US)",
"    </span>",
"    &nbsp;&mdash;&nbsp;US data from 2002 indicate that about 1.6 million people live in 17,000 licensed nursing homes, and another 900,000 live in 45,000 residential care facilities (eg, assisted living facilities and personal care homes) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/24\">",
"     24",
"    </a>",
"    ]. Rates of usage of nursing homes by the elderly in Canada, Israel, South Africa and the United States range from 4 to 7 percent and in Latin America from 1 to 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nationwide collection of data on complaints of institutional elder mistreatment is limited. State long-term care ombudsman programs (LTCOP) are federally mandated to report data via the National Ombudsman Reporting System (NORS), but underreporting is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/25\">",
"     25",
"    </a>",
"    ]. The state LTCOP may not receive reports of institutional elder mistreatment that are directed to the agency that licenses and regulates the facility [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/24\">",
"     24",
"    </a>",
"    ]. Additionally, underreporting by the facilities is suspected. Supporting this suspicion is the fact that most complaints to the state ombudsman programs are filed by facility residents, family, or friends, rather than by facility personnel.",
"   </p>",
"   <p>",
"    From 1999 to 2001, over 5000 nursing homes in the US (one third of all nursing homes) were cited for abuse violations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/26\">",
"     26",
"    </a>",
"    ]. In 2008, approximately 269,000 complaints about elder mistreatment in institutions were registered with NORS, of which about 78 percent were related to nursing home care and the rest related to assisted living, board and care, and personal care facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/27\">",
"     27",
"    </a>",
"    ]. Of the total nursing home complaints, the following percentages involve issues relevant to elder mistreatment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to respond to requests for assistance &mdash; 6.9 percent",
"     </li>",
"     <li>",
"      Injury of unknown origin, falls, improper handling &mdash; 3.2 percent",
"     </li>",
"     <li>",
"      Staff attitudes related to dignity or respect &mdash; 4.4 percent",
"     </li>",
"     <li>",
"      Symptoms unattended &mdash; 2.6 percent",
"     </li>",
"     <li>",
"      Personal property lost, stolen, used by others, destroyed, withheld &mdash; 2.2 percent",
"     </li>",
"     <li>",
"      Staff unresponsive, unavailable &mdash; 2 percent",
"     </li>",
"     <li>",
"      Physical abuse &mdash; 1.8 percent",
"     </li>",
"     <li>",
"      Resident to resident abuse &mdash; 1.3 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Verbal/mental",
"      </span>",
"      abuse &mdash; 1.4 percent",
"     </li>",
"     <li>",
"      Gross (ie, willful) neglect &mdash; 0.9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Percentages were similar for reports related to assisted living, board and care, and personal care facilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MORTALITY AND MORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prospective studies have identified a significant association between elder mistreatment and increased risk for morbidity and mortality risk. Autopsy data is often not available to determine the cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/28\">",
"     28",
"    </a>",
"    ]. Representative studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study of community dwelling adults age 65 and older, with nine years of follow-up, found that referral to adult protective services for abuse, neglect, self-neglect, and financial exploitation was associated with shorter survival after adjusting for other factors associated with increased mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/29\">",
"       29",
"      </a>",
"      ]. The risk of death was increased threefold (OR 3.1), compared to other members of the cohort, for those who experienced elder mistreatment and somewhat less (OR 1.7) for those identified with self-neglect.",
"     </li>",
"     <li>",
"      In another cohort study of older adults followed for a median of seven years, reported self-neglect increased the risk of mortality almost six-fold in the first year, and risk remained increased but at a lower rate after one year (HR 5.82 and 1.39 respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/30\">",
"       30",
"      </a>",
"      ]. Reported elder abuse was also associated with an increased mortality rate (HR 1.39). The increased mortality risk was seen in patients at all levels of cognitive and physical functioning.",
"     </li>",
"     <li>",
"      Among community-dwelling women ages 50 to 79 participating in the Women's Health Initiative, women who reported physical abuse in the prior year had the highest age-adjusted mortality rate, and women who reported either physical or verbal abuse also had higher mortality risk than women who did not report abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The health consequences of self-neglect by vulnerable elders who are incapable of adequate self-care and protection are untreated medical conditions, poor nutrition, and other health risks unless appropriate intervention takes place [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elder mistreatment can have a severe impact on the vulnerable elder who has poor social, financial and functional reserve. Health consequences include multiple hospitalizations, medical non-adherence, living in squalor, pressure ulcers, untreated psychiatric and medical illness, and falls. An incident of financial exploitation may cause the elderly victim to lose independence and lose needed support, and these losses may result in morbidity and perhaps death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elder mistreatment is often undisclosed. Many elders are either cognitively impaired and don't recognize or remember the offenses, or are reluctant to report abuse or neglect for fear of being removed from their own homes or implicating family members.",
"   </p>",
"   <p>",
"    Several risk factors and warning signs have been identified that can prompt a clinician to suspect elder mistreatment (",
"    <a class=\"graphic graphic_table graphicRef67380 \" href=\"UTD.htm?20/24/20876\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Historical factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors have been associated with increased vulnerability to abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/7\">",
"     7",
"    </a>",
"    ]. The highest rates of elder abuse are in women and in persons 80 years of age and older. The abuser is a family member (usually a spouse or adult child) in approximately 90 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/7,33\">",
"     7,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced age &mdash; Advanced age increases the vulnerability of elders to abuse or neglect, including self-neglect. In the National Elder Abuse Incidence Study (NEAIS), those over 80 years of age accounted for 19 percent of the elderly population in the US but for over half of the reports of neglect, and nearly half of the reports of financial exploitation, physical abuse and psychological abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/7\">",
"       7",
"      </a>",
"      ]. Advanced age was also associated with substantiated self-neglect in a prospective study of 2812 community-dwelling adults older than 65 who had been the subject of reports to adult protection agencies in Connecticut [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gender &mdash; Women are over-represented as victims in the NEIAS reports of all types of abuse except abandonment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/7\">",
"       7",
"      </a>",
"      ]. Male gender was a significant predictor of substantiated reports of self-neglect in a cohort of elder patients in urban Connecticut [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ethnicity &mdash; African-Americans were over-represented, while Hispanics and other minorities were under-represented as victims of neglect, psychological abuse and exploitation in the NEIAS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/7\">",
"       7",
"      </a>",
"      ]. Substantiated reports of self-neglect were more prevalent among whites in a cohort of elder patients in urban Connecticut [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disability in self-care &mdash; In the NEAIS study, 48 percent of victims of abuse were unable to care for themselves [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/7\">",
"       7",
"      </a>",
"      ]. Self-neglect was associated with impairment in instrumental activities of daily living in a study comparing 100 community-living older adults referred by Adult Protective Services for self-neglect and 100 matched adults from a community geriatrics clinic [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/35\">",
"       35",
"      </a>",
"      ]. Residents of long-term care facilities who have disabilities in self care (eg, eating, toileting, transfers, and mobility) are at increased risk for morbidity and mortality from neglect [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dementia &mdash; Dementia increases the risk for abuse, neglect and financial exploitation, as well as self-neglect [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/15,23,28,36\">",
"       15,23,28,36",
"      </a>",
"      ]. Dementia was more prevalent among elders referred to a multidisciplinary geriatrics clinic for self-neglect compared to elders referred for other reasons (51 versus 30 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/37\">",
"       37",
"      </a>",
"      ]. Cognitive impairment was found to be a predictor of a substantiated report of self-neglect [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/34\">",
"       34",
"      </a>",
"      ]. Harm as a result of self-neglect was found to be best predicted by poor performance in the domains of verbal recognition memory, executive function and conceptualization [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depression &mdash; Depression may cause a loss of capacity for self-care and protection and is a marker of elder mistreatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/28\">",
"       28",
"      </a>",
"      ], including self-neglect [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/34\">",
"       34",
"      </a>",
"      ]. The prevalence of depression was significantly higher for patients referred to a multidisciplinary geriatric clinic for self-neglect compared to those referred for other reasons (62 versus 12 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      History of hip fracture and history of stroke &mdash; These historical factors have been found to be associated with an increased risk of self-neglect in community dwelling elders [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Social isolation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/1,34,38\">",
"       1,34,38",
"      </a>",
"      ]. Feelings of loneliness have been associated with self-reported elder mistreatment [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low socioeconomic status (lower education and income levels) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      External family stressors &mdash; Illness, low socioeconomic status, death in the family, or other stressful life events involving caretakers can be risk factors for elder abuse, neglect, self-neglect and exploitation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unfavorable caretaker characteristics &mdash; Caretaker mental illness, substance abuse, history of violent or antisocial behavior, depression or financial dependency on the victim increase the risk of elder abuse, neglect and financial exploitation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/1,40\">",
"       1,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indicators of financial exploitation &mdash; Financial exploitation is suggested by a change in the ability of an elder to pay for medical services, medications, utilities, housing, or food [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/41\">",
"       41",
"      </a>",
"      ]. Another sign is transfer of property by an elder who lacks the capacity to consent to such a transfer.",
"     </li>",
"     <li>",
"      Institutional staffing shortages [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Medication issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elder mistreatment may involve administration of inappropriate medications, inappropriate doses of medications (insufficient or excessive), or failure to monitor drug therapy. Caregivers in the home or in a facility may divert medications, fail to administer them, administer them negligently, or give them in excess to render the elder docile. A self-neglecting vulnerable elder, or a vulnerable elder with an impaired caregiver, may not be able to obtain and administer necessary medications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Warning signs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Skin findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin tears, abrasions, lacerations, and bruises that are inadequately explained or occur in unusual locations may suggest elder physical abuse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin tears represent a superficial splitting of the epidermis from the underlying connective tissue resulting in a flap of skin, and are due to friction or sheer forces [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/43\">",
"       43",
"      </a>",
"      ]. They are common without mistreatment on the back of the hands or arms of elders because of age-related changes which make the skin thinner, less elastic, and with less tensile strength [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/44\">",
"       44",
"      </a>",
"      ]. In one study, the incidence of skin tears in nursing home residents was about one per year per resident, and 85 percent were on the arms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bruising (ecchymosis) results from direct force applied to the skin causing tearing of subcutaneous blood vessels and is common, without mistreatment, on the arms and hands of elders, especially if the patient is managed with antiplatelet or anticoagulant therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Burns may be suspicious if inadequately explained.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Falls are common in the elderly. Vertebral fractures are common and can be spontaneous. While hip fractures and other osteoporotic fractures may indicate accidents or self-neglect, spiral fractures of long bones, and fractures in sites other than the wrist, hip or vertebrae in a non-alcoholic elderly person may be suspicious for physical abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition may indicate neglect, if the community elder is unable to procure his or her own meals or if staff do not take time to feed nursing home patients who cannot feed themselves. Malnutrition in a vulnerable elder may also be a manifestation of financial exploitation, if the elder is left without resources to purchase food [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with malnutrition, dehydration may be a sign of elder neglect if the elder needs assistance to be able to take in sufficient fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pressure ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure ulcers are a common condition in older patients who are acutely hospitalized or require long-term institutional care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=see_link\">",
"     \"Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pressure ulcers do not necessarily indicate neglect, but may occur more readily if the standard of care for prevention is not adhered to in a patient at risk. Willful failure to follow the standard of care is abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Indicators of sexual abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is no other reasonable explanation, the following may raise a suspicion of sexual abuse:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain or soreness in the anal-genital area",
"     </li>",
"     <li>",
"      Evidence of venereal diseases in the oral or anal-genital regions",
"     </li>",
"     <li>",
"      Vaginal or rectal bleeding",
"     </li>",
"     <li>",
"      Bruises or lacerations on the vulva, abdomen, or breasts [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/28,45\">",
"       28,45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SCREENING AND ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aim of screening and assessment is to determine the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is someone who is expected to help and protect the elderly person abusing, neglecting or exploiting him or her?",
"     </li>",
"     <li>",
"      Does the elderly person have an impaired capacity for self-care and protection rendering him or her vulnerable and in need of supplemental support?",
"     </li>",
"     <li>",
"      If an individual is identified as a vulnerable elder, is there a condition or behavior that may cause harm to that elder?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Rationale for screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elder mistreatment is a major public health concern. Clinicians have ethical obligations to take care of vulnerable patients, have contact with vulnerable elders, and are best qualified to distinguish normal aging from the manifestations of abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/1,9,46\">",
"     1,9,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, controversy exists on whether universal screening of all older adults for possible mistreatment should be recommended. The US Preventive Services Task Force, citing lack of proven effectiveness for screening instruments and lack of evidence that screening improves clinical outcomes, concluded that there is insufficient evidence to support screening for abused elders in asymptomatic populations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], although others have challenged this position [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The US Medicare program requires nursing facilities to monitor residents for signs of abuse and neglect, with implementation of their minimum data set (MDS) instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/50\">",
"     50",
"    </a>",
"    ]. The American Medical Association (AMA) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/51\">",
"     51",
"    </a>",
"    ] and The Joint Commission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/52\">",
"     52",
"    </a>",
"    ] also acknowledge that elder mistreatment is a major public health concern, and that healthcare workers and institutions should do what they can to identify cases so that affected elders can be helped.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Approaches to screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Medical Association (AMA) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/46\">",
"     46",
"    </a>",
"    ] and the American Academy of Neurology (AAN) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/53\">",
"     53",
"    </a>",
"    ] specifically advise screening individuals age 65 years and older for abuse. The US Preventive Services Task Force (USPSTF), however, notes the lack of validated screening instruments and inadequate evidence that screening reduces harm related to abuse of elderly and vulnerable adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The USPSTF also found no evidence that screening causes harm, and thus does not recommend for or against screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     AMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1992, the AMA proposed that clinicians in all practice settings screen geriatric patients to identify abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/46\">",
"     46",
"    </a>",
"    ]. Components of the AMA proposal were that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should be interviewed by themselves to avoid intimidation by possible abusers",
"     </li>",
"     <li>",
"      Patients should be questioned about family composition and living arrangements",
"     </li>",
"     <li>",
"      Patients should be asked directly about abuse, neglect or exploitation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Has anyone at home ever hurt you?",
"     </li>",
"     <li>",
"      Has anyone ever touched you without your consent?",
"     </li>",
"     <li>",
"      Has anyone taken anything that was yours without asking?",
"     </li>",
"     <li>",
"      Has anyone ever scolded or threatened you?",
"     </li>",
"     <li>",
"      Have you signed any documents that you didn't understand?",
"     </li>",
"     <li>",
"      Are you afraid of anyone at home?",
"     </li>",
"     <li>",
"      Are you alone a lot of the time?",
"     </li>",
"     <li>",
"      Has anyone ever failed to help you take care of yourself when you needed help?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinicians should look for indicators of abuse, including poorly explained injuries; evidence of neglect (dehydration, malnutrition, poor hygiene, lack of medical compliance); isolation; fear of a caretaker; or transfer of funds to a caretaker",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines did not offer a readily implementable screening instrument and were not widely adopted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Abbreviated screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more straightforward approach has been suggested, involving three questions to be asked [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do you feel safe where you live?",
"     </li>",
"     <li>",
"      Who prepares your meals?",
"     </li>",
"     <li>",
"      Who handles your checkbook?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Responses might generate additional questions. For possible victims who are cognitively impaired or fearful, information may need to be obtained from persons whose motives are not in question, or corroborated by findings from physical examination.",
"   </p>",
"   <p>",
"    A variety of screening instruments have been developed to identify elder mistreatment. A number of problems affect their implementation or reliability [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overly complex and require too much time to administer",
"     </li>",
"     <li>",
"      Need for training to administer",
"     </li>",
"     <li>",
"      Need for accurate responses from a cognitively impaired or fearful victim",
"     </li>",
"     <li>",
"      Need for accurate responses from a defensive or possibly abusive caregiver",
"     </li>",
"     <li>",
"      Inadequate validation in representative populations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Screening instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two screening and assessment instruments for elder abuse, neglect and exploitation are relatively easy and fast to administer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/9\">",
"     9",
"    </a>",
"    ]: the Brief Abuse Screen for the Elderly (BASE) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], and the Elder Assessment Instrument [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Another instrument, the Conflict Tactics Scale (CTS) has been reliable with good content validity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/61\">",
"     61",
"    </a>",
"    ]. The CTS is not specific to elder mistreatment, but it is the most widely adopted instrument used in the field to determine whether an individual has been threatened or assaulted. Other brief instruments have been validated (the CASE [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/62\">",
"     62",
"    </a>",
"    ] and",
"    <span class=\"nowrap\">",
"     H-S/EAST",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/63\">",
"     63",
"    </a>",
"    ], as examples) but these, as well as the CTS, rely on victim and caretaker reports that may be intentionally or unintentionally inaccurate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Conflict Tactics Scale (CTS) involves self-report by the elder and caretaker, or other parties who interact with the elder. The scale explores tactics used to deal with conflict and generates a score based on how frequently each type of tactic is used. This scale has been shown to be reliable with content validity in the identification of physical abuse and verbal assault [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/61,64\">",
"       61,64",
"      </a>",
"      ]. The CTS does not detect neglect, either by caregivers or self-neglect.",
"     </li>",
"     <li>",
"      The Brief Abuse Screen for the Elderly (BASE) is a tool completed by clinicians trained in its use to evaluate the caretaker and the elderly patient [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/58\">",
"       58",
"      </a>",
"      ]. If abuse is suspected, the clinician indicates the type of abuse suspected, and how soon intervention is needed. Good agreement (86 to 90 percent) has been demonstrated among trained evaluators in its application as a screening instrument [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/58\">",
"       58",
"      </a>",
"      ]. The BASE tool takes about a minute to administer [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/58\">",
"       58",
"      </a>",
"      ]. Evaluation of the caregiver is required and therefore self-neglect is not addressed by this instrument.",
"     </li>",
"     <li>",
"      The Elder Assessment Instrument (EAI) is a 41-item tool in use since the early 1980s [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. The tool asks the clinician evaluator to assess the elder's independence, medical condition, physical condition, and social circumstances. There is no score generated by these evaluations, but evaluators choose whether or not there is \"no evidence,\" \"probably no evidence,\" \"probably evidence,\" \"evidence,\" or \"unable to assess\" for each of elder abuse, caregiver neglect, or exploitation. When used by nurses in an emergency department, the sensitivity was 71 percent, and specificity 93 percent, comparing the screening test results with subsequent determinations of elder mistreatment by an expert panel [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CTS, BASE and the EAI do not screen or assess for elder self-neglect, although reports of self-neglect are the most common allegations made to adult protective service agencies in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/65\">",
"     65",
"    </a>",
"    ]. Self-neglect is difficult to identify away from the home environment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/66\">",
"     66",
"    </a>",
"    ]. A specific screening tool, the Self-Neglect Severity Scale, is undergoing evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further assessment is indicated when elder mistreatment is suspected based on results of the history, physical examination, or responses to screening questions or tools.",
"   </p>",
"   <p>",
"    An assessment of cognitive and functional ability is an important part of comprehensive geriatric assessment to determine capacity for self-care and self-protection. A diminished capacity for self-care and protection renders the elder vulnerable to abuse, neglect, self-neglect and exploitation and the associated health consequences including death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a moral, ethical and in many states a legal duty to intervene in cases of vulnerable persons who lack capacity and are a danger to themselves or others. In contrast, a person with capacity may choose to live in a neglectful situation as a preferable alternative to moving from one's home. Healthcare workers and legal officials cannot intervene in cases of persons with capacity who do not consent to intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Comprehensive Geriatric Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Comprehensive Geriatric Assessment (CGA) has been evaluated by multiple researchers for case identification and assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. This involves a comprehensive history and physical examination and the use of instruments to measure cognitive ability, functional ability, and psychosocial status. The assessment is performed by a trained multidisciplinary team whose members include a geriatrician, and trained representatives from social work and nursing. The team gathers information from all reasonably available sources, often including a home visit by a member of the team. The collected data is used by the team to establish a diagnosis and treatment plan. This requires specially trained personnel and is time consuming. The CGA is being studied for outcomes in identifying elder abuse, neglect and exploitation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/9,42,70,71\">",
"     9,42,70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43624?source=see_link\">",
"     \"Comprehensive geriatric assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Mental status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of elders suspected of abuse should include a mental state examination, as well as evaluation for depression, and the ability to conduct activities of daily living (ADL) and instrumental activities of daily living (IADL). Activities of daily living include the ability to feed, bathe, dress and toilet oneself. Instrumental activities of daily living are the abilities to prepare meals, perform housework, use the telephone, and manage finances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34215?source=see_link\">",
"     \"Failure to thrive in elderly adults: Evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A case control study matched 50 adults 65 years and older who were identified by adult protective services to be in a state of self-neglect with 50 control participants (matched for age, race, gender and zip code). Poor scores on the mini-mental state examination (MMSE) and assessment of ADL and IADL were more likely among self-neglectors than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Guardianship",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians are often asked to make determinations of the need for guardianship in cases where the elders have diminished capacity for self-care and protection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/73\">",
"     73",
"    </a>",
"    ]. Legal provisions for guardianship vary among US state jurisdictions. A conceptual model, based upon legal statutes in the US and expert consensus opinion, identifies six key domains to be evaluated for determination of need for guardianship [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of a medical condition that may produce functional disability",
"     </li>",
"     <li>",
"      Cognitive impairment (short-term memory, communication, attention, executive function, and others)",
"     </li>",
"     <li>",
"      Difficulty involving everyday functioning (ability to provide nutrition, shelter and safety)",
"     </li>",
"     <li>",
"      Consideration of the individual's values and preferences",
"     </li>",
"     <li>",
"      Risk of harm and level of supervision needed",
"     </li>",
"     <li>",
"      Determination of whether less restrictive alternatives to guardianship are feasible",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Decisional and executive capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultimately, the court must determine whether the elder has sufficient capacity to self-care and self-protect to avoid danger, and whether alternative measures to the appointment of a guardian are available. The presence of such problems as disorganized thinking, hallucinations, delusions, lack of insight, and refusal to accept help are important in the determination of need for guardianship.",
"   </p>",
"   <p>",
"    The capacity for self-care and self-protection depends on whether an individual can both make and implement decisions regarding personal needs, health, and safety [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/12\">",
"     12",
"    </a>",
"    ]. This requires both intact decisional and executive capacity in relation to multiple functional domains: personal needs and hygiene; condition of home environment; activities for independent living; medical self-care; and managing financial affairs.",
"   </p>",
"   <p>",
"    Components of decisional capacity are the ability to [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Communicate a choice",
"     </li>",
"     <li>",
"      Understand the relevant information",
"     </li>",
"     <li>",
"      Appreciate the situation and its consequences",
"     </li>",
"     <li>",
"      Reason about treatment options",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Executive capacity requires executive function. Executive function refers to the ability to develop a plan, adapt to circumstances, and implement the plan.",
"   </p>",
"   <p>",
"    Decisional capacity and executive capacity can be evaluated during the history and physical examination, with further input from geriatric assessment tools, information from adult protective services agencies, family, police agencies, or evaluation of the home environment by members of a geriatric assessment team. Neuropsychological testing may be useful in cases where the capacity of the elder for self-care and self-protection remains in question.",
"   </p>",
"   <p>",
"    The capacities to consent to sexual activity, make a will, vote, drive, transfer property, consent to participation in research, and consent to treatment are capacities of importance to elders that a clinician may be asked to specifically assess. Some of these more specific capacities, especially the capacities to transfer property, consent to sexual activity, and consent to treatment, may be needed to possess the more global capacity for self-care and self-protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical, social, and legal interventions may be offered when an elder is determined to be the victim of elder mistreatment. Elders who are deemed to have the capacity to understand and to consent to protective services may reject offered interventions from an adult protection service (APS) agency. If the agency determines that the victim lacks the capacity to understand and consent to protective services and that a situation is unsafe, the agency may petition the courts for an emergency order for protective services. All but 13 of the US states and territories have statutes providing for these emergency or involuntary protective services for those without capacity to consent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/75\">",
"     75",
"    </a>",
"    ]. The court may require a statement from a clinician to support a finding of the lack of capacity to consent to protective services before such an emergency order is issued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Medical interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first obligation of the healthcare worker, in conjunction with social workers and community agencies, is to assure the safety of the at-risk elder. A home visit may sometimes be needed to make that determination.",
"   </p>",
"   <p>",
"    If the situation at the home or nursing facility is deemed safe, elders who suffer from mistreatment may still need intervention for unmet medical needs. These may include treatment for depression, reversible dementia, diabetes mellitus, hypertension, or infection. Medical evaluation and treatment can be compelled, if the victim is deemed unable to consent.",
"   </p>",
"   <p>",
"    Medical treatment and follow-up can be difficult. For example, the court may allow compelled evaluation in a medical clinic and removal of an incapacitated or incompetent person from her unsafe home, but if there is hostility to the agency and the medical providers chosen by them, resistance to and sabotage of the medical interventions may occur. Transfer of care to medical providers that are accepted by the patient and family may be needed. Follow-up by the adult protective services agency may be necessary to ensure that the patient is being taken to the provider and that the treatment plan is being followed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Social interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mistreated elder may suffer from multiple challenges to safe and comfortable living, including inadequate housing, inadequate food, shut off utilities, financial or physical inability to obtain medications, and inability to negotiate the healthcare system and arrange for medical visits or follow a treatment plan. The adult protective services agencies may be able to provide resources themselves, or activate resources from other agencies or the private sector. Law enforcement and the courts may need to be recruited by the APS to remove elders from abusive caregivers, and place them in more supportive environments or obtain guardianship.",
"   </p>",
"   <p>",
"    The adult protective services agencies and the courts are obliged to use the least restrictive alternative when an individual's autonomy is impacted in order to protect that person. The government must explore all options and choose those that accomplish the needed protection while being no more restrictive than necessary. For example, if durable powers of attorney are in place and the designated power of attorney can effect needed decisions, guardianship should not be pursued [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a healthcare worker has reason to believe that an elder is in a state of abuse, neglect, self-neglect or financial exploitation, appropriate reporting should be promptly initiated. Reporting of elder mistreatment is the most common intervention in the management of elder mistreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Statutes that address reporting of elder mistreatment to designated governmental agencies have been written in all states (and the District of Columbia) in the US. Adult protective services and long-term care ombudsman programs exist in all US jurisdictions. If there is doubt about where and how to report, one of these agencies can provide the needed information.",
"   </p>",
"   <p>",
"    In all but Colorado, New Jersey, New York, North Dakota, South Dakota, and Wisconsin, reporting is mandatory [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/77\">",
"     77",
"    </a>",
"    ]. Delaware, Indiana, Kentucky, New Mexico, North Carolina, Rhode Island, Texas, Wyoming, and other jurisdictions require reporting by anyone who suspects elder mistreatment, while most jurisdictions only require reporting by members of certain named occupations, including by healthcare workers [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/77\">",
"     77",
"    </a>",
"    ]. Penalties for failure to report suspected abuse exist in 38 states and the District of Columbia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/77\">",
"     77",
"    </a>",
"    ]. Mandatory reporting requires a clinician to report suspected abuse even if a competent elder patient specifically asks that the abuse not be reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The statutes in all but Puerto Rico and South Dakota specifically provide for immunity from any civil or criminal liability for reporting and testifying about suspected elder abuse, neglect, self-neglect or exploitation, so long as the communications are made in good faith [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If reporting is motivated by the reporter's reasonable suspicion, governmental resources will assist with investigation, assessment and case confirmation. Reporting also helps mobilize resources and interventions from the adult protective services agency, such as reactivation of utilities, medications, safety repairs of the home, and personal care services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Web resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single Web site that provides information about abuse laws for each state. Helpful resources for the clinician include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Bar Association Commission on Law and Aging &mdash; provides contact information by state (",
"      <a class=\"external\" href=\"file://www.abanet.org/aging/\">",
"       www.abanet.org/aging/",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      National Center on Elder Abuse &mdash; lists phone numbers to report suspected abuse cases by state",
"      <span class=\"nowrap\">",
"       (www.ncea.aoa.gov/NCEAroot/Main_Site/Find_Help/State_Resources.aspx)",
"      </span>",
"     </li>",
"     <li>",
"      Long-Term Care Ombudsman Resource Center (",
"      <a class=\"external\" href=\"file://www.ltcombudsman.org/\">",
"       www.ltcombudsman.org",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Administration on Aging (",
"      <a class=\"external\" href=\"file://www.aoa.gov/\">",
"       www.aoa.gov",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Interacting with law enforcement and the courts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a report of suspected mistreatment has been filed, the allegation is directed to a designated resource. This would be the adult protective services agencies for community-dwelling elders, or the state long-term care ombudsman program (or agency that licenses the facility) for residents of long-term care institutions.",
"   </p>",
"   <p>",
"    At times, immediate reporting to law enforcement is indicated. If an observer is concerned that abuse or exploitation is ongoing and requires interruption to prevent further harm, law enforcement, as well as the state protective agencies, must be notified urgently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Documentation of findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful and immediate documentation should be made of observations that support a finding of abuse, neglect, self-neglect or exploitation. What the victim or the perpetrator says should be dutifully recorded.",
"   </p>",
"   <p>",
"    Conclusions and general statements do not make good evidence for governmental agencies, law enforcement or the courts. Specific details of observations are helpful. For physical evidence of abuse, photographs may be the best evidence. The reporter should carefully record size, color, and induration of lesions, preferably with an accompanying drawing when photographs are not possible. Instead of documenting that the alleged perpetrator \"confessed\" to the abuse, it is best to record carefully the exact words of the perpetrator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3752822\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2011 report from the World Health Organization notes that there is a lack of high-quality studies of interventions designed to reduce or prevent elder maltreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/15\">",
"     15",
"    </a>",
"    ]. Outcomes were variable for multiple interventions that involved courses for professionals to heighten awareness of elder abuse or legal, psychological, and educational support programs for older individuals and their caregivers. Prevention of abuse may be promoted by programs that provide respite for caregivers, support for informal (nonprofessional) caregivers, and encourage positive attitudes towards older people within a culture.",
"   </p>",
"   <p>",
"    The authors of this topic propose several approaches to target different groups and employ a variety of strategies that can play a role in the prevention of elder abuse.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recognition that clinicians from any discipline who have contact with older adults, not just geriatricians or those working in elder care institutions, are in a position to make an important impact. Education regarding the risk factors and warning signs of elder mistreatment and the appropriate interventions (especially reporting to the appropriate governmental agencies) when elder mistreatment is suspected should involve all clinicians.",
"     </li>",
"     <li>",
"      Education to address and overcome the barriers to reporting suspected elder mistreatment. These barriers include: failure to recognize the ethical and often legal obligation to report; not knowing which agencies to report to; not realizing that only a reasonable suspicion of mistreatment is sufficient to trigger the duty to report; not understanding that there is protection from legal liability for the reporter who does so in good faith; not realizing that the report can be made confidentially; and thinking that the reporter needs the permission of the suspected victim of elder mistreatment in order to report [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Education targeting clinicians as well as non-clinical personnel who have elder contact, including individuals in the banking industry, mail carriers, salespersons, emergency medical services workers, police officers, and long-term care facility employees. The educational efforts for non-medical personnel can be very similar to those used with clinicians. There should be a focus on risk factors, warning signs, the agencies to report suspicions to, and as with clinicians, education designed to remove some of the barriers to reporting caused by ignorance.",
"     </li>",
"     <li>",
"      Awareness that most long-term care facility abuse occurs from resident to resident. Background checks for a history of criminal activity, sexual assault, or other violent behaviors may be reasonable for potential residents who are more mobile. Psychiatric patients are overrepresented in long-term care facilities and may be aggressive, younger, and more mobile than other older adults in the facility and thus able to inflict more damage. In addition to screening, there needs to be adequate monitoring of the residents for abusive behaviors. Redirection, separation of the perpetrator from the victim, the use of alarms, and perhaps expulsion of the offender may be necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/80,81\">",
"       80,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Education and administrative interventions to address conditions in institutions that may promote resident elder mistreatment by staff members. Factors that increase the likelihood that a staff member may mistreat a resident include excessive work pressure; having negative attitudes toward older adults; having negative attitudes toward their jobs; limited training; a history of drug or alcohol dependence; a staff member with a criminal record; a facility culture that tolerates placing staff and facility convenience before patient needs; and a low staff-to-resident ratio [",
"      <a class=\"abstract\" href=\"UTD.htm?17/27/17850/abstract/82-84\">",
"       82-84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/3/7218?source=see_link\">",
"       \"Patient information: Elder abuse (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elder mistreatment is the term used to include elder abuse, neglect (including self-neglect), and exploitation and is perpetrated by those with an ongoing relationship that involves an expectation of responsibility toward the elder victim. Abuse may be physical, emotional, or sexual. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Community-dwelling elders are protected in most US states by state adult protective services agencies (APS). Long Term Care Ombudsman Programs (LTCOP) or licensing agencies for the institution address issues in institutional settings. The estimates of the prevalence of elder abuse in the community range from 2 to 10 percent. Underreporting of cases to APS and LTCOP services is well recognized. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Regulatory and support services (US)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several risk factors and warning signs should prompt a clinician to evaluate a patient for elder mistreatment (",
"      <a class=\"graphic graphic_table graphicRef67380 \" href=\"UTD.htm?20/24/20876\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although clinicians have ethical obligations to provide care for vulnerable patients, because of the unproven effectiveness of screening, there is controversy about whether universal screening for possible mistreatment in all older adults should be advocated.",
"     </li>",
"     <li>",
"      We suggest screening for possible abuse, neglect, or financial exploitation targeted to older patients with risk factors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The following three questions may serve as a brief screen in the primary care setting:",
"      <br/>",
"      <br/>",
"      - Do you feel safe where you live?",
"      <br/>",
"      - Who prepares your meals?",
"      <br/>",
"      - Who handles your checkbook?",
"      <br/>",
"      <br/>",
"      Patients should be interviewed by themselves, to avoid intimidation by possible abusers. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Approaches to screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further assessment is indicated when elder mistreatment is suspected based on results of the history, physical examination, or responses to screening questions or tools. Assessment involves determination of functional and cognitive ability, including decisional and executive capacity. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first obligation of the healthcare worker, in conjunction with social workers and community agencies, is to assure the safety of the at-risk elder. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a healthcare worker has reason to believe that an elder is in a state of abuse, neglect, self-neglect, or financial exploitation, appropriate reporting should be promptly initiated. Careful and immediate documentation should be made of observations that support a finding of abuse, neglect, self-neglect, or exploitation. The adult protective services agencies and the courts are obliged to use the least-restrictive alternative when an individual's autonomy is impacted in order to protect that person. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Reporting'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H35\">",
"       'Documentation of findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/1\">",
"      Lachs MS, Pillemer K. Elder abuse. Lancet 2004; 364:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/2\">",
"      Tierney MC, Snow WG, Charles J, et al. Neuropsychological predictors of self-neglect in cognitively impaired older people who live alone. Am J Geriatr Psychiatry 2007; 15:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/3\">",
"      Tierney MC, Charles J, Naglie G, et al. Risk factors for harm in cognitively impaired seniors who live alone: a prospective study. J Am Geriatr Soc 2004; 52:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/4\">",
"      Mosqueda L, Dong X. Elder abuse and self-neglect: \"I don't care anything about going to the doctor, to be honest...\". JAMA 2011; 306:532.",
"     </a>",
"    </li>",
"    <li>",
"     Brandl B, Dyer CB, Heisler CJ, et al. Defining Elder Abuse. In: Elder Abuse Detection and Intervention: A Collaborative Approach, Publishing Company, New York 2007. p.17.",
"    </li>",
"    <li>",
"     Teaster, PB, Dugar, TA, Mendiondo, MS, et al. The 2004 Survey of State Adult Protective Services: Abuse of Adults 60 Years of Age and Older; Prepared for The National Center on Elder Abuse 2006. p. 26. Available at: www.ncea.aoa.gov/NCEAroot/Main_Site/pdf/2-14-06%20FINAL%2060+REPORT.pdf (Accessed on March 09, 2009).",
"    </li>",
"    <li>",
"     Tatara T. The National Elder Abuse Incidence Study. The National Center on Elder Abuse, 1998. Available at: www.ncea.aoa.gov/ncearoot/Main_Site/Library/Statistics_Research/National_Incident.aspx (Accessed on March 09, 2009).",
"    </li>",
"    <li>",
"     Elder Abuse: abuse, neglect and exploitation in an aging America, Bonnie RJ, Wallace RB (Eds), National Academy Press, Washington, DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/9\">",
"      Fulmer T, Guadagno L, Bitondo Dyer C, Connolly MT. Progress in elder abuse screening and assessment instruments. J Am Geriatr Soc 2004; 52:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/10\">",
"      Naik AD, Pickens S, Burnett J, et al. Assessing capacity in the setting of self-neglect: development of a novel screening tool for decision-making capacity. J Elder Abuse Negl 2006; 18:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/11\">",
"      Appelbaum PS. Clinical practice. Assessment of patients' competence to consent to treatment. N Engl J Med 2007; 357:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/12\">",
"      Naik AD, Lai JM, Kunik ME, Dyer CB. Assessing capacity in suspected cases of self-neglect. Geriatrics 2008; 63:24.",
"     </a>",
"    </li>",
"    <li>",
"     Stiegel L, Klem E. Types of Abuse: Provisions and Citations in Adult Protective Services Laws, by State (Laws Current as of 12/31/06). American Bar Association Commission on Law and Aging 2007. Available at: www.abanet.org/aging/elderabuse.shtml (Accessed on May 07, 2009).",
"    </li>",
"    <li>",
"     Stiegel L, Klem E. Information About Laws Related To Elder Abuse. American Bar Association Commission on Law and Aging 2007. Available at: www.abanet.org/aging/elderabuse.shtml (Accessed on May 07, 2009).",
"    </li>",
"    <li>",
"     European report on preventing elder maltreatment. World Health Organization, Regional office for Europe. 2011. file://www.euro.who.int/__data/assets/pdf_file/0010/144676/e95110.pdf (Accessed on December 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/16\">",
"      Cooper C, Selwood A, Livingston G. The prevalence of elder abuse and neglect: a systematic review. Age Ageing 2008; 37:151.",
"     </a>",
"    </li>",
"    <li>",
"     Disability and Activity Limitations. A Profile of Older Americans: 2007. Available at: www.aoa.gov/AoAroot/Aging_Statistics/Profile/2007/docs/2007profile.pdf (Accessed on May 07, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/18\">",
"      Laumann EO, Leitsch SA, Waite LJ. Elder mistreatment in the United States: prevalence estimates from a nationally representative study. J Gerontol B Psychol Sci Soc Sci 2008; 63:S248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/19\">",
"      Pillemer K, Finkelhor D. The prevalence of elder abuse: a random sample survey. Gerontologist 1988; 28:51.",
"     </a>",
"    </li>",
"    <li>",
"     Podnieks, E, Pillemer, K, Nicholson, J, et al. National survey on abuse of the elderly in Canada. Preliminary findings. Office of Reserach and Innovation, Ryerson Polytechnical Institute, Toronto 1989.",
"    </li>",
"    <li>",
"     Wolf R, Daichman L. Abuse of the elderly. In: World report on violence and health. Krug E, et al (Eds). World Health Organization, Geneva 2002. p.123. Available at: file://whqlibdoc.who.int/publications/2002/9241545615_eng.pdf (Accessed on April 24, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/22\">",
"      Cooper C, Selwood A, Blanchard M, et al. Abuse of people with dementia by family carers: representative cross sectional survey. BMJ 2009; 338:b155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/23\">",
"      Wiglesworth A, Mosqueda L, Mulnard R, et al. Screening for abuse and neglect of people with dementia. J Am Geriatr Soc 2010; 58:493.",
"     </a>",
"    </li>",
"    <li>",
"     Hawes C. Elder Abuse in Residential Long-Term Care settings: What is Known and What Information is Needed?. In: Elder Mistreatment: Abuse, Neglect, and Exploitation in an Aging America, Bonnie RJ, Wallace RB (Eds), National Academies Press, Washington, DC 2002.",
"    </li>",
"    <li>",
"     State Ombudsman Data: Nursing Home Complaints. Office of Inspector General, Department of Health and Human Services. Available at: www.oig.hhs.gov/ (Accessed on July 01, 2003).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/26\">",
"      Wei GS, Herbers JE Jr. Reporting elder abuse: a medical, legal, and ethical overview. J Am Med Womens Assoc 2004; 59:248.",
"     </a>",
"    </li>",
"    <li>",
"     2008 National Ombudsman Reporting System Data Tables, U.S. Administration on Aging Department of Health and Human Services. Available at: www.aoa.gov/AoARoot/AoA_Programs/Elder_Rights/Ombudsman/National_State_Data/2008/Index.aspx (Accessed on May 07, 2010).",
"    </li>",
"    <li>",
"     Dyer CB, Connolly MT, McFeeley P. The Clinical and Medical Forensics of Elder Abuse and Neglect. In: Elder Mistreatment: Abuse, Neglect, and Exploitation in an Aging America, Bonnie RJ, Wallace RB (Eds), National Academies Press, Washington DC 2002. p.340.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/29\">",
"      Lachs MS, Williams CS, O'Brien S, et al. The mortality of elder mistreatment. JAMA 1998; 280:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/30\">",
"      Dong X, Simon M, Mendes de Leon C, et al. Elder self-neglect and abuse and mortality risk in a community-dwelling population. JAMA 2009; 302:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/31\">",
"      Baker MW, LaCroix AZ, Wu C, et al. Mortality risk associated with physical and verbal abuse in women aged 50 to 79. J Am Geriatr Soc 2009; 57:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/32\">",
"      Dyer CB, Pickens S, Burnett J. Vulnerable elders: when it is no longer safe to live alone. JAMA 2007; 298:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/33\">",
"      Friedman LS, Avila S, Tanouye K, Joseph K. A case-control study of severe physical abuse of older adults. J Am Geriatr Soc 2011; 59:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/34\">",
"      Abrams RC, Lachs M, McAvay G, et al. Predictors of self-neglect in community-dwelling elders. Am J Psychiatry 2002; 159:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/35\">",
"      Naik AD, Burnett J, Pickens-Pace S, Dyer CB. Impairment in instrumental activities of daily living and the geriatric syndrome of self-neglect. Gerontologist 2008; 48:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/36\">",
"      Dong X, Simon MA, Wilson RS, et al. Decline in cognitive function and risk of elder self-neglect: finding from the Chicago Health Aging Project. J Am Geriatr Soc 2010; 58:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/37\">",
"      Dyer CB, Pavlik VN, Murphy KP, Hyman DJ. The high prevalence of depression and dementia in elder abuse or neglect. J Am Geriatr Soc 2000; 48:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/38\">",
"      Burnett J, Regev T, Pickens S, et al. Social networks: a profile of the elderly who self-neglect. J Elder Abuse Negl 2006; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/39\">",
"      Dong X, Simon MA, Gorbien M, et al. Loneliness in older chinese adults: a risk factor for elder mistreatment. J Am Geriatr Soc 2007; 55:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/40\">",
"      Lachs MS, Pillemer K. Abuse and neglect of elderly persons. N Engl J Med 1995; 332:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/41\">",
"      Reed K. When elders lose their cents: financial abuse of the elderly. Clin Geriatr Med 2005; 21:365.",
"     </a>",
"    </li>",
"    <li>",
"     Dyer CB, Connolly MT, McFeeley P. The clinical and medical forensics of elder abuse and neglect. In: Elder Mistreatment: Abuse, Neglect and Exploitation in an Aging America, Bonnie RJ, Wallace RB (Eds), The National Academies Press, Washington DC 2002. p.339.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/43\">",
"      Malone ML, Rozario N, Gavinski M, Goodwin J. The epidemiology of skin tears in the institutionalized elderly. J Am Geriatr Soc 1991; 39:591.",
"     </a>",
"    </li>",
"    <li>",
"     Griffiths CE. Aging of the skin. In: Brocklehursts's Textbook of Geriatric Medicine and Gerontology, 5th ed, Tufts R, Fillet H, Brocklehurst JC (Eds), Harcourt Brace &amp; Co, London 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/45\">",
"      Mosqueda L, Burnight K, Liao S. The life cycle of bruises in older adults. J Am Geriatr Soc 2005; 53:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/46\">",
"      Aravanis SC, Adelman RD, Breckman R, et al. Diagnostic and treatment guidelines on elder abuse and neglect. Arch Fam Med 1993; 2:371.",
"     </a>",
"    </li>",
"    <li>",
"     Nelson HD, Nygren P, McInerney Y, Klein J. Screening Women and Elderly Adults for Family and Intimate Partner Violence. U.S. Preventive Services Task Force. March 2004. Available at: www.ahrq.gov/clinic/3rduspstf/famviolence/famviolrev.htm (Accessed on September 01, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/48\">",
"      Nelson HD, Nygren P, McInerney Y, et al. Screening women and elderly adults for family and intimate partner violence: a review of the evidence for the U. S. Preventive Services Task Force. Ann Intern Med 2004; 140:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/49\">",
"      Lachs MS. Screening for family violence: what's an evidence-based doctor to do? Ann Intern Med 2004; 140:399.",
"     </a>",
"    </li>",
"    <li>",
"     MDS 2.0 for Nursing Home Nursing Home Quality Initiative. https://www.cms.gov/NursingHomeQualityInits/50_NHQIMDS20.asp (Accessed on April 28, 2009).",
"    </li>",
"    <li>",
"     American Medical Association. American Medical Association. Available at: www.ama-assn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics/opinion202.shtml (Accessed on April 28, 2009).",
"    </li>",
"    <li>",
"     2009 Standard: PC.01.02.09. Provision of Care, Treatment and Services. In: Accreditation Program: Ambulatory Health Care, CAMAC Additional Resources, The Joint Commission, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/53\">",
"      Schulman EA, Hohler AD. The American Academy of Neurology position statement on abuse and violence. Neurology 2012; 78:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/54\">",
"      Screening for Intimate Partner Violence and Abuse of Vulnerable Adults: U.S. Preventive Services Task Force Recommendation. Ann Intern Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/55\">",
"      Moyer VA, U.S. Preventive Services Task Force*. Screening for intimate partner violence and abuse of elderly and vulnerable adults: u.s. Preventive services task force recommendation statement. Ann Intern Med 2013; 158:478.",
"     </a>",
"    </li>",
"    <li>",
"     Screening and Case Identification in Clinical Settings. In: Elder Abuse: abuse, neglect, and exploitation in an aging America, Bonnie RJ, Wallace RB (Eds), National Academy Press, Washington, DC 2002. p.109.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/57\">",
"      Reis M, Nahmiash D. When seniors are abused: an intervention model. Gerontologist 1995; 35:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/58\">",
"      Reis M, Nahmiash D. Validation of the indicators of abuse (IOA) screen. Gerontologist 1998; 38:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/59\">",
"      Fulmer T, Paveza G, Abraham I, Fairchild S. Elder neglect assessment in the emergency department. J Emerg Nurs 2000; 26:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/60\">",
"      Fulmer T, Street S, Carr K. Abuse of the elderly: screening and detection. J Emerg Nurs 1984; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     Straus MA. Measuring intrafamily conflict and violence: The Conflict Tactics (CT) Scale-Form. A J Marriage Fam 1979; 41:75. Available at: file://74.125.93.132/search?q=cache:i4Hoh87SwzgJ:pubpages.unh.edu/~mas2/CTS41%2520(CTS2x- (Accessed on April 28, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/62\">",
"      Reis M, Nahmiash D. Validation of the Caregiver Abuse Screen (CASE). Can J Aging 1995; 14:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/63\">",
"      Neale AV, Hwalek MA, Scott RO, et al. Validation of the Hwalek-Sengstock Elder Abuse Screening Test. J Appl Gerontol 1991; 10:406.",
"     </a>",
"    </li>",
"    <li>",
"     Straus MA. The Conflicts Tactics Scale. In: Handbook of Family Measurement Techniques, Touliatos J, Perlmutter B, Straus M (Eds), Sage Publications, Newbury Park, CA 2001.",
"    </li>",
"    <li>",
"     Teaster PB, Dugar TA, Mendiondo MS, et al. The 2004 Survey of State Adult Protective Services: Abuse of Adults 60 Years of Age and Older. The National Committee for the Prevention of Elder Abuse and The National Adult Protective Services Association 2006. p. 26. Available at: www.ncea.aoa.gov/NCEAroot/Main_Site/pdf/2-14-06%20FINAL%2060+REPORT.pdf (Accessed on April 28, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/66\">",
"      Dyer CB, Kelly PA, Pavlik VN, et al. The making of a self-neglect severity scale. J Elder Abuse Negl 2006; 18:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/67\">",
"      Cohen HJ, Feussner JR, Weinberger M, et al. A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med 2002; 346:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/68\">",
"      Caplan GA, Williams AJ, Daly B, Abraham K. A randomized, controlled trial of comprehensive geriatric assessment and multidisciplinary intervention after discharge of elderly from the emergency department--the DEED II study. J Am Geriatr Soc 2004; 52:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/69\">",
"      Riccio D, Solinas A, Astara G, Mantovani G. Comprehensive geriatric assessment in female elderly patients with Alzheimer disease and other types of dementia. Arch Gerontol Geriatr 2007; 44 Suppl 1:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/70\">",
"      Dyer CB, Goins AM. The role of the interdisciplinary geriatric assessment in addressing self-neglect of the elderly. Generations 2000; 24:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/71\">",
"      Dyer CB, Goodwin JS, Pickens-Pace S, et al. Self-neglect among the elderly: a model based on more than 500 patients seen by a geriatric medicine team. Am J Public Health 2007; 97:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/72\">",
"      Pickens S, Naik AD, Burnett J, et al. The utility of the Kohlman Evaluation of Living Skills test is associated with substantiated cases of elder self-neglect. J Am Acad Nurse Pract 2007; 19:137.",
"     </a>",
"    </li>",
"    <li>",
"     Judicial Determination of Capacity of Older Adults in Guardianship Proceedings. American Bar Association Commission on Law and Aging - American Psychological Association 2006. Available at: file://www.apa.org/pi/aging/resources/guides/judges-diminished.pdf (Accessed on April 28, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/74\">",
"      Moye J, Butz SW, Marson DC, et al. A conceptual model and assessment template for capacity evaluation in adult guardianship. Gerontologist 2007; 47:591.",
"     </a>",
"    </li>",
"    <li>",
"     Stiegle L, Klem E. Explanation of the \"Emergency or involuntary services to victims: Comparison Chart of Provisions in Adult Protective Services Laws with Citations by State\" Chart. American Bar Association Commission on Law and Aging 2007. Available at: www.abanet.org/aging/about/pdfs/emergency_or_involuntary_services_explanation.pdf (Accessed on April 28, 2009).",
"    </li>",
"    <li>",
"     Evaluating Interventions. In: Elder Abuse: abuse, neglect, and exploitation in an aging America, Bonnie RJ, Wallace RB (Eds), National Academy Press, Washington, DC 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/77\">",
"      Welfel ER, Danzinger PR, Santoro S. Mandated Reporting of Abuse/Maltreatment of Older Adults: A Primer for Counselors. Journal of Counseling &amp; Development 2000; 78:284.",
"     </a>",
"    </li>",
"    <li>",
"     Stiegel L, Klem E. Explanation of the \"Immunity for Good Faith Reporting: Provisions and Citations in Adult Protective Services Laws, by State\" and \"Immunity for Good Faith Reporting: Criteria in Adult Protective Services Laws, by State\" Charts. American Bar Association Commission on Law and Aging 2007. Available at: www.abanet.org/aging/about/pdfs/Immunity_for_Good_Faith_Reporting_Explanation.pdf (Accessed on April 28, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/79\">",
"      Halphen JM, Varas GM, Sadowsky JM. Recognizing and reporting elder abuse and neglect. Geriatrics 2009; 64:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/80\">",
"      Rosen T, Pillemer K, Lachs M. Resident-to-Resident Aggression in Long-Term Care Facilities: An Understudied Problem. Aggress Violent Behav 2008; 13:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/81\">",
"      Rosen T, Lachs MS, Pillemer K. Sexual aggression between residents in nursing homes: literature synthesis of an underrecognized problem. J Am Geriatr Soc 2010; 58:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/82\">",
"      Natan MB, Lowenstein A, Eisikovits Z. Psycho-social factors affecting elders' maltreatment in long-term care facilities. Int Nurs Rev 2010; 57:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/83\">",
"      Lindbloom EJ, Brandt J, Hough LD, Meadows SE. Elder mistreatment in the nursing home: a systematic review. J Am Med Dir Assoc 2007; 8:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/27/17850/abstract/84\">",
"      Jogerst GJ, Daly JM, Hartz AJ. State policies and nursing home characteristics associated with rates of resident mistreatment. J Am Med Dir Assoc 2008; 9:648.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3007 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-211.167.112.15-3788567297-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17850=[""].join("\n");
var outline_f17_27_17850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REGULATORY AND SUPPORT SERVICES (US)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Domestic mistreatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Institutional mistreatment (US)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MORTALITY AND MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Historical factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Medication issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Warning signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Skin findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fractures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Dehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Indicators of sexual abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SCREENING AND ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Rationale for screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Approaches to screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - AMA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Abbreviated screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Screening instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Comprehensive Geriatric Assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Mental status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Guardianship",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Decisional and executive capacity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Medical interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Social interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Reporting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Web resources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Interacting with law enforcement and the courts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Documentation of findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3752822\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3007\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3007|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/24/20876\" title=\"table 1\">",
"      Warning signs of elder mistreatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43624?source=related_link\">",
"      Comprehensive geriatric assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34215?source=related_link\">",
"      Failure to thrive in elderly adults: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/3/7218?source=related_link\">",
"      Patient information: Elder abuse (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/20/34120?source=related_link\">",
"      Pressure ulcers: Epidemiology, pathogenesis, clinical manifestations, and staging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_27_17851="B19 symptoms in children";
var content_f17_27_17851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Range of parvovirus B19 symptoms and signs in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom or sign",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent affected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"       <td>",
"        14 to 53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"       <td>",
"        12 to 53",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sore throat",
"       </td>",
"       <td>",
"        12 to 60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pruritus",
"       </td>",
"       <td>",
"        0 to &gt;50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough",
"       </td>",
"       <td>",
"        5 to 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diarrhea",
"       </td>",
"       <td>",
"        0 to 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and/or vomiting",
"       </td>",
"       <td>",
"        0 to 33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coryza and/or conjunctivitis",
"       </td>",
"       <td>",
"        4 to 27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthralgia and/or arthritis",
"       </td>",
"       <td>",
"        0 to 9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Anderson, LJ. Pediatr Infect Dis J 1987; 6:711.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17851=[""].join("\n");
var outline_f17_27_17851=null;
var title_f17_27_17852="Ideal body weight lean body weight approximation table";
var content_f17_27_17852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Ideal body weight and approximate lean body weight in obesity (adult)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Height (in)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Height (cm)",
"      </td>",
"      <td class=\"subtitle1\">",
"       IBW* (kg)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Approximate LBW in class III obesity&bull; (kg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       <strong>",
"        Female (adult)",
"       </strong>",
"      </td>",
"      <td>",
"       60",
"      </td>",
"      <td>",
"       152",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       52",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       65",
"      </td>",
"      <td>",
"       165",
"      </td>",
"      <td>",
"       57",
"      </td>",
"      <td>",
"       60",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       178",
"      </td>",
"      <td>",
"       68",
"      </td>",
"      <td>",
"       70",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       191",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       80",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       <strong>",
"        Male (adult)",
"       </strong>",
"      </td>",
"      <td>",
"       60",
"      </td>",
"      <td>",
"       152",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       63",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       65",
"      </td>",
"      <td>",
"       165",
"      </td>",
"      <td>",
"       62",
"      </td>",
"      <td>",
"       73",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       70",
"      </td>",
"      <td>",
"       177",
"      </td>",
"      <td>",
"       76",
"      </td>",
"      <td>",
"       85",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       75",
"      </td>",
"      <td>",
"       191",
"      </td>",
"      <td>",
"       89",
"      </td>",
"      <td>",
"       97",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       203",
"      </td>",
"      <td>",
"       103",
"      </td>",
"      <td>",
"       112",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IBW: ideal body weight; LBW: lean body weight; TBW: total body weight; BMI: body mass index",
"     <br>",
"      * IBW male = 50 + (2.3 x height in inches over 5 feet); IBW female = 45.5 + (2.3 x height in inches over 5 feet).",
"      <br>",
"       &bull; Approximate LBW in class III obesity (BMI 40-45 kg/m2) for dosing emergency drugs; LBW estimate (kg) = (9270 x TBW)/(A + B x BMI) where A and B are 6680 and 216 respectively for males and 8780 and 244 respectively for females.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Formulas from: Devine BJ. Drug Intell Clin Pharm 1974; 8:560 and Hanley, MJ et al. Clin Pharmacokinet 2010; 49:71",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17852=[""].join("\n");
var outline_f17_27_17852=null;
var title_f17_27_17853="ACC AHA HRS congenital HD";
var content_f17_27_17853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/HRS guideline summary: Indications for permanent pacing in children, adolescents, and patients with congenital heart disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that permanent pacing should be performed in children, adolescents, and patients with congenital heart disease in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Advanced second- or third-degree atrioventricular (AV) block that is associated with symptomatic bradycardia, ventricular dysfunction, or a low cardiac output. (Level of Evidence C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Sinus node dysfunction with correlation of symptoms during age-inappropriate bradycardia. The definition of bradycardia varies with the patient's age and expected heart rate. (Level of Evidence B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Postoperative advanced second- or third-degree AV block that is not expected to resolve or that persists for at least 7 days after cardiac surgery. (Level of Evidence B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Congenital third-degree AV block with a wide QRS escape rhythm, complex ventricular ectopy, or ventricular dysfunction. (Level of Evidence B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Congenital third-degree AV block in the infant with a ventricular rate less than 55 bpm or with congenital heart disease and a ventricular rate less than 70 bpm. (Level of Evidence C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - Based upon the weight of evidence or opinion, it is reasonable to perform permanent pacing in children, adolescents, and patients with congenital heart disease in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Sinus bradycardia for the prevention of recurrent episodes of intra-atrial reentrant tachycardia; SND may be intrinsic or secondary to antiarrhythmic treatment. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Congenital third-degree AV block beyond the first year of life with an average heart rate less than 50 bpm, abrupt pauses in ventricular rate that are two or three times the basic cycle length, or symptoms due to chronotropic incompetence. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Sinus bradycardia with complex congenital heart disease with a resting heart rate less than 40 bpm or pauses in ventricular rate lasting longer than three seconds. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Impaired hemodynamics due to sinus bradycardia or loss of AV synchrony. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Unexplained syncope in the patient with prior congenital heart surgery complicated by transient complete heart block with residual fascicular block after a careful evaluation to exclude other causes of syncope. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established, permanent pacing may be considered in children, adolescents, and patients with congenital heart disease in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Transient postoperative third-degree AV block that reverts to sinus rhythm with residual bifascicular block. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Congenital third-degree AV block in asymptomatic children or adolescents with an acceptable rate, a narrow QRS complex, and normal ventricular function. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic sinus bradycardia after biventricular repair of congenital heart disease with a resting heart rate less than 40 bpm or pauses in ventricular rate longer than 3 seconds. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class III - There is evidence and/or general agreement that permanent pacing should not be performed in children, adolescents, and patients with congenital heart disease in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Transient postoperative AV block with return of normal AV conduction in the otherwise asymptomatic patient. (Level of Evidence: B)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic bifascicular block with or without first-degree AV block after surgery for congenital heart disease in the absence of prior transient complete AV block. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic type I second-degree AV block. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &bull; Asymptomatic sinus bradycardia if the longest relative risk interval less than three seconds and a minimum heart rate more than 40 bpm. (Level of Evidence: C)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Epstein, AE, DiMarco, JP, Ellenbogen, KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17853=[""].join("\n");
var outline_f17_27_17853=null;
var title_f17_27_17854="Mirizzi syndrome ERCP";
var content_f17_27_17854=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mirizzi syndrome seen on endoscopic retrograde cholangiopancreatography (ERCP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 206px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography in a patient with obstructive jaundice and Mirizzi syndrome shows an impacted stone in the distal cystic duct which is obstructing the common hepatic duct by extrinsic compression (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17854=[""].join("\n");
var outline_f17_27_17854=null;
var title_f17_27_17855="Angiomyolipoma renal bleed CT";
var content_f17_27_17855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F60127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F60127&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan showing renal angiomyolipoma with hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 346px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial CT scan demonstrates a large fat-containing mass arising from the posterior aspect of the left kidney (arrow) which is displaced anteriorly by the mass. The mass has ruptured producing a hematoma in the perirenal space (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_27_17855=[""].join("\n");
var outline_f17_27_17855=null;
